Searching for metastases in colorectal cancer by Grossmann, Irene
  
 University of Groningen
Searching for metastases in colorectal cancer
Grossmann, Irene
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Grossmann, I. (2010). Searching for metastases in colorectal cancer. Groningen: s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Rijksuniversiteit	  Groningen
Searching	  for	  metastases	  
in	  colorectal	  cancer
Proefschri*
ter	  verkrijging	  van	  het	  doctoraat	  in	  de	  
Medische	  Wetenschappen
aan	  de	  Rijksuniversiteit	  Groningen
op	  gezag	  van	  de
Rector	  Magniﬁcus,	  dr.	  F.	  Zwarts,
in	  het	  openbaar	  te	  verdedigen	  op




geboren	  op	  12	  maart	  1973
te	  Schwäbisch	  Hall,	  Duitsland
Promotores:	  	  	  	   	   	   	   	   Prof.	  dr.	  T.	  Wiggers	  
	   	   	   	   	   	   	   	   	   	   	   Universitair	  Medisch	  Centrum	  Groningen
	   	   	   	   	   	   	   	   	   	   	   Prof.	  dr.	  G.H.	  de	  Bock
	   	   	   	   	   	   	   	   	   	   	   Universitair	  Medisch	  Centrum	  Groningen
Copromotor:	  	  	   	   	   	   	   Dr.	  J.M.	  Klaase	  
	   	   	   	   	   	   	   	   	   	   	   Medisch	  Spectrum	  Twente,	  Enschede
Beoordelingscommissie:	   Prof.	  dr.	  J.T.M.	  Plukker	  
	   	   	   	   	   	   	   	   	   	   	   Universitair	  Medisch	  Centrum	  Groningen
	   	   	   	   	   	   	   	   	   	   	   Prof.	  dr.	  J.H.W.	  de	  Wilt	  
	   	   	   	   	   	   	   	   	   	   	   UMC	  St	  Radboud,	  Nijmegen
	   	   	   	   	   	   	   	   	   	   	   Prof.	  dr.	  R.G.H.	  Beets-­‐Tan	  








1	   Introduc>on	  and	  outline	  of	  the	  thesis
	   Staging	  before	  treatment
2	   Staging	  with	  abdominal	  CT	  before	  treatment	  is	  an	  important	  step	  towards	  
	   improving	  the	  (oncological)	  outcome	  in	  colorectal	  cancer	  (pag	  9-­‐27)
3	   Pre-­‐operaAve	  staging	  with	  chest	  CT	  in	  paAents	  with	  colorectal	  carcinoma:	  not	  as	  a	  
	   rouAne	  procedure	  (pag	  29-­‐42)
	   Follow-­‐up
4	   Results	  of	  a	  naAonal	  survey	  among	  Dutch	  surgeons	  treaAng	  paAents	  with	  colorectal	  
	   carcinoma.	  Current	  opinion	  about	  follow-­‐up	  	  (pag	  43-­‐55)
5	   CEA	  measurement	  during	  follow-­‐up	  for	  colorectal	  carcinoma	  is	  useful	  even	  if	  normal	  
	   levels	  exist	  before	  curaAve	  surgery	  	  (pag	  57-­‐68)
6	   The	  Role	  of	  High	  Frequency	  Dynamic	  Threshold	  (HiDT)	  Serum	  Carcinoembryonic	  
	   AnAgen	  (CEA)	  Measurements	  in	  Colorectal	  Cancer	  Surveillance:	  a	  (revisited)	  
	   hypothesis	  paper	  (pag	  69-­‐87)
7	   PosiAve	  psychological	  evaluaAon	  of	  an	  intensive	  follow-­‐up	  trial	  in	  colorectal	  cancer	  
	   based	  upon	  high	  frequency	  serum	  CEA	  measurements	  with	  less	  outpaAent	  clinical	  
	   visits	  (pag	  89-­‐104)
8	   Early	  recurrent	  disease	  aTer	  curaAve	  treatment	  of	  non-­‐metastaAc	  colorectal	  cancer	  
	   found	  only	  in	  paAents	  with	  locally	  advanced	  primary	  tumors;	  follow-­‐up	  may	  be	  
	   reduced	  in	  non-­‐advanced	  cases	  (pag	  105-­‐117)
9	   Summary	  /	  samenvaFng




Introduc>on	  and	  outline	  of	  the	  thesis
Colorectal	  cancer	  (CRC)	  is	  a	  common	  disease,	  with	  a	  life	  Ame	  risk	  of	  ±	  10%	  in	  the	  Western	  
populaAon	  and	  an	  incidence	  of	  10.000	  new	  paAents	  each	  year	  in	  the	  Netherlands.	  In	  
approximately	  half	  of	  these	  paAents	  metastases	  are	  found,	  either	  at	  diagnosis	  or	  during	  
follow-­‐up.	  These	  metastases	  are	  usually	  localized	  in	  the	  liver,	  peritoneal	  cavity	  or	  the	  lung.	  
In	  the	  past,	  metastaAc	  CRC	  was	  frequently	  regarded	  as	  incurable	  and	  suitable	  for	  palliaAve	  
treatment	  only.	  At	  present,	  various	  new	  and	  developing	  mulA-­‐modality	  treatment	  opAons	  
for	  liver	  and	  lung	  metastases	  and	  peritoneal	  carcinomatosis	  oﬀer	  a	  (second)	  chance	  on	  
cure.	  This	  moAvated	  renewed	  eﬀorts	  to	  opAmize	  ‘searching	  for	  metastases’	  in	  CRC.	  
Staging	  before	  treatment
Finding	  metastaAc	  disease	  at	  an	  early	  stage,	  is	  thought	  to	  increase	  the	  chances	  on	  curaAve	  
treatment.	  The	  earliest	  possible	  moment	  is	  at	  the	  Ame	  of	  diagnosis	  of	  the	  primary	  tumor.	  
Finding	  metastaAc	  disease	  before	  treatment	  may	  also	  be	  relevant	  in	  non-­‐curaAve	  
situaAons;	  colorectal	  resecAons	  know	  a	  signiﬁcant	  morbidity	  and	  mortality	  and	  it	  is	  not	  
always	  necessary	  or	  helpful	  in	  reducing	  symptoms	  of	  the	  disease.	  The	  accuracy	  of	  the	  
diagnosAc	  method	  is	  as	  important	  as	  the	  pracAcality	  of	  the	  diagnosAc	  trajectories	  in	  this	  
common	  disease.	  The	  most	  accurate	  and	  widely	  available	  imaging	  technique	  is	  a	  CT	  scan.	  
Staging	  with	  abdominal	  and	  chest	  CT	  as	  a	  rouAne	  procedure	  before	  treatment	  was	  
introduced	  as	  part	  of	  a	  regional	  guideline	  on	  CRC	  in	  2007.	  It	  was	  however	  unclear,	  which	  
actual	  beneﬁts	  could	  be	  expected	  from	  staging	  with	  CT	  before	  treatment.	  A	  CT	  scan	  is	  
expensive	  and	  incidentalomas	  may	  complicate	  clinical	  decision	  making.	  Relevant	  quesAons	  
such	  as	  the	  incidence	  of	  metastaAc	  disease	  at	  diagnosis	  and	  the	  inﬂuence	  of	  staging	  on	  the	  
treatment	  plan	  for	  the	  primary	  tumor,	  factually	  were	  unanswered.	  To	  address	  these	  
quesAons,	  a	  prospecAve	  observaAonal	  study	  was	  iniAated	  in	  the	  Medical	  Spectrum	  Twente	  
Enschede.	  A	  prospecAve	  registraAon	  of	  all	  paAents	  that	  undergo	  colorectal	  surgery	  was	  
designed	  and	  incorporated	  in	  daily	  clinical	  pracAce,	  starAng	  January	  2007.	  The	  outcomes	  of	  
these	  studies,	  which	  concern	  the	  abdominal	  and	  chest	  CT	  are	  described	  in	  chapter	  2	  and	  3.	  
Follow-­‐up
ATer	  intended	  curaAve	  treatment	  of	  colorectal	  cancer,	  paAents	  are	  subjected	  to	  a	  follow-­‐
up	  of	  5	  years.	  In	  general	  this	  consists	  of	  3	  to	  6-­‐monthly	  carcino-­‐embryonic	  anAgen	  (CEA)	  
measurements	  and	  outpaAent	  clinic	  visits,	  with	  an	  increasing	  habit	  of	  addiAonal	  biannual	  
ultrasound	  of	  the	  liver	  or	  a	  CT	  scan	  at	  regular	  intervals.	  The	  current	  Dutch	  guideline	  on	  
follow-­‐up	  does	  not	  give	  a	  clear	  recommendaAon,	  due	  to	  a	  lack	  of	  evidence	  on	  the	  opAmal	  
program	  and	  diagnosAc	  tools.
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   With	  10.000	  new	  paAents	  each	  year,	  follow-­‐up	  has	  a	  considerable	  impact	  on	  the	  
outpaAent	  clinic	  and	  is	  expensive.	  Meanwhile,	  the	  beneﬁts	  of	  follow-­‐up	  -­‐	  concerning	  the	  
oncological	  outcome-­‐	  have	  been	  highly	  disappoinAng.	  OTen,	  the	  pracAce	  of	  follow-­‐up	  in	  
colorectal	  cancer	  has	  been	  quesAoned	  but	  nonetheless	  never	  abandoned.	  Despite	  the	  lack	  
of	  evidence,	  oncological	  follow-­‐up	  is	  considered	  important.	  Follow-­‐up	  comprehends	  an	  
eﬀort	  to	  improve	  survival	  in	  cancer,	  it	  can	  oﬀer	  support	  to	  paAents	  that	  had	  a	  life	  
threatening	  disease	  and	  await	  recurrences,	  and	  it	  informs	  on	  the	  funcAonal	  outcomes	  aTer	  
treatment.	  Follow-­‐up	  contains	  a	  mulAtude	  of	  relevant	  medical	  aspects	  to	  be	  taken	  into	  
consideraAon,	  such	  as	  recurrence	  paferns,	  diagnosAc	  methods,	  therapeuAc	  and	  palliaAve	  
treatment	  opAons	  of	  recurrent	  disease.	  Also,	  not	  in	  the	  least,	  it	  has	  an	  important	  
emoAonal	  side	  to	  both	  paAents	  and	  doctors.	  An	  afempt	  to	  opAmize	  follow-­‐up	  such	  as	  has	  
been	  done	  for	  this	  thesis,	  requires	  an	  approach	  in	  which	  all	  of	  these	  aspects	  are	  
considered.
	   To	  study	  the	  opinion	  on	  follow-­‐up	  among	  Dutch	  surgeons,	  a	  naAonal	  survey	  on	  the	  
opinion	  towards	  follow-­‐up	  and	  its	  diagnosAc	  methods	  was	  done.	  This	  study	  included	  an	  
query	  on	  feasibility	  of	  a	  new	  naAonal	  trial	  (chapter	  4).	  Serum-­‐CEA	  measurement	  has	  been	  
the	  cornerstone	  of	  follow-­‐up	  for	  30	  years.	  Advantages	  of	  CEA	  are	  the	  low	  costs	  and	  the	  
pracAcality	  of	  use.	  Serum	  CEA	  however	  can	  only	  signal	  recurrent	  disease;	  its	  applicability	  as	  
a	  diagnosAc	  tool	  is	  largely	  determined	  by	  the	  ability	  to	  subsequently	  localize	  or	  exclude	  
recurrent	  disease	  with	  imaging	  techniques.	  This	  has	  been	  a	  major	  problem	  in	  the	  past	  and	  
has	  contributed	  largely	  to	  the	  downfall	  in	  appreciaAon	  of	  CEA	  as	  a	  valuable	  diagnosAc	  tool	  
in	  follow-­‐up.	  With	  the	  coming	  of	  accurate,	  widely	  available	  and	  non-­‐invasive	  imaging	  
techniques,	  this	  situaAon	  may	  change	  radically.	  Our	  second	  aim	  was,	  to	  ﬁnd	  evidence	  
supporAng	  or	  denouncing	  CEA	  as	  a	  diagnosAc	  method	  in	  follow-­‐up	  (chapter	  5	  and	  6).	  The	  
comprehensive	  review	  of	  the	  literature	  on	  CEA	  in	  follow-­‐up	  that	  followed,	  resulted	  in	  a	  
new	  follow-­‐up	  design.	  This	  new	  design	  was	  tested	  in	  a	  non-­‐randomized	  phase	  II	  trial	  
carried	  out	  in	  2008	  and	  2009	  in	  the	  Medical	  Spectrum	  Twente	  and	  University	  Medical	  
Center	  Groningen,	  on	  both	  logisAc	  feasibility	  and	  outcome.	  The	  primary	  endpoint	  was	  
eligibility	  for	  curaAve	  treatment	  of	  diagnosed	  recurrent	  disease.	  Secondary	  endpoints	  were	  
the	  ability	  to	  localize	  recurrent	  disease	  with	  standard	  imaging	  techniques	  and	  esAmaAon	  of	  
the	  opAmal	  threshold	  value.	  The	  ﬁrst	  results	  from	  this	  trial	  were	  included	  in	  the	  hypothesis	  
arAcle	  (chapter	  6).	  The	  results	  from	  a	  concomitant	  study	  concerning	  the	  psychological	  
eﬀects	  of	  this	  new	  type	  of	  follow-­‐up	  on	  paAents	  are	  described	  in	  chapter	  7.	  
Tailoring	  follow-­‐up
The	  populaAon	  with	  colorectal	  cancer	  is	  very	  heterogeneous;	  the	  risks	  on	  recurrent	  disease	  
during	  follow-­‐up	  will	  vary	  to	  a	  great	  extent	  as	  well.	  Current	  follow-­‐up	  guidelines	  do	  not	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discriminate	  between	  risk	  groups.	  AdaptaAon	  of	  follow-­‐up	  towards	  risk	  groups	  and	  
expected	  Ame	  to	  recurrent	  disease,	  thus	  a	  ‘tailor	  made’	  follow-­‐up,	  may	  reduce	  
unnecessary	  diagnosAcs	  in	  low	  risk	  groups	  and	  be	  a	  reason	  to	  (temporarily)	  intensify	  
follow-­‐up	  in	  high-­‐risk	  paAents.	  This	  will	  become	  relevant	  when	  intensive	  follow-­‐up,	  as	  
proposed	  for	  the	  naAonal	  trial,	  will	  prove	  eﬀecAve.	  The	  recurrence	  paferns	  however,	  are	  
likely	  to	  have	  changed	  as	  a	  result	  of	  both	  staging	  before	  treatment,	  neo-­‐adjuvant	  
treatment	  in	  rectal	  cancer	  and	  adjuvant	  chemotherapy	  in	  colon	  cancer.	  Our	  hypothesis	  was	  
that	  as	  a	  result	  of	  these	  changes,	  the	  average	  Ame	  to	  recurrent	  disease	  would	  be	  
prolonged	  as	  compared	  to	  the	  ‘old’	  situaAon.	  Data	  on	  recurrence	  paferns	  from	  literature	  
were	  scarce	  and	  usually	  outdated.	  The	  recurrence	  pafern	  within	  one	  year	  aTer	  surgery	  in	  
paAents	  that	  were	  staged	  before	  treatment	  with	  abdominal	  CT	  and	  treated	  according	  to	  
current	  standards,	  was	  analyzed.	  A	  limited	  risk	  group	  analysis	  on	  known	  and	  prospecAvely	  
registered	  risk	  factors	  T	  stage,	  N	  stage	  and	  emergency	  presentaAons	  was	  done,	  as	  a	  ﬁrst	  
next	  step	  towards	  reﬁnements	  in	  future	  follow-­‐up	  designs.	  The	  outcomes	  of	  this	  study	  are	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Background.	   Advanced	   colorectal	   carcinoma	   (CRC)	   is	   present	   in	   a	   relevant	  
proporAon	   of	   paAents. 	   The	   chance	   on	   curaAon	   of	   metastaAc	   CRC	   has	   been	  
improving	  in	   the	  last	  decade.	  Further, 	  less	  invasive	  procedures	  for	   incurable	  CRC	  
may	  improve	  surgical	  mortality 	  rates	  and	  the	  quality	  of	  life. 	  Staging	  may	  opAmize	  
the	  outcome	  by	  changing	  the	  treatment	  plan.	  	  
Methods.	  This	  prospecAve	  observaAonal	  study	  evaluates	  the	  outcome	  of	  rouAne	  
staging	   with	   abdominal	   CT	   in	   an	   unselected	   hospital	   populaAon	   with	   CRC	  
concerning	   liver	   metastases	   (LM),	  peritoneal	   carcinomatosis	   (PC)	   and	  T-­‐stage	   in	  
colon	  cancer	  (CC).
Findings.	  In	   this	  cohort	   of	  612	  paAents,	  31%	  had	  metastaAc	  CRC.	  Staging	  before	  
treatment	  (SCT)	  was	  omifed	  in	  16%	  of	  paAents	  (non-­‐SCT),	  mainly	  in	  paAents	  with	  
emergency	   presentaAons	   (30%).	   The	   ability	   to	   detect	   advanced	   disease	   was	  
excellent	  for	  LM	  (99%),	  good	  for	  cT	  stage	  CC	  (86%)	  and	  poor	  for	  PC	  (33%).	  Staging	  
changed	   the	   treatment	   plan	   concerning	   avoidance	   of	   resecAon	   of	   the	   primary	  
tumor	   (SCT	   5%,	  non-­‐SCT	  1%)	  and	   curaAve	   treatment	   of	   LM	   (SCT	   24%,	  non-­‐SCT	  
16%).	  
Interpreta>on.	   Staging	   can	   change	   the	   treatment	   plan	   in	   both	   curable	   and	  
incurable	  CRC.	  Lead	  points	  to	  opAmize	  staging	  rouAnes	  in	  CRC	  could	  be	  idenAﬁed.	  
The	   relevance	   of	   staging	   before	   treatment	   is	   increasing	   with	   current	  
developments	  in	  treatment	  of	  advanced	  CRC,	  with	  a	  probable	  favorable	  eﬀect	  on	  
the	  oncological	  outcome.
Background
Advanced	  colorectal	  carcinoma	  (CRC),	  that	  is	  either	  locally	  advanced	  or	  metastasized	  
disease,	  is	  present	  in	  a	  relevant	  proporAon	  of	  paAents	  diagnosed	  with	  colorectal	  cancer.	  
Synchronous	  distant	  metastases	  in	  CRC	  are	  usually	  localized	  in	  the	  liver,	  peritoneal	  cavity	  
and	  the	  lung.	  Staging	  with	  chest	  CT	  as	  a	  rouAne	  procedure	  before	  surgery	  has	  not	  shown	  to	  
be	  of	  clinical	  beneﬁt,	  mainly	  due	  to	  the	  low	  incidence	  of	  clinically	  relevant	  lung	  metastases	  
and	  low	  speciﬁcity	  of	  chest	  CT.1-­‐3	  	  Pre-­‐operaAve	  staging	  with	  abdominal	  CT	  might	  be	  
beneﬁcial	  when	  the	  accuracy	  of	  detecAng	  metastaAc	  CRC	  is	  high	  and	  the	  ﬁndings	  change	  
the	  treatment	  plan.	  Such	  ﬁndings	  include	  liver	  metastases,	  peritoneal	  carcinomatosis	  and	  
locally	  advanced	  colon	  carcinoma.	  These	  condiAons	  were	  in	  the	  past	  frequently	  regarded	  
as	  incurable	  and	  suitable	  for	  palliaAve	  measures	  only	  but	  nowadays	  various	  mulA-­‐modality	  
treatments	  oﬀer	  a	  chance	  of	  cure	  to	  selected	  paAents.4-­‐15	  For	  paAents	  with	  incurable	  
advanced	  CRC	  the	  treatment	  plan	  can	  be	  changed	  towards	  foremost	  the	  ‘best	  palliaAve	  
care’,	  which	  is	  not	  necessarily	  a	  palliaAve	  resecAon.16-­‐18	  
	   Findings	  in	  an	  unselected	  populaAon	  with	  CRC	  that	  were	  rouAnely	  staged	  with	  
abdominal	  CT,	  can	  be	  helpful	  in	  the	  debate	  on	  actual	  clinical	  relevance	  and	  preferred	  
rouAng	  of	  paAents	  with	  advanced	  disease.	  
Pa>ents	  and	  methods
The	  data	  were	  collected	  in	  the	  Medical	  Spectrum	  Twente,	  a	  large	  community	  teaching	  
hospital	  in	  the	  regional	  capital	  of	  a	  foremost	  rural	  area	  in	  the	  eastern	  part	  of	  the	  
Netherlands.	  It	  funcAons	  as	  a	  regional	  referral	  center	  for	  liver	  and	  lung	  surgery,	  but	  has	  no	  
faciliAes	  for	  the	  treatment	  of	  peritoneal	  carcinomatosis	  (PC)	  with	  hyperthermic	  
intraperitoneal	  chemotherapy	  (HIPEC).
	   The	  study	  design	  is	  a	  prospecAve	  observaAonal	  cohort	  study	  evaluaAng	  the	  outcome	  
of	  rouAne	  staging	  with	  abdominal	  CT	  concerning	  liver	  metastases	  (LM),	  PC	  and	  T-­‐stage	  in	  
colon	  cancer	  (CC).	  PaAents	  diagnosed	  with	  CRC	  from	  2007	  All	  2009	  were	  included	  in	  the	  
analysis.	  All	  surgical	  paAents	  with	  CRC	  in	  the	  study	  hospital	  are	  prospecAvely	  registered	  in	  
a	  database	  designed	  for	  colorectal	  surgery.	  PaAent	  characterisAcs,	  staging	  and	  operaAon	  
procedures,	  the	  clinical	  M	  stage	  and	  pathological	  TNM	  stage,	  post-­‐operaAve	  mortality,	  
treatment	  of	  metastases	  and	  follow-­‐up	  are	  prospecAvely	  registered.	  PaAents	  with	  the	  
diagnosis	  of	  CRC	  in	  the	  same	  3	  years	  who	  did	  not	  undergo	  surgery	  were	  idenAﬁed	  by	  the	  
regional	  cancer	  registry	  and	  retrospecAvely	  added	  to	  the	  database.	  The	  clinical	  T	  stage	  on	  
abdominal	  CT	  was	  retrospecAvely	  scored	  based	  upon	  the	  original	  radiology	  reports.	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   RouAne	  pre-­‐operaAve	  staging	  CT	  of	  chest	  and	  abdomen	  for	  paAents	  with	  CRC	  was	  
introduced	  as	  a	  regional	  CRC	  guideline	  in	  2007	  and	  includes	  paAents	  with	  emergency	  
presentaAons.	  CT	  scanning	  was	  performed	  on	  a	  16	  and	  64	  slice	  scanner	  (Toshiba	  Aquillion	  
16	  and	  64)	  aTer	  intravenous	  contrast	  injecAon	  (visipaque	  320,	  90	  ml,	  3ml/s.),	  in	  the	  portal	  
venous	  phase,	  with	  a	  slice	  thickness	  of	  1	  mm	  and	  a	  reconstrucAon	  of	  0.8	  mm.	  When	  
preoperaAve	  scanning	  was	  omifed,	  staging	  with	  abdominal	  CT	  was	  intended	  within	  3	  
months	  aTer	  surgery.	  PaAents	  with	  rectal	  cancer	  (RC),	  deﬁned	  as	  localizaAon	  below	  the	  
peritoneal	  reﬂecAon,	  were	  addiAonally	  staged	  with	  a	  pelvic	  MRI	  for	  determinaAon	  of	  the	  
local	  invasion	  and	  possible	  lymph	  node	  metastases	  (cTN	  stage)	  and	  treated	  with	  neo-­‐
adjuvant	  chemoradiaAon	  in	  case	  of	  locally	  advanced	  rectal	  cancer	  (LARC).	  From	  2008,	  all	  
colorectal	  surgery	  including	  emergency	  presentaAons	  is	  done	  or	  supervised	  by	  a	  
specialized	  colorectal	  surgeon.	  Follow-­‐up	  aTer	  curaAve	  treatment	  of	  non-­‐metastaAc	  CRC	  
consisted	  of	  3	  monthly	  CEA	  measurements	  combined	  with	  biannual	  ultrasound	  of	  the	  liver.
	   Advanced	  CRC	  was	  deﬁned	  as	  either	  locally	  advanced	  disease,	  presence	  of	  distant	  
metastases	  or	  both.	  Locally	  advanced	  colon	  cancer	  (LACC)	  was	  deﬁned	  by	  pT4	  stage.	  
Locally	  advanced	  rectal	  cancer	  (LARC)	  was	  deﬁned	  as	  all	  paAents	  that	  had	  either	  a	  T4	  
tumor	  or	  a	  T3	  tumor	  with	  a	  threatened	  circumferenAal	  margin	  on	  pelvic	  MRI.	  Incurable	  
CRC	  was	  deﬁned	  as	  all	  irradical	  (R1	  or	  R2)	  resecAons,	  when	  the	  paAent	  had	  no	  surgery	  for	  
the	  primary	  tumor,	  or	  when	  no	  curaAve	  treatment	  of	  distant	  metastases	  was	  done.	  
Emergency	  presentaAon	  in	  the	  surgical	  paAents	  was	  deﬁned	  as	  all	  non-­‐planned	  admissions	  
to	  the	  hospital	  due	  to	  symptoms	  related	  to	  the	  tumor,	  with	  ‘urgent’	  deﬁned	  as	  surgery	  
imperaAve	  within	  5	  days	  and	  ‘acute’	  procedures	  within	  6	  hours.	  Pathological	  staging	  was	  
based	  upon	  the	  TNM	  classiﬁcaAon	  2002	  (6th	  ediAon)	  and	  classiﬁed	  according	  to	  the	  
American	  Joint	  Commifee	  on	  Cancer	  (AJCC)	  stages.	  
	   PaAents	  that	  were	  staged	  with	  abdominal	  CT	  before	  treatment	  (SCT	  group)	  were	  
compared	  to	  paAents	  that	  were	  not	  (non-­‐SCT	  group)	  concerning	  paAent	  characterisAcs	  and	  
inﬂuence	  on	  the	  treatment	  plan.	  The	  ability	  of	  the	  staging	  abdominal	  CT	  to	  detect	  
advanced	  disease	  was	  analyzed	  in	  the	  surgical	  SCT	  group;	  the	  gold	  standard	  for	  PC	  and	  
LACC	  were	  peroperaAve	  ﬁndings	  conﬁrmed	  with	  histology.	  For	  LM	  the	  ﬁndings	  on	  CT	  were	  
related	  to	  peroperaAve	  ﬁndings	  in	  case	  of	  negaAve	  outcome	  of	  the	  staging	  CT	  and	  follow-­‐
up	  in	  case	  of	  indeterminate	  lesions.	  A	  risk	  group	  analysis	  on	  presence	  of	  metastases	  and	  
surgical	  mortality	  was	  done.
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Figure	  1.	  Colorectal	  cancer	  stage	  and	  treatment	  (2007-­‐2009)
R1:	  	   locally	  advanced	  tumors:	  LACC:	  colon,	  LARC:	  rectum
M1:	  	   metastases
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a	  This	  includes	  paaents	  with	  pathological	  downstaging	  a*er	  neoadjuvant	  chemoradiaaon	  
(n=69);	  stage	  0=a	  complete	  remission	  of	  histologically	  proven	  colorectal	  cancer.
b	  Staging	  of	  the	  lung	  in	  this	  cohort	  was	  done	  with	  chest	  CT	  (n=415)	  or	  chest	  X-­‐ray	  (n=197).
c	  Other	  localisaaons	  were	  brain	  and	  skeletal	  metastases.
d	  Of	  23	  paaents,	  20	  paaents	  had	  no	  surgery	  and	  3	  paaents	  had	  no	  resecaon	  resulang	  in	  an	  




Popula2on	  incidences	  of	  advanced	  colorectal	  cancer	  (Figure	  1	  and	  Table	  1)
From	  2007-­‐2009	  612	  paAents	  were	  diagnosed	  with	  colorectal	  carcinoma.	  MetastaAc	  CRC	  
(mCRC)	  was	  present	  in	  188	  paAents	  (31%).	  Incurable	  disease	  was	  present	  in	  199	  paAents	  
(33%),	  mainly	  due	  to	  mCRC	  (n=160).	  CuraAve	  treatment	  was	  achieved	  in	  413	  paAents	  
(67%).	  Curable	  advanced	  CRC	  was	  present	  in	  159	  paAents	  (38%),	  of	  whom	  28	  paAents	  had	  
mCRC.	  Most	  common	  sites	  of	  distant	  metastases	  were	  the	  liver	  (n=144,	  24%),	  peritoneal	  
cavity	  (n=49,	  8%)	  and	  the	  lung	  (n=42,	  7%).	  Staging	  with	  abdominal	  CT	  before	  treatment	  
was	  done	  in	  513	  paAents	  (84%).	  Surgery,	  either	  palliaAve	  or	  curaAve,	  was	  performed	  in	  551	  
paAents	  (90%).
Detec2on	  metasta2c	  CRC	  and	  LACC	  on	  abdominal	  CT	  (Table	  2)
LM	  were	  diagnosed	  in	  the	  cohort	  of	  surgical	  paAents	  that	  were	  staged	  before	  treatment	  
(n=463)	  in	  86	  paAents	  (19%).	  In	  73	  paAents	  the	  LM	  were	  diagnosed	  on	  the	  iniAal	  staging	  CT	  
(85%)	  and	  in	  19	  paAents	  these	  were	  suspected	  (indeterminate	  lesions).	  The	  indeterminate	  
lesions	  were	  idenAﬁed	  as	  either	  LM	  or	  benign	  lesions	  with	  addiAonal	  diagnosAc	  tesAng,	  
which	  were	  contrast-­‐enhanced	  ultrasound,	  positron	  emission	  tomography	  (PET),	  PET/CT	  or	  
MRI.	  In	  12	  paAents	  the	  indeterminate	  lesions	  were	  diagnosed	  as	  metastases	  and	  in	  7	  
paAents	  as	  benign	  lesions;	  of	  these,	  6	  paAents	  had	  a	  follow-­‐up	  of	  more	  then	  one	  year	  and	  
none	  was	  diagnosed	  with	  recurrent	  disease.	  In	  one	  paAent	  the	  liver	  metastasis	  was	  not	  
seen	  nor	  suspected	  on	  CT	  but	  found	  during	  surgery.	  The	  ability	  of	  the	  staging	  CT	  for	  
detecAng	  LM,	  summaAng	  diagnosed	  LM	  and	  secondary	  diagnosis	  aTer	  further	  analysis	  of	  
indeterminate	  lesions,	  is	  99%.	  Synchronous	  PC	  was	  diagnosed	  in	  33	  paAents;	  in	  11	  paAents	  
prior	  to	  surgery	  on	  the	  staging	  CT	  (33%),	  in	  the	  remaining	  22	  paAents	  these	  were	  found	  
during	  surgery	  for	  the	  primary	  tumor	  (67%).	  Abdominal	  CT	  did	  accurately	  stage	  pT4	  CC	  in	  
86%	  of	  paAents	  (99	  out	  of	  115).	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Table	  2.	  Detection	  advanced	  disease	  on	  abdominal	  CT
SCT	  group	  (surgical	  pa2ents)	  (n=463)	  
Diagnosed Suspected Not	  seen
Liver	  metastases n=86 73 85% 12 14% 1 1%
Peritoneal	  carcinomatosis n=33 11 33% 6 18% 16 48%
pT4	  colon	  carcinomaa	   n=115 99 86% 5 4% 11 10%
Rectum	  (n=115) Colon	  (n=348)
cM pM cM pM
n % n % n % n %
Liver	  metastases 13 11% 16 14% 61 18% 70 20%
Peritoneal	  carcinomatosis 2 2% 3 3% 9 3% 30 9%
Locally	  advanced	  disease n.a.b	   n.a. 99 29% 123 36%
cM:	  metastases	  diagnosed	  before	  treatment	  on	  staging	  CT
pM:	  ﬁnal	  conclusion,	  including	  addiaonal	  imaging	  and	  peroperaave	  ﬁndings
a	  In	  8	  paaents	  the	  local	  invasiness	  was	  not	  described	  in	  the	  original	  report,	  leaving	  115	  paaents	  
for	  evaluaaon	  
b	  Local	  invasiveness	  (cT	  stage)	  in	  rectal	  carcinoma	  was	  determined	  on	  pelvic	  MRI
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Comparison	  SCT	  and	  non-­‐SCT	  pa2ents	  (Table	  3	  and	  4)
Diﬀerences	  in	  the	  SCT	  and	  non-­‐SCT	  group	  were	  observed	  concerning	  tumor	  localizaAon	  
(proporAon	  CC	  in	  SCT	  group	  75%	  and	  non-­‐SCT	  90%),	  emergency	  procedures	  (SCT	  17%,	  non-­‐
SCT	  40%)	  and	  age	  (SCT	  mean	  69	  year,	  non-­‐SCT	  mean	  73	  year).	  Staging	  was	  omifed	  in	  30%	  
of	  emergency	  presentaAons	  (35	  of	  115)	  versus	  12%	  in	  elecAve	  surgery,	  and	  in	  19%	  of	  CC	  
(89	  out	  of	  474)	  versus	  7%	  of	  RC.
	   The	  proporAon	  of	  paAents	  that	  had	  no	  surgery	  was	  equal	  in	  the	  SCT	  (11%,	  n=50)	  
and	  the	  non-­‐SCT	  group	  (10%,	  n=11).	  In	  paAents	  that	  underwent	  surgery,	  the	  primary	  tumor	  
was	  not	  resected	  in	  5%	  in	  the	  SCT	  group	  and	  in	  1%	  in	  the	  non-­‐SCT	  group.	  When	  considering	  
Table	  3.	  Characteristics	  SCT	  versus	  non-­‐SCT	  patients



































































SCT:	  Staged	  with	  abdominal	  CT	  before	  start	  treatment
Non-­‐SCT:	  not	  staged	  with	  abdominal	  CT	  preceding	  treatment
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only	  CC	  with	  emergency	  presentaAon	  to	  parAally	  correct	  for	  the	  group	  diﬀerences,	  the	  
primary	  tumor	  was	  resected	  in	  85%	  in	  the	  SCT	  group	  (n=68)	  and	  in	  97%	  in	  the	  non-­‐SCT	  
group	  (n=34).	  In	  the	  SCT	  group	  3%	  of	  the	  colon	  carcinoma	  were	  irradically	  resected	  (n=13)	  
versus	  4%	  in	  the	  non-­‐SCT	  group	  (n=4).
	   CuraAve	  treatment	  of	  synchronous	  LM	  in	  surgical	  paAents	  was	  done	  in	  21	  paAents	  
(24%)	  in	  the	  SCT	  group	  and	  in	  3	  paAents	  (16%)	  in	  the	  non-­‐SCT	  group.	  Two	  paAents	  had	  
curaAve	  resecAon	  of	  LM	  before	  resecAon	  of	  the	  primary	  tumor	  and	  6	  paAents	  underwent	  a	  
simultaneous	  resecAon.	  An	  addiAonal	  6	  paAents	  in	  the	  SCT	  group	  were	  eligible	  for	  curaAve	  
treatment	  but	  were	  found	  irresectable	  with	  intra-­‐operaAve	  ultrasound	  (6	  out	  of	  30,	  20%).	  
Two	  paAents	  with	  PC	  were	  treated	  with	  curaAve	  intent	  in	  the	  SCT	  group.
Table	  4.	  Treatment	  outcome	  comparison	  SCT	  and	  non-­‐SCT	  group
SCT	  group non-­‐SCT	  group
Nt n= % Nt n= %
Treatment	  primary	  tumor	  (all	  pa2ents)
	  	  ResecAon
	  	  No	  resecAon
	  	  No	  surgery
in	  emergency	  surgery	  for	  CC
	  	  ResecAon
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Cura2ve	  treatment	  liver	  metastases
	  	  ElecAve	  surgery














a	  In	  an	  addiaonal	  6	  paaents	  in	  this	  group	  the	  metastases	  were	  eligible	  for	  curaave	  treatment	  on	  
CT,	  but	  turned	  out	  irresectable	  with	  intra-­‐operaave	  ultrasound	  performed	  during	  surgery	  for	  
intended	  metastasectomy.
b	  These	  3	  paaents	  were	  staged	  with	  abdominal	  CT	  a*er	  surgery
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Risk	  groups	  on	  distant	  metastases	  and	  surgical	  mortality	  (Table	  5a+b)
Risk	  factors	  for	  distant	  metastases	  are	  emergency	  presentaAon	  (incidence	  mCRC	  52%),	  
LACC	  (incidence	  mCRC	  45%)	  and	  age	  <	  70	  years	  (incidence	  mCRC	  36%).	  Risk	  factors	  for	  
surgical	  mortality	  were	  emergency	  presentaAon	  (13%	  vs	  3%),	  tumor	  localizaAon	  in	  the	  
colon	  (7%	  colon	  versus	  2%	  rectum),	  age	  >	  75	  years	  (11%	  versus	  3%)	  and	  the	  presence	  of	  
distant	  metastases	  (9%	  vs	  2%).	  The	  proporAon	  of	  surgical	  paAents	  with	  an	  emergency	  
presentaAon	  was	  21%	  (115/551).	  The	  proporAon	  of	  surgical	  paAents	  with	  LACC	  was	  29%	  
(160	  out	  of	  551).
Associa2on	  pT4	  stage	  colon	  cancer	  (LACC)	  and	  distant	  metastases
In	  LACC,	  PC	  was	  present	  in	  24%	  (38	  out	  of	  160)	  and	  LM	  in	  29%	  (46	  out	  of	  160)	  of	  surgical	  
paAents.	  The	  presence	  of	  PC	  is	  related	  to	  pT4	  tumor	  stage;	  93%	  of	  paAents	  with	  PC	  had	  a	  
pT4	  tumor	  (38	  from	  41	  surgical	  paAents).
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Table	  5.	  Risk	  groups	  on	  metastatic	  CRC	  and	  surgical	  mortality




























T-­‐stage	  colon	  cancer	  (surgical	  pa2ents)b
	  	  pT1-­‐3	  colon	  cancer







Mortality	  risk	  of	  surgical	  procedure total n= %
Agec
	  	  <	  75	  years
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  (all)
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a	  Calculated	  on	  all	  paAents	  with	  known	  AJCC	  status	  (n=589)
b	  Calculated	  on	  all	  surgical	  paAents	  with	  known	  AJCC	  status	  (n=548	  all,	  n=426	  colon)
c	  Calculated	  on	  all	  surgical	  paAents	  (n=551)
d	  Calculated	  on	  surgical	  paAents	  with	  known	  AJCC	  stage	  (n=548)
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Discussion
A	  high	  percentage	  of	  metastaAc	  CRC	  (31%)	  was	  found	  in	  this	  unselected	  hospital	  
populaAon	  of	  CRC	  paAents.	  The	  most	  notable	  change	  in	  treatment	  planning	  was	  observed	  
in	  performing	  no	  resecAon	  of	  the	  primary	  tumor	  in	  emergency	  surgery	  for	  colon	  cancer	  
when	  staging	  was	  done	  before	  surgery,	  as	  a	  consequence	  of	  diagnosing	  incurable	  disease	  
before	  surgery	  (15%	  in	  the	  SCT	  group	  versus	  3%	  in	  non-­‐SCT	  group).	  CuraAve	  treatment	  of	  
LM	  was	  more	  oTen	  done	  in	  the	  group	  of	  paAents	  that	  were	  staged	  (24%	  versus	  16%)	  and	  
included	  a	  change	  in	  immediate	  treatment	  planning	  in	  8	  paAents.	  Staging	  did	  not	  aﬀect	  the	  
treatment	  plan	  for	  PC.	  
Does	  the	  outcome	  represent	  popula2on	  based	  incidences?
In	  this	  hospital	  populaAon	  a	  small	  referral	  bias	  may	  be	  present;	  paAents	  with	  primary	  cT1	  
rectal	  tumors	  are	  referred	  for	  a	  TEM	  procedure	  in	  another	  hospital,	  few	  paAents	  with	  cT4	  
rectal	  cancer	  were	  referred	  to	  another	  hospital	  for	  intra-­‐operaAve	  radiotherapy	  and	  few	  
paAents	  were	  referred	  to	  the	  study	  center	  for	  both	  colorectal	  and	  liver	  surgery.	  The	  
esAmated	  referral	  bias	  is	  small	  and	  the	  incidences	  are	  expected	  to	  represent	  a	  fairly	  good	  
reﬂecAon	  of	  the	  populaAon	  incidences	  in	  this	  region.	  In	  a	  populaAon	  based	  analysis	  on	  
synchronous	  metastaAc	  CRC	  in	  the	  southern	  region	  of	  the	  Netherlands,	  an	  incidence	  of	  
22%	  (RC)	  to	  25%	  (CC)	  was	  found	  and	  had	  increased	  in	  the	  last	  decade.19	  This	  increase	  over	  
Ame	  is	  probably	  due	  to	  changing	  staging	  rouAnes.	  The	  incidence	  of	  metastaAc	  CRC	  in	  the	  
study	  populaAon	  is	  higher	  (31%).	  This	  may	  be	  an	  eﬀect	  of	  the	  introducAon	  of	  rouAne	  
staging	  with	  abdominal	  CT	  in	  this	  region	  that	  has	  preceded	  naAonal	  guideline	  
recommendaAons,	  and	  the	  prospecAve	  registraAon	  which	  probably	  increased	  the	  
awareness	  of	  the	  surgical	  team.	  Scanning	  protocols	  may	  inﬂuence	  the	  results	  as	  well;	  
exisAng	  variances	  in	  the	  use	  of	  intravenous	  contrast,	  slice	  thickness	  and	  reconstrucAons	  
can	  all	  inﬂuence	  the	  accuracy	  of	  abdominal	  CT	  in	  detecAng	  advanced	  disease.	  Another	  
possible	  contribuAng	  factor	  may	  be	  regional	  characterisAcs.	  The	  study	  hospital	  is	  situated	  
in	  a	  region	  that	  has	  a	  lower	  than	  average	  socio-­‐economic	  status	  and	  subjecAvely	  more	  
oTen	  delayed	  presentaAon	  to	  health	  care	  providers	  as	  compared	  to	  more	  urban	  regions	  in	  
the	  Netherlands.	  The	  proporAon	  of	  paAents	  with	  PC	  in	  the	  total	  cohort	  (8%)	  is	  probably	  an	  
underesAmaAon	  of	  the	  real	  incidence,	  due	  to	  inclusion	  of	  paAents	  that	  had	  no	  surgery	  
(10%	  of	  total	  cohort);	  abdominal	  CT	  underesAmates	  the	  presence	  of	  PC.
	  
Change	  in	  treatment	  plan	  as	  an	  outcome	  of	  the	  staging	  abdominal	  CT
Advanced	  colorectal	  cancer	  is	  present	  in	  a	  large	  proporAon	  of	  paAents	  (58%).	  The	  main	  
determinant	  for	  incurable	  advanced	  disease	  is	  metastaAc	  CRC	  (80%).	  In	  incurable	  disease	  
the	  focus	  of	  treatment	  is	  towards	  palliaAve	  care	  and	  can	  moAvate	  a	  change	  in	  treatment	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strategy.	  Staging	  leading	  to	  a	  change	  in	  surgical	  procedure	  was	  observed	  in	  this	  study,	  but	  
no	  diﬀerence	  in	  respect	  to	  performing	  no	  surgery	  at	  all,	  which	  was	  unexpected.	  This	  may	  
be	  due	  to	  diﬀerences	  in	  mo2va2on	  not	  to	  perform	  surgery;	  in	  the	  non-­‐SCT	  group	  the	  
majority	  of	  these	  paAents	  (8	  out	  of	  11)	  either	  refused	  further	  treatment	  or	  died	  before	  the	  
diagnosAc	  trajectory	  was	  ﬁnished,	  while	  in	  the	  SCT	  group	  the	  ﬁnding	  of	  incurable	  
metastaAc	  CRC	  on	  the	  staging	  CT	  was	  the	  main	  reason	  (in	  41	  from	  61	  paAents).	  The	  
necessity	  for	  surgery	  is	  highly	  dependent	  on	  the	  symptoms	  of	  the	  primary	  tumor,	  which	  
varies	  from	  asymptomaAc	  to	  obstrucAon,	  perforaAons	  and	  hemorrhagic	  complicaAons.	  
Also	  the	  paAents	  vary	  in	  age	  and	  physical	  condiAon.	  The	  evidence	  of	  a	  potenAal	  beneﬁt	  
from	  a	  palliaAve	  resecAon	  versus	  palliaAve	  treatment	  without	  resecAon,	  remains	  
conﬂicAng	  but	  tends	  to	  conclude	  the	  beneﬁt	  does	  not	  outweigh	  the	  risks	  of	  a	  resecAon.
16-­‐18,	  20	  AlternaAve	  procedures	  such	  as	  an	  enterostomy	  (via	  a	  small	  incision	  guided	  on	  
abdominal	  CT	  or	  laparoscopy)	  or	  bypass	  surgery	  in	  obstrucAve	  tumors,	  and	  radiotherapy	  in	  
bleeding	  tumors	  can	  be	  considered	  on	  an	  individual	  basis,	  as	  an	  alternaAve	  to	  resecAon	  in	  
incurable	  disease.	  In	  emergency	  presentaAons,	  these	  minimal	  invasive	  procedures	  may	  be	  
able	  to	  serve	  as	  a	  ‘bridge	  to	  deﬁniAve	  curaAve	  surgery’	  to	  achieve	  curaAon	  in	  a	  larger	  
proporAon	  of	  paAents.	  CuraAve	  treatment	  for	  LM	  was	  more	  oTen	  done	  in	  the	  SCT	  group	  
and	  included	  changes	  in	  Aming	  of	  the	  respecAve	  surgical	  procedures	  for	  the	  primary	  tumor	  
and	  LM.	  There	  is	  growing	  evidence	  these	  alternate	  strategies	  for	  LM	  are	  more	  beneﬁcial	  in	  
terms	  of	  eligibility	  of	  resecAon	  and	  the	  oncological	  outcome,10,	  11,	  21	  	  underlining	  the	  
relevance	  of	  staging	  before	  treatment.	  This	  observaAonal	  study	  cannot	  prove	  that	  the	  
chance	  on	  curaAve	  treatment	  of	  LM	  is	  higher	  when	  staging	  is	  done	  before	  treatment,	  
because	  of	  other	  diﬀerences	  between	  SCT	  and	  non-­‐SCT	  group.	  
	   The	  present	  study	  conﬁrms	  the	  ﬁnding	  of	  previous	  studies	  that	  PC	  is	  poorly	  visualized	  
on	  a	  CT	  scan.22	  This	  explains	  the	  current	  observaAon	  that	  PC	  is	  most	  oTen	  diagnosed	  
during	  surgery	  rather	  than	  during	  the	  pre-­‐operaAve	  work-­‐up.	  In	  the	  recent	  past	  PC	  was	  
regarded	  as	  a	  virtually	  incurable	  condiAon	  with	  lifle	  treatment	  opAons	  and	  therefore	  
accurate	  staging	  of	  PC	  was	  considered	  less	  important.	  This	  has	  changed	  since	  the	  
introducAon	  of	  HIPEC	  oﬀering	  a	  chance	  for	  cure	  in	  selected	  paAents.6,	  12,	  13	  Since	  HIPEC	  is	  
performed	  in	  specialized	  centers	  only,	  accurate	  pre-­‐operaAve	  staging	  of	  PC	  has	  become	  
vital	  to	  improve	  the	  outcome	  of	  these	  paAents.	  A	  high	  index	  of	  suspicion	  should	  be	  present	  
in	  paAents	  with	  locally	  advanced	  tumors	  since	  PC	  is	  present	  in	  a	  relevant	  proporAon	  of	  
these	  paAents	  (24%).	  A	  promising	  imaging	  technique	  in	  this	  respect	  may	  be	  diﬀusion-­‐
weighted	  imaging	  (DWI)	  combined	  with	  MRI	  which	  is	  thought	  to	  be	  more	  sensiAve	  to	  
detect	  and	  esAmate	  the	  extent	  of	  PC.23	  
	   LACC	  is	  present	  in	  a	  relevant	  proporAon	  of	  paAents	  (29%)	  with	  high	  incidence	  of	  
concurrent	  distant	  metastases	  (46%).	  Extensive	  local	  disease	  can	  be	  a	  reason	  for	  referral	  or	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palliaAve	  treatment.	  The	  ﬁnding	  of	  LACC	  on	  CT	  can	  be	  a	  reason	  for	  choosing	  a	  ‘bridge	  to	  
deﬁniAve	  surgery’	  in	  emergency	  surgery	  or	  when	  referral	  is	  considered.	  Such	  a	  staged	  
treatment	  plan	  will	  probably	  enlarge	  chances	  on	  a	  radical	  resecAon	  and	  can	  especially	  in	  
emergency	  surgery,	  avoid	  added	  morbidity	  and	  mortality.	  Reducing	  morbidity	  enhances	  
the	  afainability	  of	  adjuvant	  treatment	  and	  possibly,	  also	  treatment	  of	  synchronous	  
metastases.	  Perhaps	  more	  aggressive	  mulA-­‐modality	  treatment	  will	  be	  able	  to	  improve	  the	  
oncological	  outcome	  in	  LACC,	  such	  as	  with	  neo-­‐adjuvant	  chemotherapy24	  or	  radiotherapy,
25	  similar	  to	  the	  current	  approaches	  in	  LARC.7,	  26-­‐28	  
Op2mizing	  staging	  rou2nes	  before	  treatment
Staging	  tended	  to	  be	  omifed	  in	  especially	  emergency	  paAents,	  that	  are	  most	  at	  risk	  for	  
metastaAc	  disease	  and	  surgical	  mortality.	  Also	  speciﬁcally	  in	  this	  group	  it	  could	  have	  had	  
consequences	  for	  the	  immediate	  treatment	  plan	  as	  was	  observed	  in	  the	  staged	  group.	  This	  
is	  an	  important	  lead	  point	  for	  improvement.	  MulAslice	  CT	  scanning	  does	  not	  need	  to	  meet	  
logisAc	  obstacles	  in	  both	  elecAve	  and	  emergency	  presentaAons.
	   Liver	  metastases	  are	  less	  oTen	  treated	  with	  curaAve	  intent	  than	  considered	  eligible	  by	  
expert	  centers.21,	  29,	  30	  CT	  images,	  contrary	  to	  ultrasound,	  are	  reproducible	  and	  can	  be	  
implemented	  for	  (external)	  evaluaAon	  on	  eligibility	  of	  curaAve	  treatment	  by	  specialized	  
liver	  surgeons.	  UnderreporAng	  and	  underesAmaAon	  of	  small	  liver	  lesions	  result	  in	  an	  
apparently	  high	  radiological	  accuracy	  of	  abdominal	  CT,31	  however	  non-­‐reporAng	  of	  
indeterminate	  lesions	  will	  decrease	  the	  ability	  to	  signal	  LM	  on	  the	  staging	  CT.	  
DiscriminaAon	  of	  indeterminate	  liver	  lesions	  with	  addiAonal	  imaging	  causes	  no	  major	  
diagnosAc	  uncertainAes	  and	  resources,	  as	  was	  observed	  with	  indeterminate	  pulmonary	  
lesions.1-­‐3	  The	  necessity	  of	  intra-­‐operaAve	  ultrasound	  as	  the	  last	  step	  in	  the	  staging	  
procedure	  preceding	  hepaAc	  metastasectomy21	  was	  conﬁrmed	  in	  this	  study,	  with	  
cancellaAon	  of	  hepaAc	  metastasectomy	  in	  20%	  of	  paAents.	  Abdominal	  MRI	  is	  an	  equivalent	  
alternaAve	  to	  mulAslice	  CT	  scanning	  for	  LM,32	  however	  causes	  more	  logisAc	  problems.	  
	   The	  focus	  of	  staging	  has	  primarily	  been	  to	  ﬁnd	  distant	  metastases;	  the	  relevance	  of	  
determining	  cT	  stage	  became	  more	  evident	  during	  this	  study,	  towards	  esAmaAng	  
resectability	  and	  as	  a	  sign	  for	  possible	  PC.	  EsAmaAon	  of	  T	  stage	  on	  abdominal	  CT	  in	  this	  and	  
another	  study	  seems	  to	  be	  reliable.33	  Standardized	  radiology	  reports	  may	  enhance	  the	  
diagnosAc	  accuracy	  of	  T-­‐stage	  of	  CC	  on	  CT.
	   The	  absence	  of	  advanced	  disease	  idenAﬁes	  paAents	  with	  ‘common’	  curable	  CRC	  who	  
do	  not	  need	  addiAonal	  preoperaAve	  measures.	  These	  paAents	  do	  not	  necessarily	  need	  to	  
be	  discussed	  in	  a	  mulAdisciplinary	  oncological	  team	  before	  surgery;	  by	  leaving	  this	  group	  
out	  of	  the	  discussion	  based	  on	  staging	  outcome,	  the	  limited	  available	  Ame	  can	  be	  reserved	  
for	  discussing	  more	  complicated	  cases	  with	  advanced	  disease.
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Background.	  PreoperaAve	   staging	  of	   paAents	  with	   colorectal	   carcinoma	  (CRC)	   has	  
the	  potenAal	   beneﬁt	   of	   altering	   treatment	   opAons	  when	   metastases	   are	   present.	  
The	  clinical	  value	  of	  chest	  computed	  tomography	  (CT)	  in	  staging	  remains	  unclear.
Materials	  and	  Methods.	  All	  paAents	  who	  undergo	  colorectal	  surgery	  in	  our	   hospital	  
are	   prospecAvely	   registered,	   including	   paAent, 	   treatment,	   and	   histopathological	  
characterisAcs;	  outcome;	  and	  follow-­‐up.	  Since	  January	  2007,
rouAne	   preoperaAve	   staging	  CT	  of	   chest	   and	   abdomen	   for	   paAents	   with	   CRC	   has	  
been	  performed	  as	  part	  of	  our	  regional	  guidelines.	  In	  this	  observaAonal	  cohort	  study,	  
an	  analysis	  on	  outcome	  was	  done	  aTer	  inclusion	  of	  200	  consecuAve	  paAents.
Results.	  Synchronous	  metastases	  were	  present	  in	  60	  paAents	  (30%).	  Staging	  chest	  CT	  
revealed	   pulmonary	  metastases	   in	   6	   paAents,	  with	   1	   false	   posiAve	   ﬁnding.	   In	   50	  
paAents	  indeterminate	   lesions	  were	  seen	  on	  chest	  CT	  (25%).	  These	  were	  diagnosed	  
during	  follow-­‐up	  as	  true	  metastases	  (n=8),	  bronchus	  carcinoma	  (n=2),	  benign	  lesions	  
(n=25),	   and	   remaining	   unknown	   (n=15).	   UlAmately,	   synchronous	   pulmonary	  
metastases	  were	  diagnosed	   in	   13	  paAents	  (7%),	   in	   6	   paAents	  conﬁned	   to	   the	   lung	  
(3%).	  In	  none	  of	  the	  paAents	  the	  treatment	  plan	  for	  the	  primary	  tumor	  was	  changed	  
based	  on	  the	  staging	  chest	  CT.
Conclusion.	  The	  low	  incidence	  of	  pulmonary	  metastases	  and	  minimal	   consequences	  
for	   the	   treatment	   plan	   limits	   the	  clinical	   value	   of	   rouAne	   staging	  chest	   CT	   before	  
operaAon.	   It	   has	   several	   disadvantages	   such	   as	   costs,	   radiaAon	   exposure,	   and	  
prolonged	   uncertainty	   because	   of	   the	   frequent	   ﬁnding	   of	   indeterminate	   lesions.	  
Based	  on	  this	  study,	  a	  rouAne	  staging	  chest	  CT	  in	  CRC	  paAents	  is	  not	  advocated.
Background
PreoperaAve	  staging	  of	  paAents	  with	  colorectal	  carcinoma	  (CRC)	  has	  the	  potenAal	  beneﬁt	  
of	  altering	  treatment	  opAons	  when	  metastases	  are	  found.	  Synchronous	  metastases	  are	  
usually	  detected	  in	  the	  liver,	  lung	  and	  peritoneal	  cavity.	  Staging	  with	  abdominal	  CT	  for	  liver	  
metastases	  has	  resulted	  in	  various	  new	  approaches	  aimed	  at	  increasing	  the	  chance	  on	  
curaAve	  treatment.	  It	  seems	  a	  logical	  next	  step	  to	  apply	  this	  approach	  on	  synchronous	  
pulmonary	  metastases	  as	  well.	  Pre-­‐operaAve	  staging	  with	  CT	  of	  chest	  and	  abdomen	  in	  a	  
rouAne	  ‘one-­‐stop	  shop’	  sexng	  also	  has	  a	  logisAcal	  advantage,	  saving	  Ame	  for	  both	  paAent	  
and	  physician.	  The	  clinical	  beneﬁt	  of	  a	  staging	  chest	  CT	  however,	  has	  been	  controversial.	  
There	  are	  few	  studies	  describing	  the	  outcome	  and	  clinical	  relevance	  of	  a	  staging	  chest	  CT.
1-­‐5	  The	  main	  problem	  of	  staging	  with	  chest	  CT	  lies	  in	  the	  frequent	  ﬁnding	  of	  indeterminate	  
lesions	  (20-­‐30%).	  	  These	  lesions	  are	  usually	  diﬃcult	  to	  determine	  and	  seldom	  malignant	  
(10-­‐20%).1,	  3	  The	  main	  advice	  is	  not	  to	  delay	  treatment	  of	  the	  primary	  tumor	  or	  of	  liver	  
metastases	  when	  indeterminate	  lesions	  are	  found.2,	  3,	  6	  The	  outcome	  can	  be	  debated,	  
because	  in	  most	  of	  these	  studies	  the	  number	  of	  paAents	  was	  limited	  or	  were	  carried	  out	  
more	  then	  10	  years	  ago.	  Accurate	  staging	  is	  increasingly	  important	  in	  the	  oncological	  
mulAdisciplinary	  treatment	  plan	  of	  CRC.	  Rapid	  technical	  advancements	  and	  increasing	  
knowledge	  due	  to	  histopathological	  correlaAon	  studies	  7,	  8	  enhance	  the	  determinaAon	  of	  
pulmonary	  anomalies	  on	  chest	  CT.	  For	  these	  reasons	  rouAne	  staging	  with	  abdominal	  and	  
chest	  CT	  was	  decided	  upon	  as	  a	  part	  of	  our	  regional	  guidelines	  for	  colorectal	  cancer.	  The	  
aim	  of	  this	  study	  was	  to	  analyze	  the	  outcome	  and	  clinical	  beneﬁt	  of	  rouAne	  staging	  with	  
chest	  CT	  aTer	  inclusion	  of	  a	  consecuAve	  series	  of	  200	  paAents	  with	  colorectal	  cancer.	  
Methods
The	  Medical	  Spectrum	  Twente	  is	  a	  large	  teaching	  hospital	  in	  the	  Eastern	  part	  of	  the	  
Netherlands	  that	  funcAons	  as	  a	  referral	  center	  for	  liver	  and	  lung	  surgery.	  All	  paAents	  
operated	  in	  our	  hospital	  for	  CRC	  are	  prospecAvely	  registered	  in	  a	  database	  designed	  for	  
colorectal	  surgery,	  including	  paAent	  -­‐,	  treatment-­‐	  and	  histopathological	  characterisAcs,	  
outcome	  and	  follow-­‐up.	  From	  January	  2007,	  rouAne	  pre-­‐operaAve	  staging	  CT	  of	  chest	  and	  
abdomen	  for	  paAents	  with	  CRC	  was	  performed	  as	  part	  of	  our	  regional	  CRC	  guidelines,	  
when	  feasible.	  An	  analysis	  on	  beneﬁt	  was	  intended	  aTer	  inclusion	  of	  200	  paAents	  with	  
staging	  CT	  of	  chest	  and	  abdomen	  as	  a	  prospecAve	  observaAonal	  cohort	  study.	  
	   All	  paAents	  with	  colon	  and	  rectal	  cancer	  presented	  to	  our	  department,	  also	  those	  with	  
an	  urgent	  or	  acute	  presentaAon,	  were	  included.	  When	  due	  to	  acute	  circumstances	  a	  
staging	  CT	  scan	  could	  not	  be	  performed	  before	  operaAon,	  this	  was	  done	  within	  1	  month	  
aTer	  the	  operaAon.	  PaAents	  with	  rectal	  cancer	  at	  0-­‐10	  cm	  from	  the	  anal	  verge	  were	  
addiAonally	  staged	  with	  a	  pelvic	  MRI	  for	  esAmaAon	  of	  the	  local	  invasion	  (cTN	  stage).	  In	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case	  of	  cT4	  tumours	  or	  cT3	  tumours	  with	  a	  distance	  <	  1	  mm	  from	  the	  mesorectal	  fascia,	  a	  
long	  schedule	  chemoradiaAon	  consisAng	  of	  25x2	  Gy	  combined	  with	  oral	  capecitabine	  was	  
given,	  followed	  by	  surgery	  6	  to	  8	  weeks	  later.	  In	  case	  of	  cT3	  tumours	  with	  a	  distance	  of	  >	  1	  
mm	  from	  the	  mesorectal	  fascia,	  a	  short	  schedule	  radiotherapy	  consisAng	  of	  5x5	  Gy	  was	  
given,	  followed	  by	  surgery	  in	  the	  following	  week.	  Both	  according	  to	  the	  Dutch	  guidelines	  
for	  rectal	  cancer.	  A	  CT	  scan	  of	  chest	  and	  abdomen	  was	  performed	  on	  a	  16	  and	  64	  slice	  
scanner	  (Toshiba	  Aquillion	  16	  and	  64)	  aTer	  intravenous	  contrast	  injecAon	  (visipaque	  320,	  
90	  ml,	  3ml/s.),	  in	  the	  portal	  venous	  phase,	  with	  a	  slice	  thickness	  of	  1	  mm	  and	  a	  
reconstrucAon	  of	  0.8	  mm.	  Lesions	  were	  evaluated	  on	  density,	  number	  of	  lesions,	  
morphology,	  localizaAon	  and	  size.	  The	  lesions	  found	  on	  chest	  CT	  were	  deﬁned	  by	  the	  
radiologists	  as	  benign,	  malignant	  or	  indeterminate.	  Indeterminate	  lesions	  are	  deﬁned	  as	  
lesions	  seen	  on	  chest	  CT	  that	  could	  not	  be	  judged	  by	  the	  radiologist	  as	  either	  benign	  or	  
malignant.	  
	   Follow-­‐up	  was	  done	  in	  all	  paAents	  when	  feasible	  and	  consisted	  of	  3-­‐monthly	  visits	  with	  
CEA	  measurements,	  according	  to	  the	  naAonal	  guidelines.	  Indeterminate	  pulmonary	  lesions	  
were	  re-­‐evaluated	  during	  follow-­‐up,	  with	  consideraAon	  of	  individual	  paAents’	  
circumstances.	  The	  deﬁniAve	  diagnosis	  of	  pulmonary	  metastases	  was	  based	  on	  imaging	  
(aspect	  and	  growth	  rate	  on	  CT	  and/or	  PET	  scanning)	  or	  histological	  conﬁrmaAon.	  
Indeterminate	  pulmonary	  lesions	  were	  considered	  benign	  when	  there	  were	  no	  signs	  of	  
malignant	  growth	  on	  repeat	  chest	  CT	  and	  no	  increase	  in	  CEA	  aTer	  at	  least	  one	  year	  of	  
follow-­‐up.	  
Results
The	  200	  paAents	  were	  included	  between	  January	  2007	  and	  August	  2008	  (Table	  1).	  ElecAve	  
procedures	  were	  done	  in	  164	  paAents	  (81%).	  Urgent	  or	  acute	  procedures	  were	  done	  in	  36	  
paAents	  (19%)	  of	  whom	  16	  paAents	  had	  a	  staging	  CT	  aTer	  the	  surgical	  procedure.	  Findings	  
during	  follow-­‐up	  All	  July	  2009	  were	  taken	  into	  the	  analysis.
	   Synchronous	  metastases	  in	  the	  liver,	  lung	  and/or	  peritoneal	  cavity	  were	  found	  in	  60	  
paAents	  of	  the	  study	  group	  (30%)	  (Table	  2).	  Pulmonary	  metastases	  were	  diagnosed	  on	  the	  
iniAal	  chest	  CT	  in	  6	  paAents	  (3%).	  In	  one	  of	  these	  six	  paAents	  the	  pulmonary	  lesion	  turned	  
out	  to	  be	  benign	  aTer	  resecAon.	  Indeterminate	  lesions	  were	  seen	  on	  50	  staging	  chest	  CT’s	  
(25%)	  (Figure	  1).	  AddiAonal	  diagnosAc	  procedures	  done	  during	  follow-­‐up	  for	  indeterminate	  
lesions	  were	  a	  repeat	  chest	  CT	  scan	  in	  29	  paAents,	  a	  PET	  scan	  in	  11	  paAents,	  and	  a	  
bronchoscopy	  and	  percutaneous	  needle	  biopsy	  in	  4	  paAents	  (Table	  3).	  In	  2	  paAents	  the	  
percutaneous	  needle	  biopsy	  resulted	  in	  a	  small	  pneumothorax,	  in	  1	  of	  4	  paAents	  a	  deﬁnite	  
histological	  diagnosis	  could	  be	  made.	  In	  eight	  paAents	  the	  indeterminate	  lesions	  were	  
diagnosed	  as	  pulmonary	  metastases	  (16%),	  in	  two	  paAents	  as	  primary	  bronchus	  carcinoma,	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in	  25	  paAents	  as	  benign	  lesions	  and	  in	  15	  paAents	  no	  diagnosis	  was	  made	  (ﬁgure	  1).	  The	  
Ame	  to	  ﬁnal	  diagnosis	  of	  the	  indeterminate	  lesions	  took	  three	  months	  up	  to	  one	  year	  aTer	  
resecAon	  of	  the	  primary	  tumor.	  
	   UlAmately,	  13	  of	  the	  200	  study	  paAents	  had	  synchronous	  pulmonary	  metastases	  (7%)	  
(Table	  2	  and	  4).	  In	  6	  paAents	  the	  metastases	  were	  conﬁned	  to	  the	  lung	  (3%).	  Four	  of	  these	  
6	  paAents	  had	  no	  mesenterial	  lymph	  node	  metastases	  at	  the	  primary	  tumor	  site.	  The	  
prevalence	  of	  synchronous	  lung	  metastases	  was	  higher	  in	  paAents	  with	  rectal	  cancer	  (0-­‐15	  
cm	  from	  the	  anal	  verge)	  (7	  out	  of	  71,	  10%)	  than	  in	  paAents	  with	  colon	  cancer	  (6	  out	  of	  129,	  
5%).	  Three	  paAents	  with	  rectal	  tumours	  that	  had	  neo-­‐adjuvant	  treatment	  (radiaAon	  or	  
chemoradiaAon)	  turned	  out	  to	  have	  lung	  metastases	  (3	  out	  of	  40,	  8%)	  (Table	  4).	  From	  the	  
47	  paAents	  with	  liver	  metastases,	  6	  paAents	  also	  had	  lung	  metastases	  (13%).	  In	  two	  of	  six	  
paAents	  that	  had	  a	  convenAonal	  chest	  X-­‐ray	  as	  well,	  the	  metastasis	  were	  visible	  on	  chest	  X-­‐
ray.	  In	  none	  of	  the	  paAents	  with	  either	  lung	  metastases	  or	  indeterminate	  lesions	  the	  neo-­‐
adjuvant	  or	  operaAve	  plan	  for	  the	  primary	  tumor	  was	  changed.	  In	  two	  paAents	  intended	  
curaAve	  metastasectomy	  of	  true	  pulmonary	  metastases	  was	  done,	  both	  paAents	  had	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Figure	  1.	  Outcome	  of	  staging	  chest	  CT	  in	  pa>ents	  with	  CRC
All	  numbers	  refer	  to	  the	  number	  of	  paaents
*	  Reasons
No	  evalua)on:	  in	  these	  paaents	  the	  absence	  of	  presence	  of	  pulmonary	  metastases	  would	  
have	  no	  consequences	  for	  (further)	  treatment,	  such	  as	  with	  incurable	  metastases	  on	  other	  
locaaons	  or	  the	  wish	  of	  the	  paaents	  to	  receive	  no	  further	  treatment.
Deceased:	  paaents	  that	  died	  during	  hospital	  stay	  or	  within	  3	  months	  a*er	  discharge.
LTFU:	  lost	  to	  follow-­‐up,	  both	  paaents	  were	  referred	  to	  other	  hospitals	  for	  reasons	  other	  
then	  the	  indeterminate	  pulmonary	  lesions.




























Resecaon	  of	  the	  primary	  tumor 199 99%
Neo-­‐adjuvant	  treatment
Neo-­‐adjuvant	  chemoradiaaon	  rectal	  carcinoma










































@	  Neo-­‐adjuvant	  treatment	  was	  given	  to	  paaents	  with	  rectal	  carcinoma	  cT3-­‐4N1-­‐2	  on	  MRI,	  
located	  at	  0-­‐10	  cm	  (lowest	  border	  of	  the	  tumor)	  from	  the	  anal	  verge.	  From	  40	  paaents	  that	  
received	  neo-­‐adjuvant	  radiaaon	  or	  chemoradiaaon,	  11	  had	  indeterminate	  lesions	  on	  chest	  CT.
*	  This	  paaent	  iniaally	  received	  palliaave	  chemotherapy	  for	  asymptomaac	  disease	  and	  incurable	  
liver	  metastases.	  This	  strategy	  was	  changed	  when	  the	  primary	  tumor	  became	  symptomaac.
#	  Complete	  regression	  a*er	  neo-­‐adjuvant	  chemoradiaaon	  for	  rectal	  carcinoma	  (cT3-­‐4N1-­‐2)
†	  In	  this	  table,	  metastases	  that	  were	  suspected	  on	  staging	  CT	  and	  conﬁrmed	  during	  follow-­‐up	  
were	  classiﬁed	  as	  AJCC	  stage	  IV.	  Suspected	  metastases	  that	  were	  resected	  and	  histologically	  
benign,	  were	  classiﬁed	  as	  stage	  II	  or	  III	  disease.	  This	  overview	  therefore	  represents	  the	  actual	  
oncological	  status	  in	  the	  study	  cohort.
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TABLE	  2	  Localization	  of	  diagnosed	  synchronous	  distant	  metastases	  (n=60)
Incidence Cura>ve	  resec>on
Value % Value %
Liver	  metastases 47 24% 13† 28%
Lung	  metastases 13 7% 2# 15%
Peritoneal	  metastases 11 6% 1* 9%






























This	  table	  shows	  the	  deﬁnite	  classiﬁcaaon	  a*er	  staging,	  operaaon	  and	  addiaonal	  tesang	  in	  case	  
of	  indeterminate	  lesions.
†	  Only	  actual	  curaave	  resecaons	  of	  liver	  metastases	  were	  counted
#	  Both	  paaents	  had	  recurrent	  disease	  a*er	  curaave	  resecaon	  at	  5	  and	  10	  months	  post-­‐
operaavely
*	  HIPEC
TABLE	  3	  Additional	  diagnostic	  tests	  for	  indeterminate	  lesions	  
PaAents
Pa>ents	  with	  indeterminate	  pulmonary	  lesions	  (n=50) n=
Regular	  follow-­‐up	  without	  addiAonal	  diagnosAcs 9
Repeat	  chest	  CT	  scan 29
PET	  scan 11
Bronchoscopy 4
Percutaneous	  needle	  biopsy 4
Mulaple	  diagnosac	  procedures	  were	  usually	  done	  in	  a	  single	  paaent.
36
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Immediate	  diagnosis:	  diagnosed	  on	  staging	  CT.	  Delayed	  diagnosis:	  diagnosed	  a*er	  addiaonal	  diagnosac	  
procedures.	  RCT:	  chemoradiaaon,	  RT:	  short	  course	  radiotherapy	  (5x5	  Gy).	  cT:	  cT	  stage	  on	  pelvic	  MRI.	  PC:	  
peritoneal	  carcinomatosis
Size:	  largest	  pulmonary	  lesion	  on	  the	  staging	  CT.	  Number:	  either	  single	  (S)	  or	  mulaple	  (M).	  *	  These	  
lesions	  were	  primarily	  diagnosed	  as	  primary	  bronchus	  carcinoma,	  histology	  showed	  it	  were	  CRC	  
metastases.
Discussion
Like	  in	  preceding	  studies,	  this	  study	  shows	  the	  limited	  clinical	  value	  of	  a	  rouAne	  
preoperaAve	  staging	  chest	  CT	  in	  colorectal	  cancer	  paAents.	  The	  incidence	  of	  lung	  
metastases	  is	  low	  (7%),	  especially	  those	  that	  are	  conﬁned	  to	  the	  lung	  (3%).	  Only	  in	  5	  
paAents	  lung	  metastases	  were	  diagnosed	  before	  treatment	  of	  the	  primary	  tumor	  (2.5%).	  
Indeterminate	  lesions	  on	  chest	  CT	  are	  frequently	  found	  (in	  25%	  of	  paAents)	  and	  
discriminaAon	  between	  benign	  and	  malignant	  lesions	  is	  oTen	  diﬃcult.	  Only	  a	  minority	  turn	  
out	  to	  be	  metastases	  (16%).	  Staging	  with	  chest	  CT	  did	  not	  result	  in	  a	  change	  of	  the	  
treatment	  plan	  for	  the	  primary	  tumor,	  nor	  resulted	  in	  curaAve	  treatment	  of	  pulmonary	  
metastases.	  It	  does	  cause	  diagnosAc	  dilemmas,	  prolonged	  uncertainty	  and	  requires	  
resources.
	   The	  clinical	  relevance	  of	  staging	  on	  distant	  metastases	  is	  highly	  dependent	  on	  the	  
consequences	  for	  the	  treatment	  plan.	  Colorectal	  surgery	  knows	  a	  considerable	  morbidity	  
and	  mortality,	  which	  can	  be	  reduced	  when	  the	  presence	  of	  incurable	  disease	  is	  diagnosed	  
before	  the	  operaAon.	  For	  asymptomaAc	  paAents	  with	  widespread	  metastases,	  only	  
chemotherapeuAc	  treatment	  might	  be	  preferable.	  Also	  in	  symptomaAc	  paAents	  with	  
incurable	  disease,	  treatment	  alternaAves	  such	  as	  stenAng	  for	  impending	  bowel	  
obstrucAon,	  limited	  surgery	  with	  only	  colostomy,	  or	  radiaAon	  therapy	  in	  bleeding	  rectal	  
tumors,	  might	  be	  befer	  alternaAves.	  Curable	  metastases	  found	  on	  the	  staging	  CT	  can	  
result	  in	  alternaAve	  strategies	  such	  as	  neo-­‐adjuvant	  chemotherapy,	  ‘liver-­‐ﬁrst’	  approach	  or	  
simultaneous	  resecAons.	  Intended	  curaAve	  resecAon	  of	  synchronous	  liver	  metastases	  can	  
be	  done	  in	  an	  esAmated	  25%	  -­‐	  40%	  of	  paAents.9,	  10	  Consequently,	  accurate	  staging	  before	  
resecAon	  of	  colorectal	  cancer	  has	  become	  a	  requirement	  for	  opAmal	  oncological	  
treatment.	  Abdominal	  CT	  is	  a	  very	  reliable	  diagnosAc	  tool	  for	  liver	  metastases	  and	  has	  
proven	  to	  be	  befer	  than	  non	  contrast	  enhanced	  ultrasound.9,	  11,	  12	  However,	  where	  
accurate	  staging	  of	  the	  liver	  has	  resulted	  in	  changes	  in	  treatment	  plans	  and	  possible	  
favorable	  outcome,	  this	  does	  not	  seem	  to	  be	  true	  for	  pulmonary	  staging	  in	  this	  study.	  
Several	  reasons	  were	  found	  that	  contribute	  to	  the	  suggested	  diﬀerence	  between	  
synchronous	  liver	  and	  lung	  metastases.	  The	  incidence	  of	  lung	  metastases	  is	  much	  lower	  
(7%)	  and	  the	  curaAve	  opAons	  for	  synchronous	  lung	  metastases	  are	  very	  limited	  or	  may	  be	  
even	  non-­‐existent.14	  This	  might	  be	  due	  to	  the	  bad	  prognosis	  of	  synchronous	  pulmonary	  
metastases	  as	  an	  expression	  of	  tumor	  behavior,	  as	  has	  been	  suggested	  by	  other	  authors.13,	  
14,	  15	  Metastases	  conﬁned	  to	  the	  lung	  are	  rare	  (3%)	  and	  limits	  the	  value	  of	  a	  rouAne	  staging	  
chest	  CT	  when	  no	  metastases	  are	  found	  on	  the	  staging	  abdominal	  CT.	  
	   Small	  nodules	  are	  oTen	  seen	  on	  chest	  CT	  and	  are	  usually	  benign,	  as	  was	  also	  found	  by	  
Brent	  and	  Kronawifer.1,	  3	  The	  diﬃculty	  with	  these	  lesions	  is	  that	  these	  are	  usually	  too	  small	  
(between	  0.5	  and	  1	  cm)	  to	  evaluate	  on	  radiological	  characterisAcs	  such	  as	  density	  and	  
38
shape.	  DeterminaAon	  of	  the	  nature	  of	  these	  lesions	  has	  proven	  to	  be	  rather	  diﬃcult.	  PET	  
scanning	  has	  the	  same	  disadvantage	  of	  a	  limited	  discriminaAve	  capacity	  for	  small	  lesions.	  
Percutaneous	  needle	  biopsies	  for	  small	  lesions	  can	  be	  technically	  diﬃcult	  and	  are	  prone	  to	  
sampling	  error;	  when	  the	  histological	  result	  doesn’t	  show	  a	  malignancy	  a	  metastasis	  is	  sAll	  
not	  excluded.	  It	  can	  however	  be	  harmful,	  because	  of	  the	  risk	  of	  pneumothorax	  and	  
bleeding	  complicaAons.	  In	  this	  study	  it	  took	  several	  months	  up	  to	  one	  year	  aTer	  resecAon	  
of	  the	  primary	  tumor	  before	  the	  indeterminate	  lesions	  could	  be	  classiﬁed.	  Our	  deﬁniAon	  of	  
a	  benign	  lesion,	  which	  is	  no	  growth	  and	  no	  serum-­‐CEA	  increase	  aTer	  one	  year,	  however	  is	  
a	  mere	  assumpAon	  and	  no	  deﬁniAve	  prove	  the	  lesion	  is	  truly	  benign.	  On	  the	  other	  hand,	  
the	  duraAon	  and	  absence	  of	  clinically	  relevant	  disease	  does	  imply	  there	  is	  no	  need	  trying	  to	  
ﬁnd	  these	  lesions	  before	  treatment	  of	  the	  primary	  tumor.	  Staging	  with	  chest	  CT	  during	  
follow-­‐up	  might	  be	  a	  befer	  alternaAve.
	   The	  diagnosAc	  diﬃculAes	  of	  ﬁndings	  on	  chest	  CT	  are	  also	  reﬂected	  in	  literature.	  The	  
reported	  incidence	  of	  synchronous	  pulmonary	  metastases	  of	  colorectal	  cancer	  varies	  
largely,	  from	  3	  to	  18%.1,	  3,	  4,	  6	  This	  is	  likely	  inﬂuenced	  by	  the	  applied	  deﬁniAon	  of	  pulmonary	  
metastases,	  which	  is	  usually	  a	  derived	  deﬁniAon	  due	  to	  a	  lack	  of	  obtainable	  histological	  
proof.	  In	  this	  study	  neither	  the	  ‘golden’	  standard	  for	  false	  or	  true	  metastases	  was	  available.	  
Because	  of	  the	  used	  criteria	  for	  true	  metastases	  and	  study	  design,	  the	  real	  incidence	  might	  
be	  slightly	  underesAmated.	  It	  is	  however	  a	  close	  approximaAon	  of	  the	  number	  of	  paAents	  
with	  clinically	  relevant	  lung	  metastases	  in	  a	  non-­‐selected	  populaAon.
	   We	  agree	  with	  previous	  authors	  1,	  2,	  3,	  6	  that	  small	  lesions	  on	  chest	  CT	  (<	  1	  cm)	  should	  be	  
considered	  of	  limited	  clinical	  relevance	  and	  ignored	  in	  choosing	  the	  iniAal	  treatment	  plan.	  
The	  ﬁnding	  of	  large	  pulmonary	  metastases	  might	  change	  the	  treatment	  plan,	  but	  these	  
kinds	  of	  metastases	  are	  rare	  and	  oTen	  visible	  on	  chest	  X-­‐ray.	  Few	  studies	  compared	  staging	  
chest	  CT	  with	  chest	  X-­‐ray.	  Two	  studies	  compared	  a	  negaAve	  chest	  X-­‐ray	  with	  outcome	  on	  
chest	  CT	  in	  pre-­‐operaAve	  staging	  1,	  6	  concluding	  that	  a	  staging	  chest	  CT	  had	  lifle	  to	  no	  
addiAonal	  value.	  One	  other	  study	  compared	  ﬁndings	  on	  staging	  chest	  X-­‐ray	  with	  chest	  CT.	  2	  
This	  study	  showed	  that	  in	  4	  out	  of	  7	  paAents	  the	  pulmonary	  metastases	  were	  visible	  on	  
chest	  X-­‐ray.	  	  This	  number	  is	  comparable	  to	  the	  2	  out	  of	  6	  visible	  metastases	  on	  chest	  X-­‐ray	  
in	  this	  study.
	   Concerning	  the	  change	  of	  treatment	  plan	  in	  case	  of	  resectable	  liver	  metastases,	  
pulmonary	  staging	  with	  chest	  CT	  seems	  the	  best,	  most	  sensiAve	  opAon	  to	  exclude	  
extrahepaAc	  disease.	  EvaluaAon	  of	  consequences	  for	  hepaAc	  metastasectomy	  was	  not	  the	  
aim	  of	  this	  study	  and	  the	  paAent	  group	  is	  too	  small	  to	  draw	  conclusions;	  in	  the	  5	  paAents	  
with	  synchronous	  liver-­‐	  and	  lung	  metastases,	  the	  liver	  metastases	  were	  not	  resectable.	  
Povoski	  6	  did	  study	  this	  speciﬁc	  paAent	  group	  and	  concluded	  that	  chest	  CT	  had	  only	  
minimally	  improved	  detecAon	  of	  malignant	  lesions	  of	  the	  lung	  over	  chest	  X-­‐ray.	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   It	  is	  reasonable	  to	  argue	  that	  selected	  paAents	  might	  beneﬁt	  from	  a	  staging	  chest	  CT	  
instead	  of	  chest	  X-­‐ray.	  For	  instance	  paAents	  with	  compromised	  health	  that	  are	  about	  to	  
undergo	  major	  surgical	  procedures	  for	  hepaAc	  or	  peritoneal	  carcinomatosis	  or	  paAents	  
that	  will	  receive	  neo-­‐adjuvant	  treatment	  for	  rectal	  cancer.	  The	  lafer	  group	  also	  because	  
pulmonary	  metastases	  seem	  to	  occur	  more	  oTen	  in	  rectal	  cancer	  than	  in	  colon	  cancer	  and	  
the	  operaAve	  procedure	  might	  be	  more	  extensive.	  In	  our	  study	  the	  proporAon	  of	  paAents	  
with	  rectal	  cancer,	  especially	  located	  0-­‐10	  cm	  from	  the	  anal	  verge,	  is	  too	  small	  to	  draw	  
straighorward	  conclusions	  for	  this	  speciﬁc	  group	  but	  deserves	  further	  study.	  It	  is	  however	  
likely	  the	  same	  problem	  with	  indeterminate	  lesions	  on	  chest	  CT	  will	  occur.	  Future	  studies	  
on	  imaging	  techniques	  with	  a	  higher	  discriminaAve	  capacity	  for	  small	  pulmonary	  nodules	  
remain	  required	  to	  improve	  staging	  in	  high-­‐risk	  paAent	  groups.	  
	   Relevant	  disadvantages	  other	  then	  the	  diagnosAc	  diﬃculAes	  of	  rouAne	  chest	  CT	  are	  the	  
signiﬁcant	  radiaAon	  exposure	  and	  costs;	  rouAne	  staging	  with	  CT	  of	  the	  chest	  together	  with	  
CT	  of	  the	  abdomen	  is	  twice	  as	  expensive	  and	  induces	  twice	  as	  much	  radiaAon	  exposure.	  
When	  indeterminate	  lesions	  are	  seen,	  it	  may	  further	  cause	  a	  prolonged	  period	  of	  
uncertainty,	  unnecessary	  anxiety	  for	  paAents	  and	  relaAves	  and	  possibly	  lead	  to	  a	  delay	  in	  
neo-­‐adjuvant,	  surgical	  and	  adjuvant	  treatment.	  The	  need	  for	  addiAonal	  diagnosAc	  
procedures	  such	  as	  repeat	  chest	  CT’s	  with	  a	  summaAve	  radiaAon	  exposure,	  PET	  scanning	  
or	  percutaneous	  needle	  biopsies,	  further	  increases	  costs	  and	  possible	  harm	  to	  the	  paAent.	  
	   To	  conclude,	  in	  our	  opinion	  rouAne	  staging	  of	  colorectal	  cancer	  paAents	  with	  chest	  CT	  is	  
not	  advocated	  based	  on	  these	  study	  results.	  We	  believe	  that	  deﬁning	  high-­‐risk	  paAent	  
groups	  and	  predicAve	  factors	  for	  pulmonary	  metastases	  followed	  by	  either	  immediate	  
staging	  in	  selected	  paAents	  or	  ‘delayed’	  staging	  with	  chest	  CT	  during	  follow-­‐up	  might	  be	  a	  
befer	  and	  less	  expensive	  alternaAve	  to	  idenAfy	  paAents	  with	  pulmonary	  metastases.	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surgeons	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Objec>ve. 	  Follow-­‐up	  aTer	   curaAve	  resecAon	  of	  colorectal	  carcinoma	  (CRC)	  has	  been	  
subjected	   to	  debate	  concerning	  its	  eﬀecAveness	  to	  reduce	  cancer	  mortality.	  Current	  
naAonal	   and	   internaAonal	   guidelines	   advise	   CEA	   measurements	   every	   3	   months	  
during	  3	  years	  aTer	   surgery.	  The	  common	  clinical	  pracAce	  and	  opinion	  about	  follow-­‐
up	   for	   colorectal	   carcinoma,	   was	   evaluated	   by	  means	   of	   a	   survey	   among	   Dutch	  
general	  surgeons.
Methods.	  A	  web-­‐based	   survey	  of	   follow-­‐up	   aTer	   treatment	   of	   CRC	  was	  sent	   to	   all	  
registered	   Dutch	  general	   surgeons.	  A	  reply	  from	  246	  surgeons	  treaAng	  paAents	  for	  
colorectal	   carcinoma	  in	   105	  out	  of	  118	  hospitals	  was	  received	  (response	   rate	  91%).	  
QuesAons	  related	  to	  actual	   followup	  protocol, 	  opinion	  about	  serum	  CEA	  monitoring,	  
liver	   and/or	   lung	   metastasectomy,	   and	   moAvaAon	   to	   parAcipate	   in	   a	   new	   trial	  
concerning	  follow-­‐up.
Results.	  For	  the	  majority	  of	  surgeons	  the	  length	   of	  follow-­‐up	  was	  inﬂuenced	   by	  age	  
of	   the	   paAent	   (62%)	   and	   physical	   condiAon	   (76%)	   prohibiAng	   hepaAc	  
metastasectomy.	   The	   generally	   accepted	   follow-­‐up	   protocol	   consisted	   of	   CEA	  
measurements	   every	   3	   months	   in	   the	   ﬁrst	   year	   and	   six-­‐monthly	   thereaTer, 	   and	  
ultrasound	  examinaAon	   of	  the	  liver	  every	  6	  months.	  Nearly	  all	   surgeons	  (92%)	  were	  
willing	  to	  parAcipate	  in	  a	  new	  study	  of	  follow-­‐up	  protocol.
Conclusion.	   The	   adherence	   to	   naAonal	   guidelines	   for	   the	   follow-­‐up	   of	   colorectal	  
carcinoma	   is	   low.	   The	   indisAnctness	   about	   follow-­‐up	   aTer	   curaAve	   treatment	   of	  
colorectal	   carcinoma	   also	   aﬀects	  clinical	   pracAce.	  Recent	   advancements	   in	   imaging	  
techniques,	  liver	   and	   lung	   surgery	  have	   changed	   circumstances,	  which	   are	  not	   yet	  
anAcipated	  upon	   in	   current	   guidelines.	   Renewal	   of	   follow-­‐up	   based	  upon	   scienAﬁc	  
evidence	  is	  required.
Introduc>on
There	  is	  controversy	  regarding	  follow-­‐up	  aTer	  curaAve	  resecAon	  of	  colorectal	  carcinoma	  
(CRC)	  regarding	  its	  eﬀecAveness	  in	  reducing	  cancer	  mortality.	  No	  clinical	  trial	  or	  meta-­‐
analysis	  has	  unequivocally	  shown	  a	  beneﬁt	  on	  paAent	  survival.1–6	  In	  the	  past	  30	  years,	  
several	  afempts	  have	  been	  made	  to	  improve	  survival,	  either	  by	  advancements	  in	  
treatment	  or	  changing	  the	  protocol	  of	  follow-­‐up.	  Only	  serum	  CEA	  has	  proven	  to	  be	  of
(limited)	  value,	  with	  consistent	  results	  on	  lead	  Ame	  but	  inconsistent	  results	  on	  survival.1,7–
17	  Current	  guide-­‐lines18–22	  therefore	  advise	  CEA	  measurement	  every	  3	  months	  over	  3	  years.	  
To	  detect	  metachronous	  second	  colorectal	  malignancy,	  colonoscopy	  is	  advised	  every	  3	  
years.20	  Dutch	  guidelines	  are	  similar	  to	  those	  advised	  by	  the	  American	  Society	  of	  Clinical	  
Oncology.	  The	  lack	  of	  solid	  evidence	  on	  the	  beneﬁt	  of	  follow-­‐up	  has	  raised	  the	  quesAon	  
whether	  follow-­‐up	  should	  be	  conAnued.	  Technical	  developments	  in	  imaging	  and	  increased	  
use	  of	  liver	  and	  lung	  surgery	  for	  metastaAc	  disease	  outdate	  present	  guidelines	  since	  they	  
sAll	  reﬂect	  the	  results	  from	  studies	  that	  were	  done	  before	  these	  developments.
	   A	  survey	  was	  undertaken	  among	  Dutch	  general	  surgeons	  treaAng	  paAents	  with	  
colorectal	  carcinoma	  to	  assess	  the	  opinion	  on	  diagnosAc	  methods	  used	  in	  follow-­‐	  up,	  the	  
adherence	  to	  naAonal	  guidelines	  concerning	  CEA	  measurement,	  and	  the	  treatment	  of	  
recurrent	  disease.	  The	  moAvaAon	  of	  the	  respondents	  to	  parAcipate	  in	  new	  studies	  
concerning	  follow-­‐up	  was	  also	  evaluated.
Methods
A	  request	  to	  complete	  a	  web-­‐based	  survey	  was	  sent	  to	  all	  registered	  general	  surgeons	  in	  
the	  Netherlands	  (n=878).	  A	  reply	  was	  received	  from	  246	  surgeons	  treaAng	  paAents	  with	  
colorectal	  carcinoma	  from	  105	  diﬀerent	  hospitals	  out	  of	  a	  total	  of	  116	  hospitals	  in	  the	  
Netherlands	  with	  a	  surgical	  department,	  giving	  a	  response	  rate	  of	  91%.	  To	  detect	  possible	  
bias	  through	  diﬀerences	  in	  response	  rate	  within	  hospitals,	  the	  outcome	  was	  also	  calculated	  
using	  only	  one	  representaAve	  per	  hospital.	  In	  comparison	  with	  the	  outcome	  from	  all	  246	  
surgeons,	  there	  were	  no	  diﬀerences.	  The	  survey	  included	  17	  quesAons,	  with	  a	  total	  of
seven	  free	  answers	  that	  were	  categorized	  aTerwards.	  They	  related	  to	  the	  indicaAon	  for	  
follow	  up,	  actual	  local	  follow-­‐up	  pracAce,	  applicaAon	  of	  serum	  CEA	  measurement	  and
opinion	  about	  serum	  CEA	  monitoring	  in	  follow	  up.	  The	  use	  and	  availability	  of	  other	  
diagnosAc	  methods,	  both	  for	  screening	  and	  evaluaAon	  of	  suspected	  metastases,	  and	  
pracAce	  concerning	  treatment	  of	  liver	  and	  lung	  metastases	  were	  evaluated.	  Finally	  the	  




Each	  surgeon	  treated	  approximately	  30	  paAents	  with	  CRC	  per	  year.	  The	  length	  of	  follow	  up	  
was	  inﬂuenced	  by	  age	  according	  to	  62%	  (n	  =	  153)	  and	  physical	  condiAon	  prohibiAng	  
hepaAc	  metastasectomy	  according	  to	  76%	  (n	  =	  187).	  Usually	  aTer	  the	  age	  of	  80	  years	  
follow-­‐up
was	  limited.	  In	  Table	  1,	  the	  percentage	  of	  surgeons	  who	  adhered	  to	  a	  certain	  follow-­‐up	  test	  
at	  a	  speciﬁc	  moment	  is	  given.	  In	  general	  CEA	  was	  measured	  with	  a	  lower	  intensity	  than
guideline	  advice,	  especially	  in	  the	  second	  and	  third	  year,	  and	  ultrasound	  was	  used	  
regularly.	  Colonoscopy	  was	  regularly	  done	  in	  year	  1,	  3	  and	  5	  and	  one-­‐third	  requested	  a	  
yearly	  chest	  X-­‐ray.	  The	  majority	  of	  surgeons	  (65%,	  n	  1/4	  161)	  used	  the	  thresholds	  for	  the	  
CEA	  value	  as	  suggested	  in	  the	  quesAonnaire	  as	  follows:	  CEA	  <	  5	  ng/ml:	  no	  acAon,	  CEA	  >	  5	  <	  
10	  ng/ml:	  monthly	  measurement,	  evaluaAon	  for	  recurrent	  disease	  when	  CEA	  is	  rising,	  CEA	  
>	  10	  ng/
ml:	  evaluaAon	  for	  recurrent	  disease.	  CEA	  was	  not	  measured	  at	  all	  by	  6%	  of	  respondents,	  
CEA-­‐rise	  or	  doubling	  Ame	  was	  used	  by	  14%,	  a	  lower	  threshold	  was	  applied	  by	  7%	  and	  a	  
higher	  threshold	  by	  2%.	  
The	  majority	  (67%)	  chose	  helical	  computed	  tomography	  (CT)	  scanning	  of	  the	  chest	  and	  
abdomen	  for	  evaluaAon	  of	  suspected	  recurrent	  disease,	  followed	  by	  positron	  emission	  
tomography	  (PET)	  scanning	  when	  nothing	  is	  found	  on	  CT.	  Ultrasound	  was	  added	  by	  11%	  of	  
surgeons	  and	  colonoscopy	  by	  4%.	  A	  one-­‐third	  of	  surgeons	  (31%)	  treaAng	  colorectal	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Table	  1.	  Follow-­‐up	  scheme,	  current	  practice
Year 1 2 3 4 5
Month 3 6 9 12 3 6 9 12 3 6 9 12 6 12 6 12
Physical examination 89 78 50 78 17 72 16 74 4 49 5 47 30 55 26 66
CEA 63 78 50 83 20 69 20 78 8 47 8 74 28 60 25 67
Ultrasound liver 11 44 10 58 4 36 3 56 2 22 3 48 9 36 7 44
Chest X-ray 5 18 5 32 1 13 1 29 - 8 1 26 4 19 3 25
Colonoscopy 2 7 2 65 2 5 - 16 3 2 8 38 5 18 3 35
CT Abdomen 1 2 1 8 1 2 1 5 1 1 1 5 1 2 1 4
CT chest - 1 1 4 1 1 1 1 1 - 1 1 1 1 1 1
All numbers are %, in whole percentages. All % > 35 are black, between 15 and 35% dark grey 
and < 15% in light grey
carcinoma	  carried	  out	  liver	  resecAons	  as	  well.	  Analysis	  of	  the	  opinion	  concerning	  the	  
eligibility	  criteria	  for	  hepaAc	  metastasectomy	  was	  done	  for	  the	  whole	  group	  and	  separately	  
for	  the	  liver	  surgeons.	  A	  large	  majority	  of	  all	  surgeons	  (93%)	  concurred	  with	  liver	  and	  lung	  
resecAons	  for	  metastasectomy.	  A	  minority	  (27%)	  did	  not	  consider	  liver	  resecAon	  indicated	  
when	  resectable	  extrahepaAc	  disease	  was	  present.	  There	  is	  no	  disagreement	  on	  these	  two	  
criteria	  among	  the	  liver	  surgeons.	  Liver	  surgeons	  expressed	  a	  diﬀerent	  opinion	  on	  the	  
eligibility	  for	  hepaAc	  metastasectomy	  when	  lymph	  node	  involvement	  in	  the	  
hepatoduodenal ligament and bilobar disease were present.	  They	  considered	  these	  ﬁndings	  
to	  be	  less	  oTen	  a	  contraindicaAon	  for	  surgery	  (Table	  2).	  The	  majority	  of	  surgeons	  (76%)	  felt	  
that	  the	  number	  of	  metastases	  was	  not	  a	  decisive	  criterion	  for	  metastasectomy.	  When	  the	  
number	  of	  metastases	  was	  considered	  important,	  a	  maximum	  of	  three	  to	  ﬁve	  was	  
generally	  regarded	  as	  being	  amenable	  to	  surgery.
	   Nearly	  all	  surgeons	  (92%)	  were	  willing	  to	  parAcipate	  in	  a	  new	  study	  concerning	  
follow-­‐up.	  When	  imaging	  was	  added	  to	  the	  proposed	  new	  follow-­‐up	  scheme,	  ultrasound	  
was	  preferred	  above	  CT	  scan	  of	  the	  abdomen	  by	  general	  surgeons.	  When	  the	  results	  were	  
analysed	  for	  surgeons	  who	  also	  perform	  liver	  surgery,	  CT	  scanning	  was	  preferred	  above	  
ultrasound.	  Generally	  imaging	  every	  6	  months	  in	  the	  ﬁrst	  2	  years	  and	  every	  year	  in	  years	  
three,	  four	  and	  ﬁve	  was	  supported	  by	  the	  respondents	  (Table	  3).	  The	  most	  important	  
exclusion	  criteria	  for	  metastasectomy	  included	  age	  and	  physical	  condiAon.
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Macroscopic	  resectable	  metastases 96,1% 98,6%
Bilobar	  localizaAon 81,6% 96,1%
Lymph	  node	  metastases	  in	  hepatoduodenal	  ligament 17,3% 33,3%
Resectable	  extrahepaAc	  disease 73,2% 68,4%
Resectable	  lung	  metastases 92,6% 88,2%
Number	  of	  metastases	  is	  a	  criterion 23,5% 19,7%
Discussion
The	  results	  of	  this	  survey	  are	  highly	  representaAve	  for	  the	  current	  follow-­‐up	  aTer	  surgical	  
treatment	  for	  paAents	  with	  colorectal	  cancer	  in	  the	  Netherlands.	  The	  high	  response	  rate	  is	  
likely	  due	  to	  the	  easy	  accessibility	  of	  the	  survey	  on	  the	  web,	  and	  the	  present	  interest	  in	  
surgery	  for	  metastases.	  The	  results	  of	  this	  survey	  reﬂect	  the	  doubts	  and	  uncertainty	  in	  
follow-­‐up	  and	  treatment	  opAons	  for	  recurrent	  disease	  (Table	  4).	  Age	  and	  poor	  physical	  
condiAon	  are	  the	  main	  reasons	  which	  limit	  follow-­‐up.	  At	  least	  a	  quarter	  of	  surgeons	  did
not	  consider	  that	  age	  or	  physical	  condiAon	  should	  prohibit	  further	  surgical	  treatment,	  and	  
a	  reason	  therefore	  to	  limit	  follow-­‐up.	  Frequently	  expressed	  arguments	  for	  regular	  
outpaAent	  visits	  include	  quality	  control	  of	  surgical	  treatment	  and	  psychosocial	  
consideraAons.	  Both
arguments	  are	  controversial.23–26	  The	  median	  Ame	  aTer	  which	  recurrent	  disease	  is
detected	  (disease	  free	  interval)	  is	  approximately	  0.5–2	  years	  for	  liver	  metastasis,	  2–3	  years	  
for	  lung	  metastasis	  and	  0.5–1.5	  years	  for	  local	  recurrence.10,11,14,17,27–29,31–34	  The	  Ame	  aTer	  
which	  metastasis	  or	  local	  recurrence	  are	  diagnosed	  varies	  with	  the	  diagnosAc
methods	  used14,15,29–32	  and	  the	  detecAon	  of	  local	  recurrence	  might	  also	  be	  dependent	  on	  
the	  site	  of	  the	  primary	  tumour	  (colon	  or	  rectum).	  The	  common	  pracAce	  concerning	  CEA	  
measurement,	  despite	  the	  recommendaAon	  in	  naAonal	  guidelines,	  limited	  the	  three	  
monthly	  measurements	  to	  the	  ﬁrst	  year.	  ATer	  that	  the	  intensity	  of	  controls	  diminished	  to	  
every	  6	  months	  or	  more.	  Actual	  measurement	  was	  oTen	  even	  lower	  and	  never	  more	  then	  
50%	  for	  CEA	  measurement	  at	  each	  moment	  (unpublished	  results).	  Thus	  the	  present	  clinical	  
pracAce	  did	  not	  anAcipate	  the	  early	  appearance	  of	  recurrent	  disease.	  This	  might	  lead	  to	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Table	  3	  and	  4.	  Suggested	  imaging	  in	  follow-­‐up
Year 1 2 3 4 5
Month 3 6 9 12 3 6 9 12 3 6 9 12 6 12 6 12
All	  surgeons	  
Ultrasound 17 54 14 57 5 40 4 57 2 26 2 51 11 35 10 46
CT	  Abdomen 3 27 2 50 1 22 1 42 2 7 2 30 4 16 4 25
Liver	  surgeons
Ultrasound 19 43 20 32 4 26 4 39 1 22 1 30 10 23 8 28
CT	  Abdomen 4 39 1 65 1 35 1 54 1 7 1 28 5 15 4 20
All	  numbers	  are	  %,	  in	  whole	  percentages.	  All	  %	  >	  35	  are	  black,	  between	  15	  and	  35%	  dark	  grey	  and	  <	  
15%	  in	  light	  grey
missing	  more	  recurrent	  disease	  than	  is	  necessary.	  The	  logisAc	  burden	  of	  follow-­‐up	  might	  be	  
another	  reason	  for	  the	  low	  adherence	  to	  guidelines	  as	  others	  have	  reported.10,30,35	  
Finding	  eﬀecAve	  logisAc	  ways	  to	  ensure	  adherence	  to	  guidelines	  might	  enhance	  the	  
eﬀecAveness	  of	  follow-­‐up.	  A	  further	  reason	  to	  omit	  CEA	  from	  follow-­‐up	  that	  was	  
menAoned	  by	  several	  surgeons	  in	  this	  survey	  was	  that	  a	  normal	  preoperaAve	  CEA	  would	  
mean	  that	  it	  will	  not	  rise	  when	  recurrence	  occurs.	  This,	  however,	  is	  not	  valid.	  A	  normal	  
preoperaAve	  CEA	  is	  present	  in	  approximately	  50%	  of	  all	  paAents	  with	  CRC,	  and	  50%	  will	  
rise	  with	  recurrent	  disease.	  Thus	  25%	  will	  miss	  a	  chance	  of	  early	  detecAon	  when	  CEA	  
follow-­‐up	  is	  omifed.	  A	  majority	  of	  surgeons	  added	  ultrasound	  as	  a	  screening	  tool	  in	  their	  
follow-­‐up,	  though	  this	  was	  not	  included	  in	  the	  naAonal	  guidelines.	  This	  may	  be	  because	  
one	  regional	  guideline	  advises	  ultrasound	  when	  preoperaAve	  CEA	  is	  normal.	  Another	  
reason	  might	  be	  low	  conﬁdence	  in	  the	  value	  of	  CEA	  as	  a	  tumour	  marker,	  and	  the	  increasing	  
conﬁdence	  in	  imaging.	  In	  recent	  years	  major	  advances	  have	  been	  made	  in	  imaging.	  The	  
present	  mulAslice	  helical	  CT	  scan	  can	  detect	  liver	  and	  lung	  metastasis	  when	  its	  diameter	  
exceeds	  approximately	  0.5	  cm.	  It	  is	  feasible	  therefore	  to	  localize	  recurrent	  disease	  in	  lung	  
and	  liver	  as	  soon	  as	  CEA	  exceeds	  its	  threshold.15,27,36	  Thus	  a	  major	  problem	  in	  the	  past	  has	  
ﬁnally	  been	  solved.	  When	  CEA	  rises,	  recurrent	  disease	  can	  usually	  be	  localized	  and,	  where	  
feasible,	  treatment	  can	  be	  iniAated	  immediately.	  The	  ability	  of	  ultrasound	  examinaAon	  to	  
detect	  liver	  metastasis	  is	  less	  sensiAve.	  EvaluaAon	  is	  limited	  to	  the	  liver,	  while	  lung	  
metastases	  are	  also	  frequently	  curable.	  Considering	  this,	  the	  role	  of	  regular	  hepaAc	  
ultrasound	  in	  follow-­‐up	  is	  quesAonable	  when	  helical	  CT	  scanning	  of	  thorax	  and	  abdomen	  is	  
available	  instead.	  The	  frequency	  of	  performing	  a	  CT	  scan	  however,	  is	  limited	  by	  availability,	  
cost	  and	  the	  potenAal	  health	  risk	  of	  radiaAon	  exposure.	  More	  paAents	  seem	  eligible	  for	  
surgical	  treatment	  of	  metastaAc	  disease	  than	  appear	  to	  be	  eligible	  in	  the	  Netherlands.	  
Uncertainty	  exists	  regarding	  the	  criteria	  for	  liver	  resecAon	  for	  metastasis,	  as	  also	  shown	  in	  
another	  recent	  Dutch	  survey.37	  The	  diﬀerence	  of	  opinion	  between	  liver	  surgeons	  and	  
general	  surgeons	  on	  some	  criteria	  might	  be	  an	  expression	  of	  this	  ﬁnding.	  In	  the	  last	  10	  
years	  many	  criteria,	  that	  were	  previously	  considered	  contra-­‐indicaAons	  for	  
metastasectomy,	  are	  now	  being	  debated.	  Among	  these	  criteria	  are	  age,	  number	  and	  
localizaAon	  of	  metastasis,	  presence	  of	  resectable	  extrahepaAc	  disease	  and	  previous	  
metastasectomy.	  The	  increasing	  safety	  and	  technical	  advancements	  have	  resulted	  in	  more	  
older	  paAents	  becoming	  candidates	  for	  metastasectomy.	  Furthermore,	  many	  paAents	  with	  
disseminated	  colorectal	  carcinoma	  are	  relaAvely	  young	  at	  60–65	  years.	  The	  number	  and	  
involvement	  of	  mulAple	  segments	  of	  both	  liver	  and	  lung	  are	  not	  contraindicaAons,	  
provided	  they	  are	  completely	  resectable32,34,38–41	  although	  the	  Dutch	  general	  surgeons	  in	  
the	  survey	  oTen	  considered	  the	  metastasis	  count	  of	  liver	  metastasis	  (23.5%)	  and	  bilobar	  
involvement	  (18%)	  to	  prohibit	  resecAon.	  ResecAon	  of	  synchronous	  or	  metachronous	  lung	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metastases	  may	  result	  in	  long-­‐term	  survival	  equal	  to	  resectable	  metastasis	  conﬁned	  to	  only	  
one	  organ.33,34,42–44
Among	  the	  Dutch	  surgeons	  8–12%	  did	  not	  consider	  these	  paAents	  eligible	  for	  surgery.	  Re-­‐
resecAon	  of	  metastases	  of	  both	  lung	  and	  liver	  result	  in	  near	  equal	  survival	  rates	  as	  aTer	  the	  
ﬁrst	  metastasectomy.32,34,39–45	  The	  diﬀerences	  in	  opinion	  regarding	  eligibility	  for	  hepaAc	  
metastasectomy	  indicate	  ongoing	  advances	  in	  liver	  surgery,	  which	  allow	  more	  paAents	  to	  
be	  a	  candidate	  for	  curaAve	  surgery.	  The	  same	  appears	  to	  be	  true	  for	  lung	  metastasis.	  
	   There	  is	  considerable	  controversy	  about	  follow-­‐up	  aTer	  curaAve	  treatment	  of	  
colorectal	  carcinoma	  because	  it	  has	  thus	  far	  not	  been	  proven	  to	  increase	  survival	  or	  quality	  
of	  life.	  Meanwhile,	  recent	  rapid	  technical	  developments	  in	  imaging	  and	  advances	  in	  liver	  
and	  lung	  surgery	  have	  changed	  the	  circumstances.	  Review	  of	  the	  guidelines	  on	  follow-­‐up	  to	  
reﬂect	  these	  changes	  is	  required.	  The	  high	  moAvaAon	  among	  Dutch	  surgeons	  to	  parAcipate	  
in	  a	  new	  study	  appears	  to	  support	  this,	  making	  a	  naAonal	  trial	  feasible.
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Background.	  Carcinoembryonic	  anAgen	  (CEA)	  as	  a	  marker	   in	   the	   follow-­‐up	   aTer	  
curaAve	  resecAon	   of	  colorectal	   carcinoma	  (CRC)	  is	  oTen	  omifed	  from	  follow-­‐up	  
despite	  guideline	  recommendaAons.	  One	  reason	   is	  the	   assumpAon	  that	  when	  a	  
normal	   CEA	   value	   exists	   before	   curaAve	   resecAon	   of	   CRC,	   it	   will	   neither	   rise	  
during	  follow-­‐up.	  This	  study	  invesAgates	  this	  relaAonship.
Method.	  Data	  were	  derived	  from	  a	  study	  iniAated	  to	  evaluate	  treatment	  regimes	  
for	   rectal	  carcinoma	  (Dutch	  TME	   trial, 	  n=1861)	  from	  which	  954	  were	  eligible	  for	  
analysis.	  Recurrent	   disease	   occurred	   in	   272	   of	   these	   paAents	   (29.5%).	   The	  pre-­‐
operaAve	   CEA	   value	   was	   compared	   to	   CEA	   values	   during	   follow-­‐up,	   using	  
threshold	  values	  of	  2.5	  and	  5.0	  ng/ml.	  	  
Results.	  Normal	   pre-­‐operaAve	   CEA	  values	  were	  present	   in	   63%	   (CEA	  <	   5.0)	   and	  
39%	   (CEA	  <	  2.5)	  of	  paAents	  with	   recurrent	   disease.	  PaAents	  with	   a	  normal	  pre-­‐
operaAve	  CEA	  and	  recurrent	  disease	  had	  elevated	  CEA	  values	  during	  follow-­‐up	  in	  
41%	  (CEA	  <	  5.0),	  50%	  (CEA	  <	  2.5)	  and	  in	  60%	  with	  both	  threshold	  values	  when	  the	  
last	  measurement	  was	  within	  3	  months	  before	  recurrent	  disease	  was	  diagnosed.	  
Conclusion.	   A	   normal	   pre-­‐operaAve	   CEA	   is	   common	   in	   paAents	   with	   rectal	  
carcinoma.	  CEA	  does	  rise	  due	  to	  recurrent	  disease	  in	  at	  least	  50%	  of	  paAents	  with	  
normal	   pre-­‐operaAve	   values.	   Serial	   post-­‐operaAve	   CEA	   tesAng	   cannot	   be	  
discarded	  based	  on	  a	  normal	  pre-­‐operaAve	  serum	  CEA.	  
Introduc>on
Carcinoembryonic	  anAgen	  (CEA)	  as	  a	  marker	  in	  the	  follow-­‐up	  of	  colorectal	  carcinoma	  (CRC)	  
has	  been	  subjected	  to	  debate	  concerning	  it's	  eﬀecAveness	  to	  reduce	  cancer	  mortality.	  CEA	  
is	  known	  to	  have	  the	  ability	  to	  detect	  recurrent	  disease	  aTer	  curaAve	  resecAon	  of	  CRC	  at	  
an	  early	  stage,	  with	  approximately	  5	  months	  lead	  Ame	  compared	  to	  clinical	  signs	  and	  
several	  other	  tests.	  The	  eﬀect	  on	  survival	  is	  less	  clear,	  also	  due	  to	  the	  fact	  that	  only	  a	  
minority	  of	  metastasis	  can	  be	  treated	  with	  curaAve	  intent.	  Several	  follow-­‐up	  studies	  have	  
been	  done	  with	  contradicAng	  results,	  successively	  reﬂected	  in	  meta-­‐analyses	  and	  reviews	  
1-­‐6	  that	  conclude	  there	  is	  no	  consistent	  evidence	  that	  follow-­‐up	  increases	  survival.	  The	  
doubts	  about	  the	  value	  of	  CEA	  in	  follow-­‐up	  contributes	  to	  decreasing	  adherence	  to	  
guidelines	  from	  oncological	  socieAes,7-­‐10	  that	  generally	  advise	  to	  measure	  CEA	  every	  3	  
months	  in	  the	  ﬁrst	  3	  years.	  
	   Other	  arguments	  than	  lack	  of	  evidence	  may	  inﬂuence	  leaving	  CEA	  out	  of	  follow-­‐up	  as	  
well.	  One	  of	  these	  is	  the	  assumed	  relaAonship	  between	  serum	  CEA	  values	  before	  and	  aTer	  
curaAve	  surgery	  for	  colorectal	  carcinoma.	  Normal	  pre-­‐operaAve	  CEA	  values	  are	  oTen	  
considered	  a	  reason	  to	  omit	  serum	  CEA	  measurements	  from	  follow-­‐up,	  because	  it	  is	  widely	  
believed	  it	  will	  not	  rise	  with	  recurrent	  disease	  either.	  This	  belief	  is	  expressed	  in	  one	  
regional	  Dutch	  guideline	  advising	  ultrasound	  instead	  of	  CEA	  measurement	  when	  pre-­‐
operaAve	  levels	  are	  normal,	  and	  is	  also	  reported	  in	  a	  recent	  survey.11
	   The	  threshold	  value	  of	  CEA	  is	  dependent	  on	  agreement;	  the	  industrial	  standard	  is	  
2.0-­‐2.5	  ng/ml	  dependent	  on	  the	  actual	  test.	  Due	  to	  frequent	  false-­‐posiAve	  outcomes	  
caused	  by	  benign	  gastro-­‐intesAnal	  disorders	  and	  smoking,	  the	  generally	  adhered	  threshold	  
value	  in	  the	  follow-­‐up	  for	  colorectal	  carcinoma	  in	  the	  Netherlands	  is	  5.0	  ng/ml.	  	  
	   In	  literature	  only	  lifle	  evidence	  is	  available	  about	  the	  relaAonship	  between	  CEA	  values	  
before	  curaAve	  surgery	  and	  during	  follow-­‐up.	  Staab	  was	  the	  ﬁrst	  to	  describe	  the	  
relaAonship	  between	  serum	  CEA	  values:	  he	  observed	  that	  in	  40	  paAents	  with	  a	  normal	  pre-­‐
operaAve	  CEA	  value,	  none	  had	  risen	  during	  follow-­‐up.12	  Three	  other	  authors	  however,	  
published	  data	  that	  did	  demonstrate	  CEA	  elevaAons	  with	  recurrent	  disease	  when	  the	  
serum	  CEA	  value	  before	  intended	  curaAve	  treatment	  was	  normal.13-­‐15	  The	  goal	  of	  this	  study	  
is	  to	  evaluate	  the	  relaAonship	  between	  serum	  CEA	  values	  before	  and	  aTer	  curaAve	  
resecAon	  of	  rectal	  carcinoma.
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Pa2ents.	  An	  analysis	  was	  carried	  out	  on	  data	  derived	  from	  a	  study	  evaluaAng	  the	  value	  of	  
short	  course	  radiotherapy	  in	  primary	  resectable	  rectal	  carcinoma	  treated	  with	  
standardized	  surgery	  (Total	  Mesorectal	  Excision	  or	  TME	  trial)	  from	  the	  Dutch	  ColoRectal	  
Cancer	  group	  (DCRC-­‐group).	  Results	  of	  this	  study	  were	  published	  before.16,	  17	  The	  
registraAon	  included	  all	  actual	  CEA	  values	  that	  were	  measured.	  Serial	  CEA	  tesAng	  was	  
required	  every	  3	  months	  in	  the	  ﬁrst	  three	  years	  and	  every	  6	  months	  in	  year	  4	  and	  5,	  
according	  to	  the	  study	  protocol	  that	  was	  based	  on	  naAonal	  guidelines.	  From	  January	  1996	  
unAl	  December	  1999,	  1861	  paAents	  were	  included,	  and	  follow-­‐up	  data	  are	  registered	  unAl	  
March	  2006;	  the	  minimal	  follow-­‐up	  Ame	  is	  therefore	  more	  then	  6	  years.	  In	  this	  study,	  
paAents	  with	  stage	  0	  and	  IV	  were	  excluded.	  Of	  the	  remaining	  eligible	  paAents,	  the	  pre-­‐
operaAve	  CEA	  value	  and	  at	  least	  one	  post-­‐operaAve	  CEA	  value	  were	  required	  for	  inclusion	  
in	  this	  analysis.	  
	  
Methods.	  The	  deﬁniAon	  of	  "pre-­‐operaAve	  CEA"	  is	  the	  serum	  CEA	  value	  measured	  
immediately	  before	  curaAve	  resecAon	  of	  the	  primary	  tumour.	  "Post-­‐operaAve	  CEA"	  is	  the	  
serum	  CEA	  value	  aTer	  primary	  surgery	  during	  follow-­‐up.	  To	  analyze	  the	  rise	  of	  CEA	  aTer	  
curaAve	  resecAon	  in	  relaAonship	  to	  the	  pre-­‐operaAve	  CEA	  value,	  we	  compared	  pre-­‐
operaAve	  values	  to	  the	  maximum	  postoperaAve	  value.	  This	  was	  done	  both	  for	  the	  group	  
with	  and	  without	  recurrent	  disease.	  A	  separate	  analysis	  was	  performed	  for	  the	  group	  of	  
paAents	  with	  recurrent	  disease	  from	  whom	  the	  last	  post-­‐operaAve	  CEA	  was	  determined	  
less	  then	  3	  months	  before	  recurrent	  disease	  was	  diagnosed.	  To	  analyse	  the	  response	  of	  
CEA	  aTer	  curaAve	  surgery	  (expected	  decrease)	  we	  compared	  the	  pre-­‐operaAve	  CEA	  to	  the	  
minimum	  post-­‐operaAve	  value	  in	  both	  the	  paAents	  with	  and	  without	  recurrent	  disease.	  All	  
analyses	  are	  retrospecAvely	  done	  using	  two	  diﬀerent	  threshold	  values,	  being	  2.5	  ng/ml	  and	  




ATer	  exclusion	  of	  stage	  0	  and	  IV	  paAents,	  1701	  paAents	  were	  eligible	  for	  analysis.	  Stage	  I-­‐
II-­‐III	  rectal	  carcinoma	  was	  diagnosed	  in	  1665	  paAents,	  36	  paAents	  were	  not	  classiﬁed.	  Both	  
pre-­‐	  and	  postoperaAve	  CEA	  values	  were	  available	  in	  954	  paAents	  (56%).	  From	  these	  954	  
paAents,	  recurrent	  disease	  was	  diagnosed	  in	  282	  paAents	  (29.6%).	  PaAent	  demographics	  
and	  tumour	  characterisAcs	  are	  described	  in	  table	  1.	  The	  actual	  frequency	  of	  CEA	  
measurements	  was	  much	  lower	  then	  required	  and	  was	  never	  above	  50%	  at	  each	  moment	  
(ﬁgure	  1).
Rela2onship	  between	  pre-­‐	  and	  postopera2ve	  CEA	  levels
In	  paAents	  with	  recurrent	  disease	  (n=282),	  63%	  (n=179)	  had	  a	  normal	  CEA	  value	  prior	  to	  
primary	  surgery	  when	  apprehending	  a	  cut-­‐oﬀ	  value	  of	  5	  ng/ml.	  Post-­‐operaAve	  rise	  of	  the	  
CEA	  above	  this	  threshold	  occurred	  in	  41%	  (n=73).	  When	  a	  cut-­‐oﬀ	  value	  of	  2.5	  ng/ml	  was	  
used,	  39%	  (n=110)	  had	  normal	  pre-­‐operaAve	  CEA	  values.	  Elevated	  post-­‐operaAve	  values	  
were	  then	  found	  in	  50%	  (n=55)	  (table	  2).	  When	  the	  last	  CEA	  was	  measured	  within	  3	  
months	  before	  diagnosis	  of	  local	  recurrence	  or	  metastasis	  (n=127),	  CEA	  was	  elevated	  in	  
59%	  (with	  a	  threshold	  of	  5	  ng/ml)	  and	  61%	  (with	  a	  threshold	  of	  2.5	  ng/ml)(table	  3).	  
In	  paAents	  with	  no	  recurrent	  disease	  (n=672),	  77%	  (n=519)	  had	  normal	  pre-­‐operaAve	  CEA	  
values	  when	  apprehending	  a	  cut-­‐oﬀ	  value	  of	  5	  ng/ml.	  Post-­‐operaAve	  rise	  of	  the	  CEA	  above	  
this	  threshold	  during	  follow-­‐up	  occurred	  in	  4%	  (n=19).	  When	  a	  cut-­‐oﬀ	  value	  of	  2.5	  ng/ml	  
was	  used,	  50%	  (n=337)	  had	  normal	  pre-­‐operaAve	  CEA	  values.	  Elevated	  post-­‐operaAve	  
values	  were	  then	  found	  in	  13%	  (n=44).	  
	   In	  paAents	  with	  recurrent	  disease	  (n=282)	  and	  an	  elevated	  CEA	  value	  prior	  to	  primary	  
surgery	  (n=172	  at	  a	  threshold	  of	  2.5	  ng/ml,	  n=103	  at	  a	  threshold	  of	  5	  ng/ml),	  CEA	  values	  
were	  also	  elevated	  during	  follow-­‐up	  in	  79%	  (n=141	  at	  a	  threshold	  of	  2.5	  ng/ml)	  and	  82%	  
(n=81	  at	  a	  threshold	  of	  5	  ng/ml)	  (table	  2).
	   CEA	  values	  were	  normal	  aTer	  curaAve	  surgery	  in	  98%	  (n=658	  at	  a	  threshold	  of	  5	  ng/ml)	  
and	  86%	  (n=578	  at	  a	  threshold	  of	  2.5	  ng/ml)	  in	  all	  paAents	  without	  recurrent	  disease	  
(n=672)	  during	  follow-­‐up.	  When	  recurrent	  disease	  was	  diagnosed	  during	  follow-­‐up	  
(n=282),	  CEA	  values	  were	  normal	  at	  the	  ﬁrst	  measurement	  aTer	  curaAve	  surgery	  in	  81%	  
(n=228	  at	  a	  threshold	  of	  5	  ng/ml)	  and	  66%	  (n=186	  at	  a	  threshold	  of	  2.5	  ng/ml).
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Table	  1.	  Patient	  characteristics	  and	  tumour	  classification
Eligible	  pa>ents	  1	  
(n=1701)
Recurrent	  disease	  2	  
(n=282)
No	  recurrent	  disease	  3
(n=672)
Age	  



























1	  All	  paaents	  that	  are	  eligible	  for	  inclusion	  in	  this	  analysis	  (all	  minus	  stage	  0	  and	  IV	  paaents).	  2+3	  
Eligible	  paaents	  with	  known	  pre-­‐and	  postoperaave	  CEA	  values,	  in	  total	  954	  paaents.	  4	  Tumour	  
classiﬁcaaon	  according	  to	  the	  American	  Joint	  Commi_ee	  on	  Cancer	  (AJCC).
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On	  the	  X-­‐axis	  the	  moment	  in	  ame	  CEA	  is	  
recommended	  to	  be	  measured,	  in	  months	  
a*er	  primary	  surgery.
On	  the	  Y-­‐axis	  the	  percentage	  (%)	  of	  actual	  
measurements	  on	  that	  speciﬁc	  moment.
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Table	  2.	  Rela>onship	  between	  CEA	  values	  before	  and	  aaer	  cura>ve	  surgery	  1	  	  in	  pa>ents	  
with	  recurrent	  disease
n=282 Postopera>ve	  value	  <	  2.5 Postopera>ve	  value	  >	  2.5
Preopera>ve	  value	  <	  2.5 55 55	  (50%)2
Preopera>ve	  value	  >	  2.5 31 141
Postopera>ve	  value	  <	  5.0 Postopera>ve	  value	  >	  5.0
Preopera>ve	  value	  <	  5.0 106 73
Preopera>ve	  value	  >	  5.0 22 81
1	  The	  pre-­‐operaave	  value	  was	  compared	  to	  the	  highest	  CEA	  value	  measured	  during	  follow-­‐up.
2	  The	  percentage	  of	  all	  paaents	  with	  normal	  pre-­‐operaave	  CEA	  values	  (n=110)	  with	  elevated	  post-­‐operaave	  
values	  (n=55)
Table	  3.	  Rela>onship	  between	  CEA	  values	  before	  cura>ve	  surgery	  and	  at	  diagnosis	  of	  
recurrent	  disease1
n=127 Postopera>ve	  value	  <	  2.5 Postopera>ve	  value	  >	  2.5
Preopera>ve	  value	  <	  2.5 17 27	  (61%)2
Preopera>ve	  value	  >	  2.5 7 76
Postopera>ve	  value	  <	  5.0 Postopera>ve	  value	  >	  5.0
Preopera>ve	  value	  <	  5.0 28 40
Preopera>ve	  value	  >	  5.0 10 49
1	  CEA	  value	  measured	  within	  3	  months	  before	  the	  diagnosis	  of	  recurrent	  disease	  was	  established	  
2	  The	  percentage	  of	  all	  paaents	  with	  normal	  pre-­‐operaave	  CEA	  values	  (n=44)	  with	  elevated	  post-­‐operaave	  
values	  (n=27)
Discussion
Summary	  of	  the	  results
This	  study	  suggests	  that	  a	  normal	  pre-­‐operaAve	  CEA	  value	  does	  not	  mean	  it	  will	  not	  rise	  
with,	  and	  due	  to	  recurrent	  disease	  during	  follow-­‐up.	  A	  non-­‐elevated	  CEA	  at	  primary	  
diagnosis	  is	  common	  (50%),	  as	  well	  as	  a	  rise	  in	  CEA	  despite	  a	  normal	  pre-­‐operaAve	  CEA	  
(50%);	  this	  situaAon	  thus	  applies	  to	  a	  quarter	  of	  all	  colorectal	  cancer	  paAents.
Role	  of	  false-­‐posi2ve	  postopera2ve	  CEA	  levels	  inﬂuencing	  study	  results
Incidental	  rises	  in	  CEA	  due	  to	  benign	  disease	  or	  smoking	  are	  known	  and	  can	  be	  the	  cause	  of	  
‘falsely’	  elevated	  CEA	  levels	  during	  follow-­‐up.	  This	  may	  account	  for	  a	  part	  of	  the	  elevated	  
post-­‐operaAve	  CEA	  values	  in	  this	  study	  because	  a	  comparison	  was	  made	  of	  the	  pre-­‐
operaAve	  CEA	  value	  with	  the	  maximum	  CEA	  value	  during	  follow-­‐up.	  The	  proporAon	  of	  
these	  falsely	  elevated	  CEA	  levels	  was	  esAmated	  by	  performing	  the	  same	  analysis	  in	  
paAents	  with	  no	  recurrent	  disease.	  This	  turned	  out	  to	  be	  limited	  (4-­‐13%).	  Further	  the	  pre-­‐
operaAve	  CEA	  was	  compared	  with	  the	  CEA	  value	  at	  the	  Ame	  of	  the	  diagnosis	  of	  recurrent	  
disease,	  assuming	  at	  least	  these	  elevated	  CEA	  values	  are	  due	  to	  recurrent	  disease.	  The	  
percentage	  in	  this	  group	  was	  even	  higher	  (60%).	  The	  results	  of	  this	  study	  are	  in	  coherence	  
with	  other	  numbers	  reported	  in	  literature.13-­‐15
Value	  of	  CEA	  immediately	  a`er	  primary	  surgery
Not	  all	  CEA	  values	  return	  to	  normal	  aTer	  curaAve	  surgery,	  especially	  in	  the	  group	  of	  
paAents	  that	  are	  diagnosed	  with	  recurrent	  disease	  during	  follow-­‐up,	  due	  to	  residual	  
microscopic	  disease	  at	  Ame	  of	  intended	  curaAve	  surgery.	  A	  persistent	  abnormal	  post-­‐
operaAve	  CEA	  usually	  indicates	  synchronous	  metastasis	  or	  irradical	  resecAon	  and	  is	  
applicable	  as	  a	  marker	  for	  the	  eﬀecAveness	  of	  curaAve	  surgery.	  Serum	  CEA	  has	  a	  half-­‐life	  of	  
6	  to	  60	  days,	  and	  must	  be	  expected	  to	  return	  to	  normal	  within	  several	  weeks.
Considera2ons	  on	  the	  rela2onship	  between	  pre-­‐	  and	  postopera2ve	  CEA	  levels
However	  it	  does	  appear	  that	  there	  is	  a	  relaAonship	  between	  pre-­‐	  and	  postoperaAve	  CEA	  
levels.	  The	  thought	  behind	  the	  assumpAon	  of	  the	  absence	  of	  rise	  in	  normal	  preoperaAve	  
values,	  might	  not	  be	  enArely	  wrong.	  The	  likelihood	  CEA	  will	  rise	  with	  recurrent	  disease	  
when	  pre-­‐operaAve	  values	  were	  elevated	  as	  well	  is	  higher	  (78%,	  versus	  50%)	  then	  with	  
normal	  pre-­‐operaAve	  levels.	  From	  this	  observaAon,	  it	  might	  be	  true	  that	  looking	  at	  relaAve	  
CEA	  values,	  anAcipaAng	  on	  an	  individual's	  'normal	  value',	  would	  be	  a	  more	  eﬀecAve	  
manner	  of	  ﬁnding	  abnormaliAes	  then	  apprehending	  staAc	  cut-­‐oﬀ	  values.	  The	  use	  of	  
percentual	  rise	  or	  doubling	  Ame	  (DT)	  of	  serum	  CEA	  values	  might	  be	  eﬀecAve.	  A	  strong	  
prognosAc	  value	  of	  this	  alternaAve	  has	  already	  been	  demonstrated,12,	  15,	  18-­‐20	  however	  no	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clinical	  trials	  have	  been	  iniAated	  up	  unAl	  now	  to	  study	  the	  clinical	  beneﬁt.	  TheoreAcally,	  by	  
analysing	  the	  rise	  of	  CEA	  with	  measurement	  at	  an	  interval	  of	  several	  weeks,	  both	  sensiAvity	  
and	  speciﬁcity	  can	  increase.	  A	  higher	  sensiAvity	  is	  achieved	  because	  a	  rise	  in	  CEA	  can	  signal	  
recurrent	  disease	  before	  crossing	  a	  staAc	  threshold,	  especially	  in	  paAents	  with	  low	  baseline	  
values.	  A	  higher	  speciﬁcity	  is	  expected	  because	  incidental	  rises	  due	  to	  e.g.	  self-­‐limiAng	  
benign	  disease	  are	  'ﬁltered'	  by	  repeAAve	  measurements.	  Low	  speciﬁcity	  for	  malignancy	  has	  
been	  the	  main	  problem	  of	  CEA,	  which	  has	  also	  led	  to	  the	  apprehension	  of	  higher	  threshold	  
values	  then	  actually	  are	  normal.	  Use	  of	  CEA	  rise,	  there	  with	  anAcipaAng	  on	  individual	  
diﬀerences	  in	  CEA	  expression,	  might	  solve	  this	  problem.	  An	  explanaAon	  for	  the	  variances	  in	  
CEA	  expression	  may	  be	  the	  producAon	  and	  shedding	  to	  the	  circulaAon	  or	  intesAnal	  lumen	  
by	  diﬀerent	  tumour	  types.21-­‐23	  Immunohistochemical	  staining	  of	  CEA	  within	  the	  cell	  has	  
diﬀerent	  cellular	  distribuAon	  paferns	  reﬂecAng	  in	  diﬀerent	  serum	  levels.	  This	  pafern	  of	  
expression	  and	  successive	  diﬀerences	  in	  spilling	  to	  the	  circulaAon	  may	  be	  retained	  in	  
recurrent	  disease.
Conclusion
The	  majority	  of	  paAents	  with	  rectal	  carcinoma	  have	  normal	  CEA	  values	  before	  curaAve	  
surgery	  and	  half	  of	  them	  will	  express	  a	  rise	  in	  CEA	  values	  due	  to	  recurrent	  disease.	  This	  
means	  a	  signiﬁcant	  number	  of	  paAents	  will	  miss	  an	  opportunity	  on	  early	  detecAon	  of	  
recurrent	  disease	  when	  CEA	  measurements	  are	  omifed,	  due	  a	  false	  assumpAon.	  Serial	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Context:	  Following	   curaAve	   treatment	   for	   primary	   colorectal	   cancer	   (CRC),	   30	   to	   50%	   of	  
paAents	   will	   develop	   recurrent	   disease,	   commonly	   locoregional	   recurrence	   and	   distant	  
metastases	  to	  the	  liver	   and	  lung.	  For	   CRC	   there	  are	  several	  lines	  of	  evidence	  supporAng	  the	  
hypothesis	   that	   early	  detecAon	   of	   metachronous	   disease	   oﬀers	  a	   second	   opportunity	   for	  
cure.	   The	   current	   drive	   in	   clinical	   trials	   is	   towards	   detecAng	   metachronous	   disease	   in	  
asymptomaAc	   paAents	   through	   more	   intensive	   imaging	   protocols, 	  typically	   computerized	  
tomography	   (CT)	   scanning,	   but	   this	   has	   several	   limitaAons	   including:	  high	   expensive	   and	  
resource	  usage;	  high-­‐rates	  of	   ‘incidentaloma’	   incurring	  further	   costs	  for	   invesAgaAons	   and	  
treatments;	   and	   neoplasAc	   risks	   from	   cumulaAve	   radiaAon	   exposure.	   Against	   this	  
background,	   an	   alteraAve	   strategy	   is	   a	   low	   cost	   ‘triage’	   blood	   biomarker	   triggering	   and	  
direcAng	  selecAve	  CT	  usage.	  This	  paper	  revisits	  the	  potenAal	  role	  of	  serum	  carcinoembryonic	  
anAgen	   (CEA), 	   set	   against	   modern	   imaging	   techniques,	   changes	   in	   CRC	   treatment	   and	  
clinically-­‐linked	  decision-­‐making	  soTware.	  
Limita>ons	   of	   past	   studies:	   A	   comprehensive	   review	   of	   the	   literature	   (1978-­‐2008)	  
demonstrates	  that	   the	   iniAal	  promise	   of	  serum	  CEA	  as	  an	  eﬀecAve	  surveillance	  tool	   in	   the	  
sexng	   of	   CRC	   has	   been	   tarnished	   through	   perpetuaAon	   of	   poorly	   designed	   and	  
underpowered	   studies. 	   Speciﬁc	   limitaAons	   included:	   tesAng	   CEA	   as	   only	   an	   ‘add-­‐on’	  
diagnosAc	  tool;	  lack	  of	  standardizaAon	  of	  threshold	  values;	  use	  of	  staAc	   thresholds;	  too	   low	  
measurement	  frequency;	  mismatch	   in	  Aming	  on	  expected	  Ame	  of	   recurrent	  disease.	  Major	  
changes	   in	  treatment	   of	  metastaAc	  CRC	   further	   cause	  a	  decrease	  of	  clinical	   applicability	  of	  
past	  trial	  outcomes.
Revisited	  hypothesis:	  In	  1982,	  Staab	  hypothesized	  that	  the	  opAmal	  beneﬁt	  of	  serum	  CEA	  as	  
a	   surveillance	   tool	   is	   through	   high-­‐frequency	   triage	   using	   a	   dynamic	   threshold	   (HiDT)	  
approach.	   Evidence	   supporAng	  this	  hypothesis	   was	   found	   in	   an	   evaluaAon	   of	   biochemical	  
characterisAcs	  of	  serum	  CEA	  tests	  and	  retrospecAve	  studies	  showing	  the	  superior	  predicAve	  
value	  of	   a	  dynamic	   threshold	   value	  as	   compared	   to	   a	   staAc	   threshold	   value.	  A	   preceding	  
pilot	  trial	  has	  set	  forth	  the	  protocol	  for	  a	  naAonal	  randomized	  trial.
Future	   trial	   design:	   	   A	  mulA-­‐centred	   randomized	   phase	   III	   study	  opAmizing	   the	   usage	   of	  
HiDT	   against	   resectability 	   of	   recurrent	   disease	   as	   the	   primary	   outcome	   measure	   is	  
commencing	   recruitment	   in	   the	   Netherlands	   in	   2010.	   A	   clinically	   integrated	   computer-­‐
assistant	   support	   system	   is	   a	   key	  component	   of	   the	   trial	   design	   and	   will	   concurrently	   be	  
Context
Following	  curaAve	  treatment	  for	  primary	  colorectal	  cancer	  (CRC),	  30	  to	  50%	  of	  paAents	  will	  
develop	  recurrent	  disease,	  commonly	  locoregional	  recurrences	  and	  distant	  metastases	  to	  
the	  liver	  and	  lung.	  Unlike	  most	  adult	  solid	  malignancies,	  for	  CRC,	  there	  are	  several	  lines	  of	  
evidence	  supporAng	  the	  hypothesis	  that	  early	  detecAon	  of	  metachronous	  disease	  oﬀers	  a	  
second	  opportunity	  for	  cure.1,	  3-­‐5
	   Serum	  CEA	  has	  been	  the	  hallmark	  in	  follow-­‐up	  of	  colorectal	  carcinoma	  for	  30	  years.	  
There	  has	  been	  considerable	  controversy	  concerning	  the	  beneﬁts	  of	  serum	  CEA	  in	  follow-­‐
up.	  Five	  meta-­‐analyses	  were	  carried	  out	  analyzing	  the	  evidence	  of	  the	  eﬀecAveness	  of	  
follow-­‐up	  in	  colorectal	  cancer	  on	  survival.1-­‐5	  	  Only	  a	  small	  survival	  gain	  was	  seen,	  
predominantly	  when	  frequent	  serum	  CEA	  measurements	  were	  included	  in	  the	  follow-­‐up.1,	  
3-­‐5	  Most	  of	  the	  studies	  included	  in	  the	  meta-­‐analyses	  however,	  analyzed	  the	  eﬀect	  of	  
follow-­‐up	  in	  general,	  oTen	  consisAng	  of	  a	  wide	  variety	  and	  combinaAons	  of	  diagnosAc	  
tests.5	  This	  limits	  the	  evidence	  on	  the	  diagnosAc	  accuracy	  of	  a	  speciﬁc	  diagnosAc	  test.	  The	  
meta-­‐analyses	  therefore	  do	  not	  necessarily	  reﬂect	  the	  diagnosAc	  value	  of	  serum	  CEA	  in	  
follow-­‐up	  and	  the	  controversy	  concerning	  the	  role	  of	  serum	  CEA	  has	  not	  been	  solved.
	   The	  current	  drive	  in	  clinical	  trials	  is	  towards	  detecAng	  metachronous	  disease	  in	  
asymptomaAc	  paAents	  through	  more	  intensive	  imaging	  protocols,	  typically	  computerized	  
tomography	  (CT)	  scanning,	  but	  this	  has	  several	  limitaAons	  including:	  high	  expensive	  and	  
resource	  usage;	  high-­‐rates	  of	  ‘incidentaloma’	  incurring	  further	  costs	  for	  invesAgaAons	  and	  
treatments;	  and	  neoplasAc	  risks	  from	  cumulaAve	  radiaAon	  exposure.	  
	   Against	  this	  background,	  an	  alternaAve	  strategy	  is	  a	  low	  cost	  ‘triage’	  blood	  biomarker	  
triggering	  and	  direcAng	  selecAve	  CT	  usage.	  This	  paper	  revisits	  the	  potenAal	  role	  of	  serum	  
carcinoembryonic	  anAgen	  (CEA),	  set	  against	  modern	  imaging	  and	  CRC	  treatment	  and	  
clinically-­‐linked	  decision-­‐making	  soTware,	  as	  such	  a	  surveillance	  tool.	  
Limita>ons	  of	  past	  studies
A	  comprehensive	  review	  of	  the	  literature	  (1978-­‐2008)	  was	  performed,	  using	  search	  term	  
[Carcinoembryonic	  anAgen]	  AND	  [Colorectal	  neoplasm],	  limited	  to	  the	  subheadings	  
[analysis],	  [diagnosAc	  use],	  [blood],	  [standards]	  and	  limited	  to	  ‘human’	  and	  ‘English	  
language’.	  AddiAonal	  relevant	  references	  found	  in	  arAcles	  were	  included.	  Review	  arAcles	  
were	  used	  as	  a	  reference	  but	  not	  included	  in	  the	  analysis.	  SelecAon	  of	  the	  abstracts	  was	  
made	  on	  the	  available	  informaAon	  concerning	  clinical	  use	  of	  CEA	  in	  follow-­‐up	  aTer	  curaAve	  
resecAon	  of	  CRC.	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   From	  1978	  All	  2008	  26	  original	  clinical	  trials	  evaluaAng	  the	  outcome	  of	  follow-­‐up	  aTer	  
curaAve	  treatment	  of	  colorectal	  carcinoma	  which	  included	  serum	  CEA	  measurements	  were	  
published	  (Table	  1).6-­‐31	  One	  publicaAon	  was	  excluded	  from	  analysis	  because	  it	  concerned	  a	  
double	  publicaAon.	  The	  25	  clinical	  trials,	  and	  a	  few	  follow-­‐up	  studies	  that	  did	  not	  include	  
serum	  CEA	  measurements,	  have	  resulted	  in	  ﬁve	  meta-­‐analyses	  on	  follow-­‐up	  in	  CRC.1-­‐5	  The	  
25	  original	  arAcles	  were	  analyzed	  on	  actual	  tesAng	  the	  diagnosAc	  capacity	  of	  serum-­‐CEA,	  
the	  clinically	  applied	  threshold	  value	  of	  serum-­‐CEA,	  Aming	  of	  follow-­‐up	  and	  measurement	  
frequency.
	   Most	  studies	  evaluated	  follow-­‐up	  regimes	  consisAng	  of	  various	  diagnosAc	  tests.	  In	  only	  
5	  from	  25	  clinical	  trials,	  diﬀerent	  serum	  CEA	  regimes	  were	  compared,6-­‐10	  from	  which	  3	  
studies	  were	  randomized	  controlled	  trials.8-­‐10	  The	  results	  of	  these	  studies	  show	  a	  
consistent	  beneﬁcial	  eﬀect	  of	  serum	  CEA	  measurements	  on	  both	  the	  rate	  of	  curaAve	  
resecAon	  of	  recurrent	  disease	  and	  survival	  (table	  2).	  In	  the	  meta-­‐analyses	  the	  majority	  of	  
included	  trials	  did	  not	  compare	  diﬀerent	  CEA	  regimes	  (Table	  3).	  These	  meta-­‐analyses	  
therefore,	  do	  not	  reﬂect	  the	  diagnosAc	  capacity	  of	  serum	  CEA	  in	  follow-­‐up.
	   The	  average	  staAc	  normal	  value	  of	  serum-­‐CEA	  is	  2.0-­‐2.5	  ng/ml.	  To	  increase	  speciﬁcity	  
and	  prevent	  the	  situaAon	  of	  inability	  to	  localize	  recurrent	  disease	  with	  imaging	  techniques	  
or	  relaparotomy	  in	  the	  past,	  the	  clinically	  applied	  staAc	  threshold	  value	  has	  oTen	  been	  
increased	  to	  5	  ng/ml	  or	  higher.	  From	  the	  25	  studies,	  all	  except	  one	  study	  used	  a	  staAc	  
threshold	  value.	  A	  threshold	  value	  of	  ≤	  2.5	  ng/ml	  was	  applied	  in	  3	  studies	  (13%),	  of	  	  ≥	  5	  ng/
ml	  in	  8	  studies	  (32%)	  and	  in	  14	  studies	  the	  applied	  threshold	  value	  was	  not	  menAoned.	  
Applying	  a	  higher	  threshold	  value	  results	  in	  a	  decrease	  in	  sensiAvity	  and	  with	  that,	  in	  a	  
possible	  delay	  of	  diagnosis	  of	  recurrent	  disease.
	   DiagnosAc	  tests	  for	  recurrent	  disease	  are	  most	  sensiAve	  when	  the	  Aming	  is	  aimed	  at	  
the	  expected	  Ame	  to	  recurrence	  through	  opAmizing	  the	  pre-­‐test	  probability.	  Data	  from	  the	  
25	  clinical	  studies	  revealed	  that	  local	  recurrences	  were	  found	  on	  average	  between	  6	  
months	  and	  2	  years,	  liver	  metastases	  between	  6	  and	  18	  months	  and	  pulmonary	  metastases	  
between	  24	  and	  36	  months.	  In	  the	  clinical	  trials	  (calculaAon	  based	  op	  22	  trials),	  a	  
measurement	  frequency	  of	  once	  per	  ≤	  3	  months	  was	  apprehended	  in	  91%	  of	  trials	  in	  the	  
ﬁrst	  year,	  53%	  in	  the	  second	  year	  and	  25%	  in	  the	  third	  year.	  The	  measurement	  frequency	  
actually	  carried	  out	  is	  only	  46	  to	  62%	  of	  the	  reported	  measurement	  frequency,	  as	  was	  
shown	  in	  6	  independent	  studies.7,	  13,	  22,	  46-­‐48	  This	  implies	  that	  the	  Aming	  and	  measurement	  
frequency	  in	  most	  studies	  and	  in	  clinical	  pracAce	  has	  been	  insuﬃcient	  to	  expect	  any	  
beneﬁcial	  eﬀect	  of	  serum-­‐CEA	  in	  follow-­‐up	  for	  CRC.
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TABLE	  1	  	  Clinical	  studies	  on	  follow-­‐up	  including	  CEA	  measurements	  
Year Type	  trial** N= Recurrence	  rate
N= %
MarAn 1980 ProspecAve,	  ComparaAve 300 60 20%
Lim 1980 RetrospecAve,	  Non-­‐comparaAve 127 20 16%
Steele 1982 RetrospecAve,	  Non-­‐comparaAve 770 86 11%
Minton 1984 ProspecAve,	  ComparaAve 400 130 33%
Hine 1984 ProspecAve,	  Non-­‐comparaAve 626 171 27%
Staab 1985 ProspecAve,	  Non-­‐comparaAve 426 67 16%
Ovaska* 1990 RetrospecAve,	  Non-­‐comparaAve 507 149 29%
Behbehani 1990 ProspecAve,	  Non-­‐comparaAve 123 34 27%
Moertel 1993 RetrospecAve,	  Non-­‐comparaAve 1216 417 34%
McCall 1993 ProspecAve,	  Non-­‐comparaAve 311 98 32%
Makela 1995 ProspecAve,	  Non-­‐comparaAve 106 43 41%
Ohlsson 1995 RCT,	  ComparaAve 107 35 33%
Pietra 1998 RCT,	  ComparaAve 207 46 22%
Schoemaker 1998 ProspecAve,	  Non-­‐comparaAve 325 ? ?
Graham 1998 RetrospecAve,	  Non-­‐comparaAve 1356 421 31%
Wichmann 2000 ProspecAve,	  Non-­‐comparaAve 1321 306 23%
Komborozos 2001 RetrospecAve,	  Non-­‐comparaAve 113 113 100%
Bleeker 2001 ProspecAve,	  Non-­‐comparaAve 496 213 43%
Glover 2002 RetrospecAve,	  Non-­‐comparaAve 100 32 32%
Secco 2002 RCT,	  ComparaAve 337 184 55%
Chau 2004 ProspecAve,	  Non-­‐comparaAve 530 154 29%
Bonthuis 2004 RetrospecAve,	  Non-­‐comparaAve 564 149 26%
Grossmann	  EM 2004 RCT,	  Non-­‐comparaAve 985 139 14%
Rodriquez 2006 RCT,	  Non-­‐comparaAve 259 69 27%
Fernandes 2006 ProspecAve,	  Non-­‐comparaAve 120 23 19%
*	  Results	  of	  this	  study	  were	  published	  twice,	  therefore	  only	  one	  study	  is	  taken	  into	  analysis
**	  Concerning	  CEA	  :	  all	  grey-­‐marked	  studies	  were	  comparaave	  concerning	  CEA
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TABLE	  2	  Effect	  of	  CEA	  measurements	  in	  follow-­‐up	  
on	  resectability	  of	  recurrent	  disease	  and	  5	  year	  survival
CEA	  measurement	  
frequency	  (months)
Recurrence	  rate Cura)ve	  resec)on	  
recurrent	  disease
5	  yr	  survival
Control Intensive Control Intensive Control Intensive Control Intensive
Secco none 3	  (HR)
6	  (LR)




Pietra 6 3 19% 25% 10% 65% 58% 73%
Ohlsson none 3 33% 37% 17% 40% 67% 75%











*	  at	  the	  ame	  of	  publicaaon	  the	  FU	  ame	  ranged	  from	  0-­‐4	  years,	  a*er	  which	  58%	  of	  paaents	  were	  sall	  alive
**	  The	  5	  year	  disease	  free	  survival	  between	  FU	  with	  CEA	  every	  1-­‐2	  months	  as	  compared	  to	  “any	  less	  frequent	  
interval”.
TABLE	  3	  	  Summary	  of	  meta-­‐analyses	  on	  follow-­‐up	  for	  colorectal	  cancer	  and	  inclusion	  of	  
trials	  that	  compared	  different	  CEA	  regimes
Year Studies* +	  CEA Conclusions	  
Bruinvels 1994 7 3 A	  signiﬁcant	  increase	  on	  survival	  is	  found	  only	  when	  CEA	  assays	  
are	  included	  in	  follow-­‐up.
Kievit** 2000 14 3** Overall	  survival	  gain	  by	  intensive	  follow-­‐up	  varies	  between	  
0.5-­‐2.0%.	  No	  sub-­‐analysis	  on	  the	  role	  of	  CEA.
Renehan 2002 5 2 Intensive	  follow	  was	  associated	  with	  a	  reducaon	  in	  all	  cause	  
mortality	  (combined	  risk	  0.81,	  95%	  CI	  0.70-­‐0.94).	  The	  eﬀect	  was	  
most	  pronounced	  []	  that	  used	  computed	  tomography	  and	  
frequent	  measurements	  of	  CEA	  (RR	  0.73	  95%	  CI	  0.6-­‐0.89)
Jeﬀery 2002 5 2 There	  was	  evidence	  that	  an	  overall	  survival	  beneﬁt	  exists	  for	  
paaents	  undergoing	  more	  intensive	  follow-­‐up	  (OR	  0.67,	  95%	  CI	  
0.53-­‐0.84).	  Because	  of	  wide	  variaaon	  in	  the	  FU	  programmes	  used	  
[]	  it	  is	  not	  possible	  to	  infer	  from	  the	  data	  the	  best	  combinaaon	  and	  
frequency	  of	  clinic	  visits	  and	  addiaonal	  invesagaaons.
Tjandra 2007 8 3 Intensive	  follow-­‐up	  a*er	  curaave	  resecaon	  of	  colorectal	  cancer	  
improved	  overall	  survival	  and	  reresecaon	  rate	  for	  recurrent	  
disease.	  Regular	  surveillance	  with	  CEA	  (p=0.0002)	  and	  colonoscopy	  
(p=0.04)	  demonstrated	  a	  signiﬁcant	  impact	  on	  overall	  mortality.
*	  Total	  of	  randomised	  controlled	  trials	  and	  non-­‐randomised	  comparaave	  trials.
**	  From	  4	  clinical	  studies	  it	  could	  not	  be	  retrieved	  whether	  CEA	  regimes	  were	  diﬀerent	  and	  compared,	  in	  7	  
studies	  no	  diﬀerent	  CEA	  regimes	  were	  compared.
Historical	  context:	  changes	  in	  clinical	  prac>ce
The	  role	  of	  imaging	  techniques
LocalizaAon	  of	  recurrent	  disease	  in	  follow-­‐up	  has	  been	  a	  major	  problem	  in	  the	  past,	  
inﬂuencing	  the	  results	  from	  clinical	  trials	  carried	  out	  before	  2000.	  Serum	  CEA	  can	  signal	  
recurrent	  disease	  as	  a	  ﬁrst-­‐line	  screening	  tool,	  but	  for	  the	  deﬁnite	  diagnosis	  and	  treatment,	  
the	  site	  and	  extent	  of	  recurrent	  disease	  must	  be	  localized.	  	  When	  recurrent	  disease	  is	  
suspected	  but	  no	  certainty	  or	  treatment	  can	  be	  oﬀered	  to	  the	  paAent,	  follow-­‐up	  only	  
results	  in	  a	  loss	  of	  life	  quality	  and	  should	  be	  prevented.	  Up	  unAl	  this	  century,	  is	  has	  been	  
very	  diﬃcult	  to	  localize	  recurrent	  disease	  with	  non-­‐invasive	  techniques.	  A	  second	  look	  
laparotomy	  aimed	  at	  potenAally	  curable	  liver	  metastases	  has	  been	  standard	  of	  care	  unAl	  
the	  late	  eighAes	  and	  has	  been	  the	  hallmark	  in	  most	  clinical	  trials	  included	  in	  this	  analysis.	  
Because	  of	  the	  invasive	  nature	  of	  this	  ‘diagnosAc	  test’,	  the	  demands	  on	  accuracy	  of	  the	  
screening	  test	  have	  been	  high.	  Nowadays,	  non-­‐invasive	  tests	  such	  as	  mulAslice	  computed	  
tomography	  (CT),	  MagneAc	  reseonance	  imaging	  (MRI),	  contrast-­‐enhanced	  ultrasound	  and	  
Positron	  Emission	  Tomography	  (PET)	  can	  localize	  recurrent	  disease	  of	  >	  1	  cm	  in	  liver	  and	  
lung	  and	  locoregional	  recurrence.	  This	  situaAon	  lowers	  barriers	  to	  act	  upon	  signals	  
indicaAng	  possible	  recurrent	  disease	  from	  ﬁrst-­‐line	  screening	  with	  serum-­‐CEA.	  The	  
discriminaAve	  capacity	  of	  available	  imaging	  techniques	  however,	  is	  limited	  for	  smaller	  
lesions.	  When	  serum	  CEA	  is	  used	  in	  follow-­‐up	  as	  a	  ﬁrst	  line	  detector	  of	  recurrent	  disease,	  
the	  applied	  threshold	  value	  should	  be	  adapted	  to	  the	  likelihood	  of	  actual	  localizaAon	  on	  
imaging	  techniques.	  A	  threshold	  of	  at	  least	  50%	  detected	  lesions	  on	  imaging	  following	  
posiAve	  serum	  CEA	  test	  results	  should	  be	  apprehended.	  This	  to	  prevent	  recurrence	  of	  the	  
‘old’	  problem	  of	  inability	  of	  localizaAon	  and	  with	  that,	  the	  inability	  to	  oﬀer	  treatment	  or	  
support.	  The	  reverse	  situaAon	  that	  may	  occur	  is	  recurrent	  disease	  that	  does	  not	  result	  in	  
an	  increase	  in	  serum	  CEA	  value.	  A	  signiﬁcant	  proporAon	  of	  paAents	  have	  normal	  serum	  
CEA	  values	  with	  CRC	  or	  recurrent	  disease.	  This	  was	  reviewed	  in	  three	  studies.23,	  39,	  49	  The	  
proporAon	  varied	  from	  23%	  All	  60%,	  depending	  on	  the	  clinically	  applied	  (staAc)	  threshold	  
value.	  When	  respecAng	  a	  threshold	  value	  of	  2.5	  ng/ml,	  the	  proporAon	  of	  paAents	  with	  
normal	  CEA	  values	  will	  be	  approximately	  25%	  at	  iniAal	  presentaAon.	  Because	  of	  diﬀerent	  
tumor	  behavior	  the	  proporAon	  of	  serum	  CEA	  ‘negaAve’	  disease	  is	  probably	  lower	  with	  
recurrent	  disease,	  however	  this	  has	  not	  been	  described.	  It	  has	  been	  a	  wide	  believe	  that	  a	  
normal	  serum	  CEA	  value	  at	  iniAal	  presentaAon,	  implies	  that	  the	  serum	  CEA	  value	  will	  not	  
rise	  either	  in	  case	  of	  recurrent	  disease.	  Although	  there	  is	  indeed	  a	  tendency	  serum-­‐CEA	  
‘negaAve’	  tumors	  less	  oTen	  show	  an	  increase	  in	  serum	  CEA	  value	  with	  recurrent	  disease,	  
more	  then	  60%	  will	  show	  a	  rise	  with	  recurrent	  disease.49	  Serum	  CEA	  measurements	  can	  
therefore	  not	  be	  discarded	  based	  on	  an	  iniAal	  normal	  CEA	  value.	  However,	  there	  will	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always	  remain	  paAents	  that	  have	  recurrent	  disease	  with	  normal	  staAc	  serum	  CEA	  values.	  
TheoreAcally,	  applying	  a	  dynamic	  threshold	  value,	  might	  reduce	  the	  number	  of	  serum	  CEA	  
‘negaAve’	  paAents;	  also	  in	  lower	  ranges	  of	  serum	  CEA	  values	  a	  pafern	  of	  rise	  can	  be	  
observed	  and	  may	  be	  more	  sensiAve	  than	  staAc	  threshold	  values.	  Also	  with	  this	  approach	  
there	  will	  always	  remain	  paAents	  that	  have	  recurrent	  disease	  with	  unchanging	  serum	  CEA	  
values.	  Any	  CEA	  based	  follow-­‐up	  protocol	  should	  therefore	  include	  imaging	  techniques,	  
aimed	  at	  the	  expected	  Ame	  of	  recurrent	  disease.	  
Paierns	  of	  recurrence.
The	  treatment	  of	  colorectal	  carcinoma	  has	  changed	  considerably	  in	  the	  past	  decade,	  
changes	  that	  should	  be	  taken	  into	  account	  in	  interpreAng	  past	  study	  results	  and	  future	  
consideraAons	  concerning	  follow-­‐up.	  Since	  the	  introducAon	  of	  neo-­‐adjuvant	  
chemoradiaAon	  combined	  with	  TME	  surgery,	  the	  incidence	  of	  local	  recurrence	  in	  rectal	  
cancer	  has	  decreased	  and	  the	  outcome	  in	  survival	  improved	  signiﬁcantly.50,	  51	  The	  expected	  
Ame	  to	  recurrence	  aTer	  combined	  treatment	  for	  rectal	  cancer	  seems	  to	  increase.52	  RouAne	  
pre-­‐operaAve	  staging	  with	  abdominal	  CT,	  as	  is	  now	  adviced	  in	  naAonal	  guidelines,	  is	  likely	  
to	  cause	  a	  shiT	  from	  previous	  “early”	  metachronous	  to	  now	  synchronous	  liver	  metastases	  
and	  with	  that,	  change	  the	  incidence	  and	  pafern	  of	  recurrent	  disease.	  High-­‐risk	  paAents	  
with	  colon	  cancer	  that	  either	  have	  lymph	  node	  metastases	  or	  unfavorable	  
histopathological	  features	  (such	  as	  tumor	  perforaAon,	  serosal	  inﬁltraAon	  or	  locally	  
advanced	  tumors,	  angio-­‐invasive	  or	  perineural	  growth)	  receive	  adjuvant	  chemotherapy	  up	  
to	  9	  months	  aTer	  operaAon.	  Modern	  adjuvant	  chemotherapy	  consisAng	  of	  5-­‐FU/
leucovorin	  combined	  with	  oxaliplaAn	  (XELOX	  or	  FOLFOX)	  decreases	  the	  incidence	  of	  
recurrent	  disease	  within	  4	  years	  aTer	  surgery	  and	  prolongs	  the	  Ame	  to	  recurrence	  of	  liver	  
and	  lung	  metastases.53,	  54	  A	  signiﬁcant	  part	  of	  clinical	  trials	  analyzed	  in	  this	  arAcle	  have	  
been	  carried	  out	  before	  neo-­‐adjuvant	  (chemo)radiaAon	  had	  become	  the	  standard	  of	  care.	  
The	  incidence	  of	  recurrent	  disease	  aTer	  curaAve	  treatment	  of	  stage	  0-­‐III	  colorectal	  cancer	  
will	  therefore	  probably	  decrease	  as	  an	  eﬀect	  of	  staging	  and	  (neo)adjuvant	  treatment.	  On	  
the	  other	  hand,	  synchronous	  liver	  and	  peritoneal	  metastases	  can	  more	  oTen	  be	  treated	  
with	  curaAve	  intent	  with	  modern	  mulAmodality	  treatment	  opAons.	  ATer	  curaAve	  
treatment,	  these	  paAents	  have	  a	  chance	  on	  recurrent	  disease	  of	  approximately	  50%.	  
Recurrences	  in	  paAents	  can	  oTen	  again	  be	  treated	  with	  curaAve	  intent.	  Inclusion	  of	  these	  
paAents	  in	  follow-­‐up	  trials,	  which	  are	  paAents	  that	  were	  previously	  not	  treated	  with	  
curaAve	  intent	  and	  excluded	  from	  follow-­‐up	  trials,	  will	  alternately	  increase	  the	  incidence	  of	  
recurrent	  disease	  during	  follow-­‐up.	  In	  an	  analysis	  on	  recurrence	  pafern	  in	  a	  populaAon	  
rouAnely	  staged	  with	  abdominal	  CT	  and	  treated	  according	  to	  current	  standards,	  the	  chance	  
on	  early	  recurrence	  is	  low	  and	  limited	  to	  paAents	  with	  locally	  advanced	  tumors	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[Grossmann,	  chapter	  8].	  A	  rough	  esAmate	  on	  the	  current	  chance	  on	  recurrent	  disease	  is	  
30-­‐50%,	  the	  expected	  Ame	  to	  recurrence	  is	  between	  12	  and	  36	  months	  and	  might	  be	  
prolonged	  to	  more	  then	  5	  years	  in	  deﬁned	  risk	  groups.	  In	  the	  light	  of	  these	  changes	  the	  
outcomes	  of	  follow-­‐up	  trials	  on	  recurrence	  pafern	  should	  be	  taken	  into	  account	  in	  future	  
follow-­‐up	  and	  trial	  designs.	  
Logis>c	  considera>ons
One	  of	  the	  reasons	  that	  may	  have	  contributed	  to	  the	  striking	  absence	  of	  clinical	  trials	  
applying	  HiDT	  serum	  CEA	  measurements	  is	  the	  logisAc	  burden	  and	  costs	  of	  intensive	  
screening.	  Colorectal	  cancer	  is	  the	  second	  most	  common	  malignancy	  with	  a	  life	  Ame	  
chance	  of	  approximately	  10%	  in	  the	  Western	  populaAon.	  Frequent	  outpaAent	  clinic	  visits	  
combined	  with	  serum	  CEA	  measurement	  for	  all	  paAents	  treated	  with	  curaAve	  intent	  is	  not	  
feasible,	  neither	  eﬀecAve;	  outpaAent	  clinic	  visits	  with	  physical	  examinaAon	  do	  not	  
contribute	  to	  early	  detecAon	  of	  recurrent	  disease	  22	  and	  it	  can	  be	  an	  unnecessary	  burden	  
for	  the	  (elderly)	  paAent.	  This	  situaAon	  may	  have	  contributed	  to	  the	  notable	  low	  adherence	  
to	  current	  guideline	  recommendaAons	  on	  the	  measurement	  frequency	  of	  serum	  CEA	  as	  
well.	  The	  soluAon	  to	  the	  logisAc	  problems	  induced	  by	  HiDT	  is	  serum	  CEA	  measurement	  
without	  outpaAent	  clinic	  visits.	  This	  can	  nowadays	  be	  supported	  with	  automated	  
processing,	  signalling	  and	  sharing	  of	  test	  results	  with	  the	  paAent	  via	  the	  telephone	  or	  
internet.	  Prototype	  soTware	  (CEA	  watch)	  has	  been	  designed	  and	  tested	  in	  a	  preceding	  
pilot	  trial	  on	  the	  HiDT	  approach,	  with	  good	  experiences.	  PaAents’	  experiences	  with	  HiDT	  
without	  outpaAent	  clinic	  visits	  was	  evaluated	  in	  a	  psychological	  study	  on	  paAents	  in	  this	  
preceding	  pilot	  trial	  and	  showed	  this	  approach	  is	  well	  tolerated	  and	  even	  preferred	  by	  
paAents	  above	  care	  as	  usual	  [Reijnen,	  chapter	  7].
Conclusion
Summarizing,	  the	  diagnosAc	  accuracy	  of	  serum	  CEA	  has	  been	  underesAmated	  because	  of	  
the	  methodology	  of	  clinical	  trials.	  Evidence	  supporAng	  the	  clinical	  value	  of	  serum	  CEA	  on	  
increasing	  the	  eligibility	  of	  curaAve	  resecAon	  of	  recurrent	  disease	  detected	  in	  
asymptomaAc	  paAents	  and	  successively	  on	  survival	  is	  available.	  The	  threshold	  value,	  
measurement	  frequency	  and	  interpretaAon	  of	  serum	  CEA	  values,	  and	  the	  Aming	  on	  
expected	  Ame	  of	  recurrent	  disease	  have	  been	  far	  from	  opAmal	  in	  the	  past	  in	  both	  clinical	  
trials	  and	  clinical	  pracAce.	  The	  changing	  clinical	  context	  	  limits	  the	  value	  of	  the	  outcomes	  of	  
past	  clinical	  trials.	  CuraAve	  treatment	  opAons	  for	  recurrent	  disease	  have	  been	  improved	  
considerably	  in	  the	  last	  decade,	  and	  more	  accurate	  non-­‐invasive	  imaging	  techniques	  and	  
computer	  support	  in	  medical	  care	  are	  available	  supporAng	  intensive	  follow-­‐up	  with	  serum	  




Serum	  CEA	  reﬂects	  the	  expression	  of	  an	  embryonic	  protein	  on	  the	  cell	  surface,	  which	  has	  a	  
funcAon	  in	  the	  embryonic	  Assue	  development.	  This	  protein	  is	  expressed	  in	  the	  adult	  
situaAon	  in	  malignancies	  and	  inﬂammatory	  disease.	  Serum	  CEA	  reﬂects	  the	  expression	  of	  
the	  embryonic	  protein	  on	  the	  cell	  surface	  as	  an	  anAgen	  response.	  There	  is	  a	  relaAon	  
between	  tumor	  growth	  and	  serum	  CEA;	  most	  tumors	  have	  an	  exponenAal	  growth	  pafern	  
followed	  by	  an	  exponenAal	  rise	  in	  CEA.36,	  39	  Following	  these	  observaAons,	  Staab	  
hypothesized	  in	  1982	  that	  the	  opAmal	  beneﬁt	  of	  serum	  CEA	  as	  a	  surveillance	  tool	  is	  
through	  high-­‐frequency	  measurements	  using	  a	  dynamic	  threshold.15,	  35	  This	  hypothesis	  was	  
revisited	  by	  means	  of	  a	  systemaAc	  review	  of	  the	  literature,	  and	  has	  acted	  upon	  changes	  in	  
the	  clinical	  context	  of	  colorectal	  cancer.	  The	  hypothesis	  was	  tested	  a	  prospecAve	  pilot	  trial	  
from	  which	  the	  iniAal	  results	  are	  discussed.	  
Biochemistry,	  sensi2vity	  and	  speciﬁcity	  of	  serum	  CEA
Serum	  CEA	  measurements	  tests	  are	  based	  on	  monoclonal	  anAbodies	  that	  bind	  CEA	  and	  as	  
with	  each	  diagnosAc	  test,	  has	  measurement	  errors.	  Standard	  measurements	  errors	  of	  
serum	  tests	  are	  divided	  in	  four	  types.	  The	  intra-­‐assay	  test	  variaAon,	  that	  is	  the	  variaAon	  in	  
test	  result	  when	  using	  the	  same	  blood	  sample,	  is	  approximately	  2-­‐10%.	  The	  inter-­‐assay	  
variaAon,	  that	  is	  the	  variaAon	  in	  test	  result	  using	  the	  same	  blood	  sample	  in	  two	  diﬀerent	  
tests,	  is	  4-­‐12%	  in	  the	  lower	  ranges	  (<	  15	  ng/ml)	  and	  up	  to	  20%	  in	  higher	  ranges.42,	  43	  The	  
diﬀerences	  between	  tests	  and	  laboratories	  are	  relaAvely	  small;	  meaning	  the	  accuracy	  of	  
the	  assay	  is	  high.	  This	  allows	  comparison	  between	  studies	  and	  hospitals.43	  The	  intra-­‐
individual	  variaAon,	  that	  is	  the	  variaAon	  in	  serum	  CEA	  values	  within	  one	  person	  without	  
evidence	  of	  disease,	  is	  9.3%.	  The	  inter-­‐individual	  variaAon,	  that	  is	  the	  diﬀerence	  in	  normal	  
value	  between	  individuals,	  is	  approximately	  55%.44	  Referencing	  the	  CEA	  value	  on	  the	  
paAent’s	  previous	  value	  can	  eliminate	  this	  last	  and	  largest	  measurement	  error.	  This	  
requires	  repeated	  measurements	  and	  interpretaAon	  of	  the	  changes	  in	  serum	  CEA	  value.
Because	  of	  the	  other	  three	  measurement	  variaAons,	  the	  threshold	  value	  for	  rise	  should	  not	  
be	  lower	  then	  15%.	  The	  staAc	  threshold	  value	  as	  recommended	  by	  industrial	  standards	  
ranges	  from	  2.0	  –	  2.5	  ng/ml,	  the	  opAmal	  dynamic	  threshold	  is	  not	  formulated	  thus	  far.	  
	   The	  clinically	  opAmal	  threshold	  value	  is	  dependent	  on	  the	  desired	  sensiAvity	  and	  
speciﬁcity	  in	  the	  target	  populaAon.	  SensiAvity	  must	  be	  high	  in	  follow-­‐up	  to	  adequately	  
detect	  recurrent	  disease.	  A	  high	  speciﬁcity	  is	  of	  importance	  to	  minimize	  unnecessary	  
diagnosAc	  evaluaAon	  based	  on	  test	  results,	  especially	  when	  the	  test	  is	  applied	  as	  a	  
screening	  tool.	  Follow-­‐up	  requires	  both,	  as	  a	  screening	  tool	  in	  a	  high-­‐risk	  populaAon.	  The	  
speciﬁcity	  increases	  when	  the	  pre-­‐test	  probability	  is	  high;	  meaning	  the	  test	  is	  most	  
accurate	  in	  a	  high-­‐risk	  populaAon.	  In	  four	  studies	  the	  sensiAvity	  and	  speciﬁcity	  of	  serum	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CEA	  on	  staAc	  threshold	  values	  ranging	  from	  2.5-­‐20	  ng/ml	  was	  calculated.13,	  20,	  26,	  45	  The	  
pooled	  results	  show	  a	  consistent	  pafern	  of	  a	  low	  accuracy	  between	  2.5	  and	  10	  ng/ml.	  This	  
is	  likely	  caused	  by	  the	  overlap	  of	  abnormal	  CEA	  values	  with	  benign	  disease	  in	  these	  lower	  
ranges	  and	  the	  inter-­‐individual	  variaAon.	  The	  diﬀerence	  between	  malignancies	  and	  
inﬂammatory	  disease	  is	  that	  malignancies	  will	  conAnue	  to	  grow	  where	  inﬂammatory	  
disease	  is	  usually	  self-­‐limiAng.	  The	  accuracy	  can	  be	  improved	  by	  using	  intra-­‐individual	  rise,	  
because	  this	  eliminates	  the	  inter-­‐individual	  variaAon	  and	  shows	  the	  potenAally	  
discriminaAve	  padern	  of	  rise.	  This	  requires	  repeated	  measurement	  and	  consequently	  a	  
high	  measurement	  frequency.	  The	  opAmal	  measurement	  frequency	  for	  this	  approach	  has	  
been	  addressed	  in	  three	  studies.6,	  15,	  33	  Based	  on	  their	  retrospecAve	  data,	  all	  suggested	  a	  
frequency	  in	  the	  order	  of	  every	  one	  All	  two	  months.	  
	   Summarizing,	  with	  evaluaAng	  the	  pafern	  of	  rise	  the	  inter-­‐individual	  variaAon	  can	  be	  
eliminated	  and	  a	  higher	  discriminaAve	  capacity	  between	  malignancy	  and	  inﬂammatory	  
disease	  is	  expected.	  This	  increases	  speciﬁcity	  and	  allows	  interpretaAon	  of	  serum	  CEA	  
values	  in	  lower	  ranges	  of	  values,	  thus	  increasing	  sensiAvity	  as	  well.	  In	  short;	  interpretaAon	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TABLE	  4	  Quan>ta>ve	  rise	  of	  CEA	  in	  pa>ents	  with	  recurrent	  disease
Year Nr	  pat Nr	  RD Doubling	  Ame* Rise	  per	  30	  
days*
Absolute	  rise
Steele 1982 767 469 1.5%	  -­‐	  15.2%
Staab ’78-­‐85	   114 10	  -­‐	  231	  days -­‐
Boey 1984 146 51 20%
Staab 1985 667 78 -­‐ 0.6	  –	  4.4	  ng/ml
Carl 1993 259 163 74	  –	  164	  days -­‐
Umehara 1993 31 60	  (18–153)	  days -­‐
Korenaga 1997 17 86	  (±	  18)	  days -­‐
Yamamoto 2004 36 41-­‐110	  days -­‐
Irvine 2007 139 46 -­‐ -­‐ >	  1	  ng/ml	  above	  1st	  
post-­‐operaave	  level
Tanaka** 2008 43 150	  days -­‐
*	  when	  a	  diﬀerenaaaon	  per	  type	  of	  metastases	  was	  made,	  the	  lower	  and	  upper	  limits	  are	  given	  from	  
all	  analyses	  on	  possible	  curable	  metastases	  (liver,	  lung	  and	  peritoneal	  metastases	  or	  local	  recurrence).
**	  In	  this	  study	  the	  threshold	  value	  of	  CEA-­‐DT	  as	  a	  prognosac	  factor	  was	  calculated:	  no	  data	  were	  
available	  on	  average	  CEA-­‐DT	  in	  paaents	  with	  recurrent	  disease.
of	  serum	  CEA	  values	  with	  a	  dynamic	  threshold	  based	  upon	  high	  frequency	  measurements	  
(HiDT)	  can	  largely	  improve	  the	  accuracy.
Evidence	  of	  the	  hypothesis	  in	  past	  clinical	  trials
A	  search	  with	  [Carcinoembryonic	  anAgen]	  limited	  to	  subdivisions	  *analysis,	  *diagnosAc	  
use,	  *blood	  and	  *standards	  AND	  ‘doubling	  Ame’,	  and	  a	  search	  with	  [Carcinoembryonic	  
anAgen]	  AND	  [Colorectal	  neoplasm]	  AND	  ‘doubling	  Ame’	  or	  ‘rise’	  was	  done,	  both	  limited	  to	  
‘human’	  and	  ‘English	  language’.	  Relevant	  references	  were	  included	  in	  the	  study.	  	  Abstracts	  
were	  selected	  on	  informaAon	  on	  clinical	  relevant	  informaAon	  on	  use	  of	  a	  dynamic	  
threshold	  value	  of	  CEA.	  Twelve	  arAcles	  were	  included	  13,	  15,	  32	  -­‐	  41	  and	  analyzed	  on	  study	  
design,	  clinical	  eﬀecAveness	  and	  quanAtaAve	  results	  on	  CEA	  rise	  found	  with	  recurrent	  
disease.	  The	  hypothesis	  on	  using	  a	  dynamic	  threshold	  value	  was	  evaluated	  in	  a	  few	  studies.	  
In	  the	  study	  of	  Steele,	  the	  predicAve	  capacity	  of	  using	  a	  staAc	  versus	  dynamic	  threshold	  
value	  (of	  	  >	  3%	  rise	  per	  month)	  was	  compared	  in	  a	  retrospecAve	  analysis	  of	  767	  paAents	  
with	  CRC	  [13].	  The	  proporAon	  of	  paAents	  with	  recurrent	  disease	  without	  rise	  varied	  from	  
10	  -­‐	  27%,	  the	  proporAon	  of	  paAents	  with	  recurrent	  disease	  with	  rise	  varied	  from	  33	  -­‐	  84%	  
(variaAon	  dependent	  on	  the	  lower	  limit	  staAc	  threshold	  value).	  The	  dynamic	  threshold	  
value	  (rise)	  had	  a	  much	  stronger	  predicAve	  capacity	  for	  recurrent	  disease	  than	  the	  actual	  
height	  of	  the	  serum	  CEA	  value,	  supporAng	  the	  hypothesis	  on	  HiDT.	  Another	  trial	  
recalculated	  in	  retrospect	  the	  pafern	  of	  rise	  and	  found	  a	  median	  increase	  of	  20%	  per	  
month	  in	  case	  of	  recurrent	  disease	  as	  compared	  to	  median	  rise	  of	  0.3%	  in	  recurrence	  free	  
paAents.32	  Only	  one	  clinical	  trial	  applying	  CEA-­‐rise	  in	  follow-­‐up	  has	  been	  carried	  out	  by	  
Staab.35	  This	  study	  showed	  a	  modest	  survival	  beneﬁt	  aTer	  3	  years	  (5	  versus	  25%),	  
comparing	  paAents	  that	  had,	  or	  refused	  relaparotomy	  induced	  by	  CEA	  rise.	  This	  study	  does	  
not	  prove	  a	  befer	  outcome	  when	  applying	  a	  dynamic	  threshold	  value	  in	  CEA	  as	  compared	  
to	  other	  follow-­‐up	  methods,	  however	  it	  does	  suggest	  that	  early	  detecAon	  and	  treatment	  of	  
recurrent	  disease	  may	  result	  in	  a	  survival	  beneﬁt.	  Further	  this	  study	  has	  been	  carried	  out	  in	  
a	  Ame	  none-­‐invasive	  imaging	  techniques	  to	  localize	  recurrent	  disease	  were	  not	  yet	  
available.	  Most	  studies	  on	  CEA	  rise	  or	  doubling	  Ame	  evaluated	  the	  extent	  of	  rise	  with	  
recurrent	  disease	  that	  may	  help	  the	  determinaAon	  of	  the	  accurate	  threshold	  value	  (Table	  
4).13,	  32,	  33,	  37-­‐41	  None	  analyzed	  the	  pafern	  of	  rise	  and	  decrease	  with	  inﬂammatory	  disease	  or	  
smoking.	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Evidence	  of	  the	  hypothesis	  from	  the	  preceding	  phase	  II	  pilot	  trial
A	  phase	  II	  trial	  was	  started	  in	  2007	  evaluaAng	  the	  clinical	  applicability	  and	  outcomes	  of	  
HiDT	  in	  follow-­‐up	  aTer	  curaAve	  treatment	  of	  colorectal	  cancer.	  The	  primary	  endpoint	  is	  the	  
eligibility	  of	  curaAve	  treatment	  (increase	  to	  30%),	  secundary	  endpoints	  are	  the	  ability	  to	  
localize	  recurrent	  disease	  on	  imaging	  techniques	  (CT,	  minimum	  50%)	  and	  feasibility	  of	  the	  
computer	  supported	  protocol.	  This	  study	  was	  done	  in	  two	  diﬀerent	  hospitals.	  One	  hospital	  
(n=64)	  applied	  monthly	  serum-­‐CEA	  measurements	  with	  a	  dynamic	  threshold	  value	  of	  >	  
10%	  rise	  each	  month	  in	  two	  consecuAve	  measurements.	  The	  other	  hospital	  (n=177)	  
applied	  serum	  CEA	  measurements	  every	  3	  months,	  which	  was	  repeated	  aTer	  6	  weeks	  in	  
case	  of	  a	  rise	  of	  >	  10%.	  In	  both	  hospitals	  a	  rouAne	  CT	  of	  abdomen	  was	  performed	  at	  year	  1	  
and	  a	  CT	  of	  chest	  and	  abdomen	  at	  year	  2.	  
	   Recurrences	  up	  unAl	  2	  years	  aTer	  curaAve	  treatment,	  up	  unAl	  now,	  were	  found	  in	  28	  
paAents	  (12%)	  (ﬁgure	  1).	  Of	  28	  paAents	  with	  recurrent	  disease,	  12	  paAents	  (43%)	  were	  
eligible	  for	  curaAve	  treatment.	  The	  sensiAvity	  of	  HiDT	  serum	  CEA	  measurements	  was	  79%	  
and	  the	  speciﬁcity	  was	  88%	  in	  a	  mean	  range	  between	  2.5	  and	  10	  ng/ml.	  Mean	  increase	  
factor	  per	  month	  was	  1.48	  in	  the	  recurrence	  group.	  	  In	  a	  subgroup	  analysis	  of	  paAents	  from	  
the	  ﬁrst	  hospital	  who	  had	  false	  posiAve	  rises	  in	  CEA	  values	  (n=8),	  other	  causes	  such	  as	  
inﬂammatory	  disease	  (n=3)	  and	  dysplasAc	  polyps	  (n=2)	  were	  found	  as	  the	  cause	  of	  the	  rise;	  
in	  these	  paAents	  CEA	  values	  decreased	  aTer	  treatment.	  The	  mean	  increase	  factor	  per	  
month	  in	  the	  group	  of	  paAents	  with	  false	  posiAve	  rises	  in	  CEA	  was	  1.25.	  
	   The	  dynamic	  threshold	  value	  applied	  in	  the	  study	  is	  probably	  too	  low;	  approximately	  
half	  of	  the	  paAents	  with	  a	  rise	  in	  CEA	  did	  not	  have	  recurrent	  disease.	  A	  soluAon	  for	  this	  
problem	  -­‐next	  to	  alteraAon	  of	  the	  threshold	  value-­‐	  	  is	  to	  focus	  addiAonal	  diagnosAcs	  on	  
both	  possible	  recurrence,	  inﬂammatory	  diseases	  and	  dysplasAc	  polyps	  via	  colonoscopy.	  
Computer	  supported	  follow-­‐up	  was	  feasible	  and	  posiAvely	  rewarded	  by	  the	  treaAng	  
physiocians	  (Verberne,	  unpublished	  results).
	   A	  subgroup	  analysis	  of	  the	  eﬀect	  of	  smoking	  on	  base	  CEA	  values	  was	  done	  in	  one	  
hospital	  (n=44).	  The	  mean	  base	  CEA	  value	  for	  smokers	  who	  did	  not	  show	  a	  rise	  in	  CEA	  
(n=11)	  was	  5.1,	  were	  the	  mean	  base	  value	  of	  non-­‐smokers	  without	  rise	  in	  CEA	  (n=23)	  was	  
2.9	  ng/mL.	  The	  non-­‐smokers	  with	  recurrent	  disease	  (n=5)	  showed	  a	  mean	  rising	  factor	  of	  
1.32	  per	  month,	  and	  the	  smokers	  (n=2)	  showed	  a	  mean	  rising	  factor	  of	  1.39	  per	  month.	  
	   These	  preliminary	  results	  show	  an	  improved	  accuracy	  when	  applying	  a	  dynamic	  




A	  mulA-­‐center	  randomized	  phase	  III	  study	  on	  the	  usage	  of	  HiDT	  of	  serum	  CEA	  as	  a	  low	  cost	  
‘triage’	  blood	  biomarker	  triggering	  and	  direcAng	  selecAve	  CT	  usage	  compared	  to	  care	  as	  
usual	  is	  commencing	  recruitment	  in	  the	  Netherlands	  in	  2010.	  All	  paAents	  aTer	  curaAve	  
treatment	  of	  AJCC	  stage	  II-­‐IV	  colorectal	  cancer	  and	  ﬁt	  to	  undergo	  major	  surgery	  for	  
recurrent	  disease	  are	  eligible	  for	  this	  study.	  The	  intervenAon	  will	  be	  bi-­‐monthly	  serum	  CEA	  
measurements	  applying	  a	  dynamic	  threshold	  value	  of	  20%	  rise	  and	  yearly	  CT	  of	  chest	  and	  
abdomen	  at	  year	  1,	  2	  and	  3.	  The	  control	  group	  is	  care	  as	  usual.	  A	  clinically	  integrated	  
computer-­‐assisted	  support	  system	  is	  a	  key	  component	  of	  the	  trial	  design	  and	  will	  
concurrently	  be	  evaluated.	  The	  study	  will	  be	  performed	  in	  10	  hospitals	  by	  the	  use	  of	  a	  
stepped	  wedge	  design.	  Diﬀerent	  clusters	  cross	  over	  at	  diﬀerent	  Ame	  points	  in	  one	  
direcAon	  –	  from	  control	  to	  intervenAon.	  The	  Ame	  at	  which	  the	  cluster	  may	  start	  the	  
intervenAon	  is	  randomized,	  the	  baseline	  starAng	  point	  is	  October	  1st	  2010.	  The	  primary	  
outcome	  measure	  is	  the	  eligibility	  of	  intended	  curaAve	  treatment	  of	  recurrent	  disease.	  
Secundary	  outcome	  measures	  are:	  overall	  and	  disease	  free	  survival;	  opAmizing	  the	  
threshold	  value	  set	  against	  afainability	  of	  localizing	  recurrent	  disease	  on	  imaging;	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Objec>ve.	  The	   aim	   of	   the	   study	  was	   to	   evaluate	   the	   psychological	   eﬀects	   of	   an	  
intensive	   follow-­‐up	   scheme	   aTer	   curaAve	   treatment	   of	   colorectal	   cancer	   based	  
upon	  high-­‐frequency	  dynamic	  threshold	  (HiDT)	   serum	  CEA	  measurements	  and	  less	  
outpaAent	   clinic	   visits,	   as	   a	   feasibility	   study	   for	   a	   naAonal	   randomized	   trial	   on	  
follow-­‐up.	  
Design	  and	  Method.	   In	  this	  cross-­‐secAonal	  study, 	  138	  paAents	  were	   sent	  a	  postal	  
quesAonnaire	  to	  evaluate	  the	  eﬀects	  on	  the	  paAents’	  axtude	  and	  saAsfacAon,	  the	  
preference	   for	   follow-­‐up	   program,	   depression, 	   anxiety	   and	   cancer	   worries.	  
Responders	  in	   the	  intervenAon	  group	   (n=49)	  were	  compared	   to	   the	   care	  as	  usual	  
group.	  One	  way	  ANCOVA	  was	  used	  for	  staAsAcal	  analysis.
Results.	  PaAents	  in	  the	  intervenAon	  group	  were	  more	  saAsﬁed	  with	  their	  follow-­‐up	  
program	  (p	  =	  0.02).	  Most	  paAents	  (67%)	  preferred	  their	  current	  follow-­‐up	  program,	  
though	   the	   majority	   of	   the	   intervenAon	   paAents	   (62%)	   had	   a	   second	   preferred	  
opAon	   for	   the	   monthly	   blood	   tests	   with	   less	   contact	   with	   the	   physician.	   No	  
signiﬁcant	   diﬀerences	   were	   found	   between	   the	   intervenAon	   group	   and	   the	  
reference	   group	   according	   to	   the	  axtude	   towards	   follow-­‐up,	  anxiety,	  depression	  
and	  cancer	  worries.	  
Conclusion.	  The	   posiAve	   evaluaAon	   of	   the	  follow-­‐up	  based	   upon	  HiDT	  serum	  CEA	  
measurements	  without	  concomitant	  outpaAent	  clinic	  visits	  implies	  such	  approach	  is	  
feasible	   in	   respect	   to	   the	   psychological	   eﬀects	   of	   intensive	   screening	   ‘from	   a	  
distance’.
Introduc>on
Colorectal	  cancer	  is	  the	  third	  most-­‐common	  type	  of	  cancer	  in	  the	  Netherlands,	  with	  an	  
occurrence	  of	  10.000	  new	  paAents	  each	  year.	  ATer	  curaAve	  resecAon	  paAents	  are	  
subjected	  to	  a	  follow-­‐up	  program	  that	  consist	  of	  outpaAent	  clinic	  visits	  each	  3	  to	  6	  months	  
during	  5	  years,	  complemented	  with	  serum	  CEA	  measurements	  and	  imaging	  techniques.	  
The	  main	  goals	  of	  follow-­‐up	  are	  early	  detecAon	  of	  asymptomaAc	  recurrent	  disease	  and	  
metachronous	  tumors,	  evaluaAon	  of	  the	  funcAonal	  outcome	  of	  treatment	  and	  to	  answer	  
quesAons.	  1
The	  impact	  of	  follow-­‐up	  on	  quality	  of	  life	  can	  be	  both	  posiAve	  and	  negaAve.	  It	  may	  oﬀer	  
support	  and	  conﬁrmaAon	  but	  can	  also	  induce	  fear	  and	  worries.2-­‐12	  In	  general,	  paAents	  have	  
a	  posiAve	  axtude	  towards	  follow-­‐up	  schedules	  2,	  3	  and	  the	  advantages	  are	  felt	  to	  outweigh	  
the	  disadvantages.3	  Many	  paAents	  feel	  reassured	  13	  and	  prefer	  rouAne	  follow-­‐up	  4	  even	  if	  
the	  visit	  leads	  to	  anxiety	  and	  there	  is	  no	  guarantee	  recurrences	  can	  be	  detected	  or	  treated.
4-­‐6	  PaAents	  have	  high	  expectaAons	  of	  follow-­‐up,7	  believing	  that	  an	  early	  detecAon	  of	  
recurrence	  will	  lead	  to	  a	  higher	  chance	  to	  survive.	  Previous	  studies	  have	  shown	  that	  a	  
higher	  frequency	  of	  follow-­‐up	  visits	  does	  not	  lead	  to	  more	  distress	  but	  does	  increase	  
conﬁdence.2,	  14
The	  eﬃcacy	  of	  follow-­‐up	  aTer	  curaAve	  treatment	  of	  colorectal	  cancer	  has	  been	  under	  
debate;	  a	  survival	  beneﬁt	  achieved	  through	  early	  detecAon	  and	  treatment	  of	  recurrent	  
disease	  has	  been	  observed	  only	  in	  studies	  that	  included	  serum	  CEA	  measurements.15-­‐17	  
A	  new	  type	  of	  intensive	  follow-­‐up	  regime	  based	  upon	  high	  frequency	  dynamic	  threshold	  
(HiDT)	  serum	  CEA	  measurements	  is	  intended	  as	  a	  naAonal	  randomized	  trial	  in	  the	  
Netherlands.	  This	  new	  regime	  is	  largely	  carried	  out	  ‘from	  a	  distance’,	  meaning	  that	  a	  higher	  
frequency	  of	  serum	  CEA	  measurements	  is	  done	  with	  a	  decrease	  of	  outpaAent	  clinic	  visits.	  
PaAents	  are	  informed	  about	  their	  CEA	  values	  by	  postal	  mail.	  In	  the	  Medical	  Spectrum	  
Twente	  and	  University	  Medical	  Center	  Groningen	  a	  preceding	  phase	  II	  trial	  was	  carried	  out.	  
An	  evaluaAon	  of	  the	  psychological	  eﬀects	  of	  intensive	  follow-­‐up	  ‘from	  a	  distance’	  was	  
intended	  as	  a	  feasibility	  study	  for	  the	  naAonal	  trial.	  This	  study	  evaluates	  the	  eﬀects	  of	  the	  
follow-­‐up	  protocol	  on	  the	  paAents’	  axtude	  and	  saAsfacAon	  with	  the	  follow-­‐up	  program,	  
the	  preferences	  for	  follow-­‐up	  type,	  depression,	  anxiety	  and	  cancer	  worries.
93
Pa>ents	  and	  methods
PaAents	  that	  had	  curaAve	  treatment	  of	  colorectal	  cancer	  (pathological	  AJCC	  stage	  II	  and	  III)	  
within	  one	  year	  before	  inclusion	  and	  were	  ﬁt	  to	  undergo	  eventual	  metastasectomy,	  were	  
eligible	  for	  inclusion	  in	  the	  phase	  II	  trial	  and	  ‘marked’	  as	  eligible	  in	  their	  paAent	  records.	  
Approval	  of	  the	  Medical	  Ethical	  Commifee	  was	  obtained	  in	  both	  study	  centers	  under	  
governance	  of	  the	  University	  Medical	  Center	  Groningen	  (METc2007/015,	  NL15366.042.07).	  
This	  cross-­‐secAonal	  survey	  was	  performed	  in	  2009	  among	  60	  paAents	  who	  parAcipated	  in	  
the	  phase	  II	  clinical	  trial	  in	  the	  Medical	  Spectrum	  Twente	  and	  80	  paAents	  that	  had	  ‘care	  as	  
usual’.	  PaAents	  in	  the	  intervenAon	  group	  (n	  =	  60)	  had	  monthly	  serum	  CEA	  measurements	  
and	  a	  6	  to	  12	  monthly	  outpaAent	  clinic	  visit.	  PaAents	  with	  an	  increase	  in	  CEA-­‐level	  in	  two	  
consecuAve	  months	  were	  invited	  by	  telephone	  for	  further	  examinaAons	  in	  the	  hospital.	  In	  
case	  of	  a	  normal	  CEA-­‐level	  paAents	  received	  the	  result	  by	  lefer.	  PaAents	  had	  access	  to	  the	  
hospital	  for	  intermifent	  appointments	  with	  a	  physician,	  in	  case	  of	  quesAons	  or	  worries.	  
The	  intervenAon	  group	  paAents	  were	  asked	  to	  take	  part	  in	  the	  study	  by	  a	  physician,	  the	  
reference	  group	  were	  selected	  at	  random	  among	  the	  paAents	  that	  were	  already	  marked	  as	  
eligible	  for	  this	  study	  but	  were	  not	  asked	  to	  parAcipate	  due	  to	  logisAc	  reasons	  (no	  
outpaAent	  clinic	  visits	  during	  inclusion	  period).	  These	  paAent	  had	  ‘care	  as	  usual’,	  consisAng	  
of	  an	  outpaAent	  clinic	  visit	  every	  3	  to	  6	  months	  with	  concurrent	  serum	  CEA	  measurements. 	  
A	  total	  of	  61	  paAents	  were	  asked	  to	  parAcipate	  in	  the	  phase	  II	  trial,	  of	  whom	  60	  paAents	  
consented	  and	  one	  refused.	  To	  test	  the	  quesAonnaire	  2	  paAents	  of	  this	  group	  were	  
selected	  to	  take	  part	  in	  an	  interview.	  A	  set	  of	  138	  quesAonnaires	  was	  sent	  to	  the	  paAents,	  
of	  which	  58	  to	  the	  paAents	  of	  the	  intervenAon	  group	  and	  80	  to	  respondents	  of	  the	  
reference	  group.	  The	  quesAonnaires	  were	  analyzed	  anonymously.
Ques2onnaires
Apart	  from	  general	  data	  concerning	  sociodemographic	  status	  and	  medical	  history,	  in	  the	  
postal	  quesAonnaire	  the	  following	  topics	  were	  covered:
AFtudes	  Towards	  follow-­‐up.	  PaAents	  were	  asked	  to	  ﬁll	  out	  a	  validated	  15-­‐item	  
quesAonnaire	  on	  axtudes	  towards	  follow-­‐up	  that	  had	  been	  used	  to	  evaluate	  the	  follow-­‐up	  
of	  colorectal	  cancer.3,	  7	  This	  quesAonnaire	  consists	  of	  four	  subscales:	  communicaAon	  (with	  
the	  physician),	  reassurance,	  nervous	  anAcipaAon,	  and	  speciﬁc	  perceived	  disadvantages	  of	  
follow-­‐up.	  For	  the	  communicaAon	  and	  the	  reassurance	  scales,	  a	  higher	  score	  meant	  a	  more	  
posiAve	  evaluaAon	  (range	  0-­‐100).	  For	  the	  nervous	  anAcipaAon	  and	  the	  disadvantages	  
scales,	  a	  higher	  score	  meant	  more	  negaAve	  eﬀects	  (range	  0-­‐100).	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Anxiety	  and	  depression	  were	  examined	  by	  the	  Dutch	  version	  of	  the	  Hospital	  Anxiety	  and	  
Depression	  Scale	  (HADS).18	  Within	  this	  quesAonnaire	  higher	  scores	  meant	  more	  anxiety	  
and	  more	  depression.
Lerman	  developed	  a	  scale	  to	  measure	  cancer	  worries.19	  In	  this	  study	  we	  used	  the	  Dutch	  
version	  of	  this	  Cancer	  Worry	  Scale.	  Within	  this	  quesAonnaire	  paAents	  with	  higher	  scores	  
had	  more	  cancer	  worries.	  
Sa>sfac>on	  was	  measured	  by	  a	  quesAonnaire	  speciﬁcally	  designed	  for	  this	  study.	  This	  5-­‐
item	  quesAonnaire	  (α	  =	  0,90)	  was	  measured	  by	  a	  10-­‐point	  scale	  (Table	  4).	  The	  higher	  the	  
score,	  the	  more	  saAsﬁed	  the	  paAent	  was.
To	  measure	  pa>ents’	  preferred	  follow-­‐up	  program	  paAents	  had	  to	  declare	  which	  program	  
they	  preferred	  the	  most	  and	  which	  program	  they	  preferred	  the	  least.	  The	  paAents	  had	  the	  
choice	  between	  4	  opAons;	  (1)	  no	  follow-­‐up,	  (2)	  visits	  to	  the	  physician	  every	  3	  to	  6	  months	  
(the	  current	  mode	  of	  the	  reference	  group),	  (3)	  every	  month	  a	  blood	  test	  or	  (4)	  every	  month	  
a	  blood	  test	  with	  every	  6	  months	  to	  every	  year	  a	  visit	  to	  the	  physician	  (current	  mode	  of	  the	  
intervenAon	  group).	  A	  higher	  score	  meant	  a	  less	  preferred	  opAon	  for	  follow-­‐up	  (most	  
preferred	  =	  1	  to	  less	  preferred	  =	  4).	  AddiAonally,	  paAents	  were	  asked	  if	  they	  would	  like	  to	  
know	  when	  they	  have	  recurrences	  even	  if	  they	  are	  asymptomaAc	  but	  cannot	  be	  treated.	  
The	  higher	  the	  score,	  the	  more	  the	  paAents	  would	  like	  to	  know	  if	  they	  have	  recurrent	  
disease.	  The	  exact	  quesAons	  about	  the	  saAsfacAon	  and	  preferences	  of	  paAents	  are	  shown	  
in	  the	  appendix.
The	  cross-­‐secAonal	  design	  exists	  of	  quesAonnaires	  which	  were	  sent	  to	  the	  paAents’	  homes. 	  
The	  quesAonnaires	  were	  sent	  at	  a	  random	  Ame,	  not	  at	  a	  speciﬁc	  moment	  before	  or	  aTer	  a	  
follow-­‐up	  appointment.	  
Data	  analysis
All	  data	  were	  analyzed	  using	  SPSS	  (StaAsAcal	  Package	  of	  the	  Social	  Science)	  for	  Windows.	  	  
DescripAve	  staAsAcs	  were	  performed	  for	  all	  variables.	  The	  diﬀerences	  in	  paAent	  
characterisAcs	  between	  the	  two	  study	  groups	  were	  measured	  by	  the	  Chi	  square	  test	  and	  
the	  Mann	  Whitney	  U	  test.	  To	  asses	  the	  scale-­‐diﬀerences	  in	  axtude	  towards	  follow-­‐up,	  
saAsfacAon	  and	  eﬀects,	  the	  staAsAcal	  procedure	  for	  one	  way	  ANCOVA	  was	  used.	  
AssociaAons	  between	  paAents’	  preferred	  follow-­‐up	  and	  axtudes	  towards	  follow-­‐up,	  
saAsfacAon	  and	  eﬀects	  were	  tested	  using	  Spearman’s	  rank-­‐order	  correlaAon.	  It	  was	  
decided	  to	  include	  gender	  as	  a	  covariate	  in	  all	  subsequent	  analyses	  because	  of	  a	  group	  
diﬀerence	  aTer	  response	  in	  division	  of	  gender.	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Results
The	  response	  rate	  in	  the	  intervenAon	  group	  was	  84%	  (49	  out	  of	  58)	  and	  in	  the	  reference	  
group	  75%	  (60	  out	  of	  80).	  There	  were	  signiﬁcantly	  more	  males	  than	  females	  in	  the	  
intervenAon	  group	  (79%	  versus	  53%).	  No	  signiﬁcant	  diﬀerences	  between	  the	  groups	  were	  
found	  on	  the	  other	  demographic	  variables	  (Table	  1).
Table	  1:	  Patient	  characteristics
IntervenAon	  group
n	  =	  49	  (%)
Reference	  group
n=	  60	  	  (%)
p	  *
Average	  age	   67 67 n.s.
Number	  of	  men 38	  (79) 30	  (53) 0.01
ComposiAon	  of	  the	  family
	  	  	  	  	  Living	  alone
	  	  	  	  	  Living	  together









	  	  	  	  	  None
	  	  	  	  	  Yes	  <	  20	  years









	  	  	  	  	  Primary	  school
	  	  	  	  	  <	  Higher	  General	  	  Secondary	  	  	  	  
	  	  	  	  	  	  	  EducaAon	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  








Working 9(19) 8	  (14) n.s.
Co	  morbidity 18	  (39) 32	  (56) n.s.
*	  Chi	  square	  and	  Mann	  Whitney	  U	  test
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Advantages	  outweigh	  disadvantages	  














Bad	  sleeping	  before	  follow-­‐up
Postpone	  plans	  aTer	  follow-­‐up
Dread	  follow-­‐up















Follow-­‐up	  rather	  at	  General	  PracAAoner
InvesAgaAons	  burdensome	  











Ask	  about	  things	  at	  follow-­‐up
Discuss	  mafers	  of	  concern
Do	  people	  pay	  afenAon	  to	  you















SaAsfacAon	  with	  doctor-­‐paAent	  contact
Suﬃcient	  informaAon	  about	  follow-­‐up	  procedure





























*(p)	  =	  scale	  diﬀerence	  measured	  by	  One	  way	  ANOVA	  with	  gender	  as	  a	  covariate
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Aftude
No	  signiﬁcant	  diﬀerences	  were	  found	  between	  the	  two	  study	  groups.	  From	  the	  outcomes	  
in	  Table	  2	  it	  can	  be	  deduced	  that	  the	  majority	  of	  the	  paAents	  in	  both	  study	  groups	  felt	  
rather	  reassured	  by	  their	  own	  follow-­‐up	  program,	  the	  intervenAon	  group	  experienced	  less	  
nervous	  anAcipaAon	  in	  comparison	  to	  the	  paAents	  in	  the	  reference	  group	  and	  the	  
reference	  group	  reported	  more	  disadvantages	  in	  the	  follow-­‐up	  program.	  PaAents	  were	  
moderately	  posiAve	  about	  the	  communicaAon	  with	  the	  physician.	  Summarizing,	  both	  study	  
groups	  reported	  a	  rather	  posiAve	  axtude	  towards	  the	  follow-­‐up	  program.	  
Sa2sfac2on	  and	  preferences
The	  intervenAon	  group	  had	  signiﬁcant	  higher	  scores	  in	  every	  separate	  item	  of	  the	  
saAsfacAon	  scale	  in	  comparison	  to	  the	  reference	  group	  (p=0.02)	  (table	  2).	  PaAents	  in	  the	  
intervenAon	  group	  would	  more	  oTen	  like	  to	  have	  the	  knowledge	  of	  the	  presence	  of	  
recurrent	  disease	  in	  comparison	  to	  the	  paAents	  in	  the	  reference	  group,	  even	  if	  there	  would	  
be	  no	  curaAve	  treatment	  opAons;	  this	  diﬀerence	  was	  signiﬁcant	  (p=0.03)	  (table	  2).	  
Eﬀects
No	  signiﬁcant	  diﬀerences	  were	  found	  between	  intervenAon	  and	  reference	  group	  
concerning	  anxiety,	  depression	  and	  cancer	  worries	  in	  follow-­‐up	  (table	  2).	  The	  majority	  of	  
the	  paAent	  groups	  reported	  somewhat	  or	  no	  anxiety.	  Depression	  was	  present	  in	  only	  a	  
minority	  of	  the	  paAents	  with	  a	  diﬀerence	  in	  occurrence	  favouring	  the	  intervenAon	  group.	  
More	  paAents	  in	  the	  reference	  group	  reported	  oTen,	  to	  almost	  always,	  having	  cancer	  
worries,	  in	  comparison	  to	  the	  intervenAon	  group	  (P	  =	  0,04).	  
Pa2ents	  preferred	  op2on	  for	  follow-­‐up
In	  the	  intervenAon	  group	  the	  majority	  chose	  for	  their	  current	  mode	  (monthly	  blood	  tests	  
and	  visits	  to	  the	  doctor	  every	  6	  to	  12	  months).	  In	  the	  reference	  group	  about	  half	  of	  the	  
respondents	  preferred	  their	  present	  mode	  (3-­‐6	  monthly	  visits	  to	  the	  physician).	  PaAents	  
had	  the	  opAon	  to	  point	  out	  their	  second	  preferred	  choice	  for	  a	  follow-­‐up	  program.	  Some	  of	  
the	  paAents	  only	  declared	  their	  ﬁrst	  choice;	  therefore	  the	  number	  of	  cases	  diﬀered	  within	  
the	  ﬁrst	  and	  second	  choice.	  More	  than	  half	  of	  the	  paAents	  in	  the	  intervenAon	  group	  chose	  
the	  opAon	  with	  the	  monthly	  blood	  test	  without	  visits	  to	  the	  physician.	  The	  paAents	  in	  the	  
reference	  group	  chose	  very	  diversely	  for	  their	  second	  choice.	  The	  least	  afracAve	  opAon	  
was	  follow-­‐up	  without	  an	  established	  follow-­‐up	  program.
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Associa2ons	  in	  preference	  for	  a	  follow-­‐up	  program
A	  stronger	  preference	  for	  the	  intensive	  follow-­‐up	  was	  found	  among	  the	  paAents	  in	  the	  
reference	  group	  in	  case	  they	  had	  higher	  scores	  for	  nervous	  anAcipaAon	  (table	  4).	  PaAents	  
in	  the	  intervenAon	  group	  with	  a	  lower	  score	  for	  saAsfacAon	  preferred	  the	  follow-­‐up	  
program	  with	  contact	  with	  the	  physician.	  In	  the	  reference	  group	  a	  lower	  score	  on	  
saAsfacAon	  meant	  a	  higher	  preference	  for	  their	  current	  mode.	  PaAents	  in	  the	  intervenAon	  
group	  with	  higher	  scores	  on	  depression	  had	  a	  higher	  preference	  for	  the	  most	  intensive	  
follow-­‐up	  program.	  PaAents	  in	  the	  reference	  group	  with	  higher	  scores	  for	  depression	  and	  
cancer	  worries	  had	  a	  stronger	  preference	  for	  the	  most	  intensive	  follow-­‐up.	  PaAents	  in	  the	  
reference	  group	  with	  higher	  scores	  for	  anxiety,	  depression	  and	  cancer	  worries	  even	  had	  a	  
stronger	  preference	  for	  the	  monthly	  blood	  test,	  without	  visits	  to	  the	  physician.	  They	  opted	  
less	  for	  their	  current	  mode.
Table	  3.	  Preferred	  options	  for	  follow-­‐up









Most	  intensive	  follow-­‐up	   33	  (67) 5	  (14) 20	  (34) 13	  (22)
Intensive	  follow-­‐up	   6	  (12) 23	  (62) 4	  (7) 14	  (24)
Less	  intensive	  follow-­‐up	   8	  (16) 8	  (22) 32	  (54) 10	  (17)
No	  follow-­‐up 2	  (4) 1	  (3) 3	  (5) 5	  (8)
Most	  intensive	  follow-­‐up:	  monthly	  blood	  tests	  +	  6	  monthly	  visits	  to	  the	  physician
Intensive	  follow-­‐up:	  monthly	  blood	  tests
Less	  intensive	  follow-­‐up:	  3-­‐6	  monthly	  visits	  to	  the	  physician
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Table	  4.	  	  Spearman’s	  Rho	  correlation	  between	  preferences	  and	  attitude	  
towards	  follow-­‐up,	  satisfaction	  and	  effects
AFtude
IntervenAon	  group	  (n	  =	  49) Reference	  Group	  (n	  =	  60)
Most	  int.	   Int. Less	  int. Most	  int.	   Int. Less	  int.
Reassurance -­‐0.28 -­‐0.05 0.24 0.13 -­‐0.20 0.08
Nervous	  anAcipaAon -­‐0.18 0.06 0.28 -­‐0.14 -­‐0.32* 0.26
General	  disadvantages -­‐0.05 0.09 -­‐0.07 -­‐0.15 -­‐0.21 0.13
CommunicaAon -­‐0.12 0.21 0.12 0.18 0.28 -­‐0.22
SaAsfacAon -­‐0.23 0.32* 0.04 0.12 0.26 0.31*
Anxiety -­‐0.08 -­‐0.07 -­‐0.16 -­‐0.27 -­‐0.42** 0.33*
Depression 0.13 0.10 0.32* -­‐0.35* -­‐0.52** 0.39**
Cancer	  Worries -­‐0.19 -­‐0.08 0.05 -­‐0.31* -­‐0.48** 0.41**
Int.:	  intensive
*.	  Correlaaon	  is	  signiﬁcant	  at	  the	  0,05	  level	  (2-­‐tailed)
**.	  Correlaaon	  is	  signiﬁcant	  at	  the	  0,01	  level	  (2-­‐tailed)
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Discussion	  and	  conclusion
This	  study	  was	  the	  ﬁrst	  which	  measured	  the	  eﬀects	  of	  an	  intensive	  follow-­‐up	  program	  
’from	  a	  distance’;	  the	  main	  diﬀerence	  in	  follow-­‐up	  between	  the	  two	  groups	  was	  the	  
frequency	  of	  serum	  CEA	  measurements,	  from	  which	  the	  results	  were	  communicated	  by	  
lefer	  instead	  of	  in	  direct	  communicaAon	  with	  the	  physician.	  Only	  the	  level	  of	  saAsfacAon	  
diﬀered	  signiﬁcantly,	  favouring	  the	  intervenAon	  group	  (p	  =	  0.02).
PaAents	  did	  not	  experience	  many	  negaAve	  aspects	  of	  the	  follow-­‐up	  program.	  As	  in	  other	  
studies,3,	  5,	  7	  paAents	  felt	  reassured	  by	  regular	  follow-­‐up.	  It	  is	  however	  reasonable	  that	  
paAents	  have	  posiAve	  feelings	  towards	  the	  follow-­‐up	  program.	  They	  are	  oTen	  grateful	  for	  
the	  curaAve	  treatment	  and	  have	  posiAve	  beliefs	  in	  the	  eﬃcacy	  of	  the	  follow-­‐up	  program.	  
This	  is	  even	  more	  so	  because	  all	  paAents	  were	  treated	  with	  curaAve	  intent	  and	  the	  
majority	  of	  the	  paAents	  received	  a	  posiAve	  result	  of	  the	  medical	  tests	  up	  unAl	  now.	  There	  
were	  few	  paAents	  with	  suspicion	  on	  or	  diagnosed	  recurrent	  disease	  during	  the	  study	  
period.	  Whether	  this	  concerned	  paAents	  that	  returned	  the	  quesAonnaire	  is	  not	  known,	  
because	  of	  the	  anonymous	  processing	  of	  the	  quesAonnaires.	  The	  posiAve	  feelings	  towards	  
follow-­‐up	  does	  cause	  diﬃculty	  in	  ﬁnding	  more	  opAmal	  strategies	  in	  follow-­‐up	  programs,	  
because	  diﬀerences	  will	  be	  less	  pronounced.20	  However,	  although	  taking	  this	  eﬀect	  into	  
account	  is	  important	  in	  designing	  new	  follow-­‐up	  strategies,	  ﬁnding	  a	  more	  opAmal	  
approach	  was	  not	  the	  aim	  of	  this	  study.
PaAents	  who	  suﬀered	  from	  more	  anxiety,	  depression	  and	  cancer	  worries	  preferred	  a	  more	  
intensive	  follow-­‐up	  program,	  which	  is	  in	  agreement	  with	  the	  ﬁnding	  that	  paAents	  who	  
have	  more	  distress	  need	  more	  reassurance.21	  The	  level	  of	  anxiety,	  depression	  and	  cancer	  
worries,	  and	  axtude	  towards	  follow	  up	  however	  did	  not	  diﬀer	  between	  both	  groups,	  so	  
this	  eﬀect	  could	  not	  be	  conﬁrmed	  in	  these	  study	  results.	  Intensive	  follow-­‐up	  may	  lead	  to	  
less	  instead	  of	  more	  distress,	  which	  may	  be	  the	  reason	  for	  the	  higher	  paAents’	  saAsfacAon	  
in	  the	  intervenAon	  group.	  
IntervenAon	  group	  paAents	  more	  oTen	  reported	  a	  preference	  for	  knowing	  the	  presence	  of	  
recurrent	  disease,	  even	  when	  no	  therapeuAc	  opAons	  existed.	  This	  may	  have	  been	  caused	  
by	  the	  awareness	  of	  possible	  recurrent	  disease	  through	  the	  study	  informaAon	  in	  the	  
intervenAon	  group.	  Most	  paAents	  (67%)	  preferred	  their	  current	  follow-­‐up	  program,	  
reﬂecAng	  their	  general	  saAsfacAon	  with	  their	  follow-­‐up.	  The	  majority	  of	  the	  intervenAon	  
paAents	  (62%)	  had	  a	  second	  preferred	  opAon	  for	  the	  monthly	  blood	  tests	  with	  less	  contact	  
with	  the	  physician.	  The	  communicaAon	  with	  the	  physician	  was	  reported	  as	  moderately	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posiAve.	  The	  outpaAent	  clinic	  visit	  and	  contact	  with	  the	  physician	  seem	  to	  be	  less	  
important	  than	  opAmal	  oncological	  screening	  to	  the	  paAents.	  
A	  limitaAon	  of	  the	  present	  study	  is	  that	  paAents	  were	  not	  assigned	  to	  one	  of	  the	  study	  
groups	  in	  a	  randomized	  controlled	  manner.	  However	  the	  inclusion	  was	  near	  random	  by	  the	  
chance	  of	  having	  an	  outpaAent	  clinic	  visit	  in	  the	  inclusion	  period	  (which	  lasted	  3	  months)	  
and	  all	  but	  one	  of	  the	  asked	  paAents	  agreed	  to	  parAcipate	  in	  the	  trial.	  PaAents	  from	  the	  
experimental	  group	  might	  have	  been	  slightly	  more	  posiAve	  due	  to	  fact	  that	  they	  were	  
invited	  to	  parAcipate	  in	  this	  study	  (Hawthorne	  eﬀect).	  The	  more	  posiAve	  experience	  of	  the	  
intervenAon	  group	  may	  also	  have	  been	  due	  to	  the	  explicit	  reassurance	  that	  paAents	  could	  
contact	  the	  physician	  in	  between	  visits	  when	  quesAons	  or	  worries	  existed.	  This	  reassurance	  
was	  not	  always	  explicitly	  given	  to	  the	  paAents	  in	  the	  reference	  group,	  possibly	  causing	  bias.	  
Important	  issues	  in	  this	  new	  type	  of	  follow-­‐up	  are	  adequate	  informaAon	  on	  the	  follow-­‐up	  
program	  and	  the	  accessibility	  of	  the	  outpaAent	  clinic	  in	  case	  of	  worries	  or	  quesAons.	  The	  
possibility	  for	  intermifent	  appointments	  on	  the	  outpaAent	  clinic	  for	  the	  paAents	  in	  the	  
intervenAon	  group,	  has	  barely	  been	  used	  during	  the	  trial	  and	  is	  therefore	  logisAcally	  
feasible.	  Several	  paAents	  expressed	  the	  importance	  of	  Amely	  and	  predictable	  feedback	  on	  
test	  results	  and	  direct	  contact	  with	  the	  physician	  by	  phone	  in	  case	  of	  worrisome	  ﬁndings	  of	  
the	  blood	  tests.	  Signalling	  and	  processing	  of	  test	  results	  and	  reporAng	  to	  the	  paAent	  should	  
therefore	  be	  Aghtly	  organized,	  preferably	  with	  an	  automated	  support	  system.
Follow-­‐up	  programs	  in	  itself	  have	  a	  posiAve	  eﬀect	  on	  reassurance	  and	  remain	  important	  
for	  paAents	  aTer	  curaAve	  treatment	  of	  cancer.	  This	  should	  obviously	  be	  based	  on	  real	  
paAents’	  needs	  and	  posiAvely	  aﬀect	  the	  oncological	  outcome.	  New	  types	  of	  follow-­‐up	  
should	  therefore	  be	  evaluated	  for	  medical	  eﬀecAveness,	  opAmal	  communicaAon	  and	  
paAents’	  needs.	  The	  posiAve	  evaluaAon	  of	  the	  intervenAon	  group	  and	  the	  preference	  of	  
the	  intervenAon	  group	  for	  the	  monthly	  serum	  CEA	  blood	  test	  over	  visits	  to	  the	  physician	  
imply	  that	  an	  intensive	  follow-­‐up	  program	  with	  less	  outpaAent	  clinic	  visits	  as	  intended	  in	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Would	  you	  indicate	  through	  giving	  a	  report	  mark	  from	  1	  to	  10	  how	  saAsﬁed	  you	  are	  about	  
the	  follow-­‐up	  program	  you	  follow?	  
Would	  you	  indicate	  through	  giving	  a	  report	  mark	  from	  1	  to	  10	  how	  saAsﬁed	  you	  are	  about	  
the	  number	  of	  follow-­‐up	  visits	  you	  get?
Would	  you	  indicate	  through	  giving	  a	  report	  mark	  from	  1	  to	  10	  how	  saAsﬁed	  you	  are	  about	  
the	  contact	  you	  have	  with	  the	  physician?
Do	  you	  think	  you	  get	  enough	  informaAon	  about	  the	  follow-­‐up	  program	  aTer	  your	  
treatment	  for	  colorectal	  cancer?
Would	  you	  indicate	  through	  giving	  a	  report	  mark	  from	  1	  to	  10	  how	  saAsﬁed	  you	  are	  about	  
the	  informaAon	  you	  receive	  of	  the	  physician	  during	  the	  follow-­‐up	  visit?
Pa2ents’	  preferences
I	  would	  like	  to	  know	  when	  I	  have	  recurrent	  disease,	  even	  if	  I	  would	  know	  it	  can’t	  be	  treated	  
in	  any	  way	  and	  I	  wouldn’t	  have	  complaints	  for	  months.
	  not	  at	  all	   	  somewhat	   	  Rather	   	  Very	  much
Pa2ents’	  preferred	  op2on	  for	  a	  follow-­‐up	  program
What	  if	  you	  could	  choose	  your	  preferred	  opAon	  for	  a	  follow-­‐up	  program.	  Which	  follow-­‐up	  
program	  would	  you	  prefer?	  Extend	  marks	  from	  1	  to	  4:
1	  for	  the	  follow-­‐up	  program	  you	  mostly	  prefer
2	  for	  the	  follow-­‐up	  program	  you	  rather	  prefer
3	  for	  the	  follow-­‐up	  program	  you	  less	  prefer
4	  for	  the	  follow-­‐up	  program	  you	  least	  prefer
(please	  ﬁll	  in	  all	  four	  diﬀerent	  marks	  on	  the	  dofed	  lines)
…..	   Intensive	  follow-­‐up	  program	  with	  visits	  to	  the	  physician	  every	  6	  months	  to	  once	  a	  
year	  and	  every	  month	  a	  blood	  test
…..	   Intensive	  follow-­‐up	  program	  with	  a	  blood	  test	  every	  month	  and	  only	  contact	  with	  
the	  physician	  in	  case	  of	  quesAon	  or	  problems
…..	   Less	  intensive	  follow-­‐up	  program	  with	  a	  visit	  to	  the	  physician	  every	  3	  to	  6	  months	  
including	  a	  blood	  test





Early	  recurrent	  disease	  aaer	  cura>ve	  treatment	  
of	  non-­‐metasta>c	  colorectal	  cancer	  found	  only	  in	  
pa>ents	  with	  locally	  advanced	  primary	  tumors;	  
follow-­‐up	  may	  be	  reduced	  in	  non-­‐advanced	  cases
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Background:	   Over	   the	   last	   decade	   several	   changes	   in	   clinical	   pracAce,	   such	   as	  
rouAne	  staging	  before	  treatment	  with	   abdominal	   CT	  and	   (neo)	  adjuvant	   combined	  
treatment, 	  are	  likely	  to	  inﬂuence	  the	  recurrence	  pafern	   in	  colorectal	  cancer	   (CRC).	  
The	  eﬃcacy	  and	  cost-­‐eﬀecAveness	  of	   follow-­‐up	  (FU)	  may	  be	  enhanced	  with	  up-­‐to-­‐
date	  esAmates	  on	  incidence	  and	  expected	  Ame	  to	  recurrent	  disease	  (RD).	  
Pa>ents	   and	   methods:	  A	  consecuAve	   series	  of	   paAents	  with	   non-­‐metastaAc	   CRC	  
treated	   with	   curaAve	   intent,	   was	   analyzed	   on	   pafern	   of	   RD	   within	   one	   year	  
(treatment	  period	  2007-­‐2008,	  n=190).	  All	  paAents	  were	  staged	  with	  abdominal	  CT.	  
Data	   were	   derived	   from	   a	   prospecAve	   hospital-­‐populaAon	   based	   registry	   of	  
colorectal	   surgery.	  A	  post-­‐hoc	  analysis	  on	   the	   risk	  factors	  pT,	  pN	   and	  urgency	  was	  
done.
Results:	  The	   incidence	  of	   RD	   within	  1	   year	   was	   6%	   (n=12);	  all	   these	  paAents	   had	  
locally	  advanced	  primary	  tumours	  (colon	  cancer	   10,	  rectal	  cancer	   2).	  The	   incidence	  
of	  early	  RD	  was	  17%	   in	  locally	  advanced	  disease	  and	  0%	   in	  non-­‐advanced	  CRC. 	  The	  
post-­‐hoc	  mulAvariate	  analysis	  showed	  pT4	  stage	  as	  main	  risk	  factor	  for	  early	  RD	  (OR	  
14.9,	  95%	  CI	  2.9-­‐76.8).	  
Conclusion:	  FU	  aimed	   at	  the	  detecAon	   of	  RD	  in	   the	  ﬁrst	   year	   aTer	   treatment	  may	  
not	   be	   necessary	   in	   staged	   paAents	   with	   non-­‐advanced	   CRC,	   but	   cannot	   be	  
postponed	   in	   paAents	   with	   locally	  advanced	   primary	   tumors.	  This	   study	   is	  a	   ﬁrst	  
eﬀort	  towards	  an	  individualized	  risk-­‐adapted	  FU.	  
Background
Colorectal	  cancer	  (CRC)	  is	  a	  common	  disease	  with	  a	  life	  Ame	  risk	  of	  ±	  10%	  in	  the	  Western	  
populaAon.	  Approximately	  half	  of	  these	  paAents	  will	  develop	  liver	  metastases,	  peritoneal	  
carcinomatosis	  or	  locoregional	  recurrence.	  In	  the	  past,	  metastaAc	  CRC	  was	  frequently	  
regarded	  as	  incurable	  and	  suitable	  for	  palliaAve	  measures	  only,	  but	  nowadays	  various	  
mulAmodality	  treatments	  oﬀer	  a	  chance	  for	  cure	  to	  selected	  paAents.1-­‐6	  This	  has	  set	  forth	  
the	  rouAne	  of	  staging	  with	  abdominal	  CT	  on	  distant	  metastases	  before	  treatment	  and	  
renewed	  eﬀorts	  to	  opAmize	  follow-­‐up	  (FU).	  
	   The	  pafern	  of	  recurrent	  disease	  (RD)	  is	  likely	  to	  change	  as	  an	  eﬀect	  of	  staging,	  by	  
ﬁnding	  metastaAc	  CRC	  at	  an	  earlier	  stage,	  i.e.	  before	  treatment.	  Developments	  in	  (neo)	  
adjuvant	  treatment	  modaliAes	  in	  the	  last	  decade	  have	  changed	  recurrence	  paferns	  as	  
well,	  with	  a	  decrease	  in	  incidence	  and	  a	  possible	  delay	  of	  RD	  as	  compared	  to	  historical	  
data.7-­‐9	  These	  changes	  in	  recurrence	  paferns	  are	  relevant	  in	  designing	  new	  FU	  trial	  
strategies.	  	   	   Currently,	  the	  highest	  intensity	  of	  FU	  is	  apprehended	  in	  the	  ﬁrst	  year	  aTer	  
surgery.10
The	  aim	  of	  this	  study	  is	  to	  analyze	  the	  recurrence	  pafern	  within	  one	  year	  aTer	  surgery,	  in	  a	  
consecuAve	  series	  of	  non-­‐metastaAc	  CRC	  paAents	  that	  were	  staged	  with	  abdominal	  CT	  and	  
curaAvely	  treated	  according	  to	  current	  clinical	  pracAce.	  
Pa>ents	  and	  methods
The	  data	  were	  collected	  in	  the	  Medical	  Spectrum	  Twente,	  a	  large	  community	  teaching	  
hospital	  in	  the	  Netherlands,	  which	  funcAons	  as	  a	  referral	  center	  for	  liver	  and	  lung	  surgery.
The	  study	  design	  is	  a	  prospecAve	  observaAonal	  study	  in	  an	  unselected	  hospital	  paAent	  
populaAon	  operated	  from	  January	  2007	  All	  December	  2008.	  The	  recurrence	  pafern	  within	  
one	  year	  aTer	  surgery	  (‘early	  RD’)	  was	  analyzed	  in	  a	  cohort	  of	  paAents	  who	  were	  staged	  
with	  abdominal	  CT,	  underwent	  treatment	  with	  curaAve	  intent	  for	  non-­‐metastaAc	  CRC	  and	  
had	  a	  follow-­‐up	  of	  at	  least	  12	  months	  (Figure	  1).	  FU	  consisted	  of	  3-­‐monthly	  outpaAent	  
clinic	  visits	  with	  serum	  CEA	  measurements	  and	  biannual	  ultrasound	  of	  the	  liver.	  Of	  190	  
paAents	  included	  in	  the	  analysis,	  64	  paAents	  parAcipated	  in	  a	  phase	  II	  FU	  trial	  consisAng	  of	  
monthly	  serum	  CEA	  measurements	  and	  abdominal	  CT	  1	  and	  2	  years	  aTer	  surgery.
	   All	  surgical	  paAents	  with	  CRC	  in	  the	  study	  hospital	  are	  prospecAvely	  registered	  in	  a	  
database	  designed	  for	  colorectal	  surgery,	  which	  includes	  the	  staging	  procedures,	  paAent	  -­‐,	  
treatment-­‐	  and	  histopathological	  characterisAcs,	  outcome	  and	  FU.	  PaAents	  are	  staged	  
according	  to	  the	  TNM	  classiﬁcaAon	  (6th	  ediAon)	  and	  classiﬁed	  according	  to	  the	  American	  
Joint	  Commifee	  on	  Cancer	  (AJCC)	  stages.	  Rectal	  cancer	  is	  deﬁned	  as	  a	  primary	  
adenocarcinoma	  located	  below	  the	  peritoneal	  reﬂecAon.	  Locally	  advanced	  rectal	  cancer	  
(LARC)	  is	  deﬁned	  as	  a	  cT4	  tumor	  or	  a	  cT3	  tumor	  with	  a	  threatened	  circumferenAal	  margin	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on	  pelvic	  MRI.	  Locally	  advanced	  colon	  cancer	  (LACC)	  is	  deﬁned	  by	  pT4	  stage.	  LARC	  was	  
treated	  with	  neoadjuvant	  chemoradiaAon	  (25	  x	  2	  Gy	  and	  oral	  capecitabine)	  for	  
downstaging,	  small	  cT3	  rectal	  cancer	  received	  pre-­‐operaAve	  5x5	  Gy	  radiotherapy.	  Adjuvant	  
chemotherapy	  (5FU	  combined	  with	  oxaliplaAn)	  was	  oﬀered	  to	  colon	  cancer	  paAents	  with	  
relevant	  risk	  factors	  (lymph	  node	  metastases,	  pT4	  colon	  cancer,	  angio-­‐invasive	  or	  
perineural	  growth).	  Emergency	  surgery	  is	  deﬁned	  as	  all	  non-­‐planned	  admissions	  to	  the	  
hospital	  due	  to	  symptoms	  related	  to	  the	  tumor	  and	  includes	  both	  urgent	  (surgery	  
imperaAve	  within	  5	  days)	  and	  acute	  surgical	  procedures	  (surgery	  imperaAve	  within	  6	  
hours).
	   A	  post-­‐hoc	  analysis	  on	  risk	  on	  early	  RD	  was	  performed	  concerning	  the	  prognosAc	  
factors	  pT,	  pN	  and	  urgency	  of	  surgical	  treatment.	  StaAsAcal	  analysis	  was	  carried	  out	  using	  
the	  Fisher	  Exact	  test	  and	  Pearson	  Chi-­‐Square	  test	  where	  appropriate.	  MulAvariate	  logisAc	  
regression	  analysis	  was	  performed	  to	  idenAfy	  independent	  risk	  factors	  for	  recurrence.	  The	  
data	  were	  analyzed	  using	  SPSS	  soTware	  and	  considered	  staAsAcally	  signiﬁcant	  when	  p	  <	  
0.05.
Results
Of	  the	  354	  paAents	  operated	  for	  CRC	  in	  the	  analyzed	  period,	  96	  paAents	  had	  synchronous	  
metastases	  (27%).	  Twenty-­‐ﬁve	  percent	  (88	  of	  354)	  of	  all	  paAents	  had	  incurable	  disease,	  
consisAng	  of	  paAents	  with	  either	  incurable	  distant	  metastases	  (n=72)	  or	  irradical	  or	  no	  
resecAons	  (n=16).	  Staging	  with	  abdominal	  CT	  was	  done	  in	  90%	  of	  the	  paAents.	  (Table	  1,	  
Figure	  1).	  
	   From	  the	  analyzed	  group	  of	  190	  paAents	  with	  non-­‐metastaAc,	  curaAvely	  treated	  CRC	  
(Figure	  1),	  12	  paAents	  (6%)	  had	  RD	  within	  1	  year;	  2	  paAents	  had	  LARC	  (cT3-­‐4,	  ypT3)	  and	  10	  
paAents	  had	  LACC	  (pT4).	  Locally	  advanced	  primary	  tumors	  were	  present	  in	  72	  paAents,	  of	  
whom	  39	  paAents	  had	  LACC	  and	  33	  LARC.	  The	  incidence	  of	  RD	  in	  locally	  advanced	  CRC	  
within	  one	  year	  was	  17%	  (12	  out	  of	  72)
	   RD	  was	  most	  oTen	  localized	  in	  the	  peritoneal	  cavity	  (n=5)	  and	  the	  liver	  (n=5).	  Four	  of	  
these	  12	  paAents	  were	  treated	  with	  curaAve	  intent.	  The	  individual	  paAent	  and	  tumor	  
characterisAcs	  of	  the	  twelve	  paAents	  with	  early	  RD	  are	  shown	  in	  table	  3.
	   A	  post-­‐hoc	  analysis	  was	  performed	  on	  (y)pT	  stage,	  (y)pN	  stage	  and	  urgency	  (Table	  4).	  
The	  strongest	  prognosAc	  factors	  in	  the	  univariate	  analysis	  for	  early	  recurrence	  were	  T	  stage	  
(pT4	  ,	  RR	  17.1	  (3.9-­‐76.9),	  p	  <	  0.001)	  and	  urgency	  (emergency	  procedures,	  RR	  7.3	  (2.6-­‐20.8),	  
p	  =	  0.001).	  A	  strong	  correlaAon	  was	  found	  between	  urgency	  and	  pT	  stage.	  In	  the	  
mulAvariate	  analysis	  only	  pT	  stage	  (pT4;	  OR	  14.9	  95%	  CI	  2.9-­‐76.8)	  was	  staAsAcally	  
signiﬁcant	  with	  urgency	  reaching	  borderline	  signiﬁcance.	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Neo-­‐adjuvant	  chemoradiaAon	  rectal	  carcinoma
Neo-­‐adjuvant	  radiotherapy	  (5x5Gy)	  rectal	  carcinoma
Chemotherapya
















































a	  Both	  paaents	  were	  treated	  in	  a	  palliaave	  se}ng	  with	  chemotherapy.	  Because	  of	  local	  
complicaaons	  of	  the	  tumor	  during	  chemotherapy	  they	  underwent	  a	  palliaave	  resecaon.
b	  Both	  paaents	  were	  treated	  with	  a	  liver-­‐ﬁrst	  approach,	  consisang	  of	  neo-­‐adjuvant	  chemotherapy	  
followed	  by	  liver	  surgery,	  a*er	  that	  short-­‐course	  radiotherapy	  (5x5	  Gy)	  followed	  by	  rectal	  resecaon.
c	  Based	  on	  6th	  ed.	  TNM	  classiﬁcaaon,	  including	  ypTN	  a*er	  downstaging	  (n=33)
d	  Incurable	  disease	  was	  deﬁned	  as	  irradical	  resecaon	  (R1	  and	  R2)	  or	  distant	  metastases	  that	  could	  
not	  be	  treated	  with	  curaave	  intent.
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a	  Based	  on	  6th	  ed.	  TNM	  classiﬁcaAon,	  including	  ypTN	  aTer	  downstaging	  (n=33)
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1 M 63 Rectum	  cT3N1 Yes ElecAve ypT3 ypN0 No 8 Liver C
2 M 79 Rectum	  cT4N1 Yes ElecAve ypT3 ypN0 No 10 Liver C
3 F 63 Colon	   No Acute pT4 pN0 Yes 10 LR+PC P
4 F 80 Colon No Acute pT4 pN0 Yes 5 PC P
5 F 72 Colon No Acute pT4 pN1 No 10 PC P
6 F 92 Colon No Acute pT4 pN1 Yes 6 Incisional P
7 F 69 Colon No ElecAve pT4 pN1 No 9 Liver P
8 F 84 Colon No ElecAve pT4 pN2 Yes 9 Brain P
9 F 65 Colon No ElecAve pT4 pN2 Yes 3 Liver C
10 M 61 Colon No ElecAve pT4 pN2 Yes 10 LR C
11 M 70 Colon No Acute pT4 pN2 No 6 Liver	  /	  lung P
12 M 64 Colon No Acute pT4 pN2 Yes 11 PC P
Abbreviaaons;	  LR:	  local	  recurrence,	  PC:	  peritoneal	  carcinomatosis,	  RCT:	  neo-­‐adjuvant	  chemoradiaaon,	  ChT:	  
chemotherapy,	  RD:	  recurrent	  disease
a	  adjuvant	  chemotherapy	  that	  was	  actually	  received;	  paaents	  may	  not	  have	  received	  CT	  due	  to	  physical	  condiaon,	  
age	  or	  individual	  wishes.
b	  TTRD:	  Time	  all	  diagnosis	  of	  recurrent	  disease	  a*er	  surgery	  primary	  tumor
c	  Treatment	  of	  recurrent	  disease:	  C:	  intended	  curaave	  treatment,	  P:	  palliaave	  treatment
Discussion	  
Recurrent	  disease	  in	  the	  ﬁrst	  year	  aTer	  curaAve	  treatment	  of	  non-­‐metastaAc	  CRC	  seems	  to	  
be	  limited	  to	  paAents	  with	  locally	  advanced	  primary	  tumors.	  These	  results	  do	  suggest	  that	  
FU	  in	  the	  ﬁrst	  year	  aTer	  surgery	  aimed	  at	  detecAon	  of	  RD	  can	  safely	  be	  postponed	  in	  non-­‐	  
advanced	  CRC	  and	  be	  focused	  primarily	  on	  assessing	  the	  funcAonal	  outcomes	  and	  
psychological	  support	  adapted	  to	  the	  individual	  paAent’s	  need.	  The	  outcomes	  in	  this	  study	  
quesAon	  the	  current	  emphasis	  of	  FU	  in	  the	  ﬁrst	  year	  aTer	  treatment	  as	  was	  reported	  in	  a	  
naAonal	  Dutch	  survey.10
	   An	  important	  determinant	  of	  Ame	  to	  recurrent	  disease	  (TTRD)	  is	  the	  intensity	  of	  FU.11-­‐13	  
In	  this	  study,	  the	  intensity	  was	  moderately	  high	  with	  3-­‐monthly	  CEA	  measurements	  and	  
biannual	  imaging	  of	  the	  liver	  as	  part	  of	  the	  regular	  FU	  protocol.	  Also,	  one	  third	  of	  paAents	  
were	  included	  in	  an	  intensive	  phase	  II	  FU	  trial.	  In	  previous	  FU	  trials	  the	  average	  TTRD	  was	  
already	  between	  10	  and	  24	  months;11-­‐18	  early	  RD	  diagnosed	  in	  these	  studies	  most	  oTen	  
were	  liver	  metastases	  found	  within	  few	  months	  aTer	  surgery.	  The	  high	  incidence	  of	  
synchronous	  metastases	  and	  low	  incidence	  of	  early	  recurrences	  in	  this	  study	  as	  compared	  
to	  previous	  FU	  studies	  does	  suggest	  that	  the	  majority	  of	  ‘early	  metachronous’	  liver	  
metastases	  are	  now	  diagnosed	  before	  treatment	  with	  abdominal	  CT.	  The	  outgrowth	  of	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Table	  4.	  Risk	  factors	  for	  early	  recurrence	  (<	  1	  year)
Univariate	  analysis MulAvariate	  analysis





























26% 7.3 2.6-­‐20.8 0.001 3.35 0.9-­‐13.2 0.083
Total 190 12 6%
Abbreviaaons:	  RD:	  Recurrent	  disease,	  RR:	  relaave	  risk	  OR:	  odds	  raao,	  CI:	  conﬁdence	  interval,	  p-­‐value:	  
probability	  value
micrometastases	  further,	  is	  likely	  to	  be	  prevented	  or	  postponed	  by	  the	  more	  eﬀecAve	  
adjuvant	  chemotherapy	  in	  colon	  cancer	  paAents	  that	  is	  usually	  administered	  up	  to	  9-­‐10	  
months	  aTer	  surgery.8,	  9
	   To	  both	  opAmize	  the	  eﬃcacy	  and	  reduce	  costs	  of	  FU	  in	  future	  trials	  and	  protocols,	  
assessment	  of	  ‘current’	  recurrence	  paferns	  is	  essenAal.	  This	  study	  elaborates	  on	  the	  
eﬀects	  of	  rouAne	  staging	  and	  changed	  treatment	  on	  early	  recurrences	  only,	  and	  found	  T	  
stage,	  not	  N	  stage,	  as	  the	  most	  important	  prognosAc	  factor	  for	  early	  RD.	  However,	  since	  
this	  risk	  factor	  was	  found	  in	  a	  post-­‐hoc	  analysis,	  it	  will	  need	  conﬁrmaAon	  and	  reﬁnement	  
from	  prospecAve	  studies	  that	  will	  include	  a	  more	  extensive	  risk	  analysis	  on	  prognosAc	  
parameters.	  Next	  to	  changes	  in	  early	  recurrences,	  staging	  and	  changes	  in	  treatment	  of	  CRC	  
will	  probably	  aﬀect	  the	  incidence	  and	  pafern	  of	  ‘late’	  recurrences	  as	  well.	  In	  rectal	  cancer	  
the	  eﬀects	  of	  neo-­‐adjuvant	  treatment	  on	  TTRD	  was	  already	  described	  in	  a	  systemaAc	  
review.7	  The	  incidence	  was	  reduced	  and	  the	  TTRD	  prolonged,	  leading	  to	  the	  suggesAon	  
that	  an	  esAmated	  8	  years	  of	  FU	  might	  be	  necessary	  for	  deﬁniAve	  assessment	  of	  
therapeuAc	  results.	  Adjuvant	  chemotherapy	  consisAng	  of	  5FU	  combined	  with	  oxaliplaAn	  in	  
stage	  III	  colon	  cancer	  has	  led	  to	  a	  modest	  improvement	  in	  disease	  free	  survival	  3	  to	  4	  years	  
aTer	  curaAve	  treatment.8,	  9	  The	  results	  from	  these	  studies	  suggest	  that	  the	  incidence	  of	  RD	  
has	  decreased.	  Another	  explanaAon	  might	  be	  that	  the	  occurrence	  of	  RD	  has	  been	  
prolonged	  to	  aTer	  4	  years	  since	  long-­‐term	  results	  have	  not	  yet	  been	  described.
	   To	  conclude,	  new	  esAmaAons	  on	  prevalence	  and	  expected	  TTRD	  from	  paAent	  
populaAons	  staged	  and	  treated	  according	  to	  current	  standards,	  are	  needed	  to	  opAmize	  FU	  
on	  both	  the	  eﬃcacy	  and	  cost-­‐eﬀecAveness.	  The	  developments	  in	  treatment	  of	  metastaAc	  
CRC	  in	  the	  last	  decades	  have	  moAvated	  new	  eﬀorts	  to	  improve	  follow-­‐up,	  as	  intended	  in	  a	  
forthcoming	  naAonal	  FU	  trial	  in	  the	  Netherlands.	  CRC	  is	  a	  common	  disease	  and	  intensive	  
FU	  can	  be	  expensive.16	  IdenAﬁcaAon	  of	  low	  and	  high-­‐risk	  groups	  might	  lead	  to	  a	  diﬀerent	  
policy	  in	  follow	  up.	  This	  can	  be	  beneﬁcial	  to	  both	  groups	  of	  paAents	  for	  psychological,	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The	  outcome	  of	  the	  ﬁrst	  study	  (chapter	  2)	  evaluaAng	  the	  relevance	  of	  staging	  with	  
abdominal	  CT	  before	  treatment,	  supports	  this	  as	  a	  rouAne	  procedure	  for	  all	  CRC	  paAents.	  
In	  the	  described	  unselected	  hospital	  populaAon	  of	  612	  paAents,	  a	  high	  percentage	  of	  
metastaAc	  CRC	  (31%)	  was	  found.	  The	  ability	  of	  abdominal	  CT	  to	  ﬁnd	  metastaAc	  CRC	  was	  
good	  for	  liver	  metastases	  (LM),	  but	  poor	  for	  peritoneal	  carcinomatosis	  (PC).	  EsAmaAon	  of	  
T-­‐stage	  of	  colon	  cancer	  (CC)	  on	  abdominal	  CT	  was	  fairly	  good	  and	  may,	  following	  the	  
observed	  strong	  relaAon	  between	  colonic	  T-­‐stage	  and	  PC,	  be	  able	  to	  serve	  as	  a	  surrogate	  
indicator	  for	  PC.	  The	  most	  notable	  change	  in	  treatment	  planning	  was	  observed	  in	  
performing	  no	  resecAon	  of	  the	  primary	  tumor	  in	  emergency	  surgery	  for	  CC,	  as	  a	  
consequence	  of	  diagnosing	  incurable	  metastaAc	  disease.	  This,	  and	  the	  ﬁnding	  of	  metastaAc	  
CRC	  in	  nearly	  half	  of	  emergency	  paAents,	  underlines	  the	  relevance	  of	  staging	  in	  all	  
urgencies.	  It	  was	  however	  observed	  that	  ‘emergency	  staging’	  tended	  to	  be	  omifed,	  mainly	  
due	  to	  logisAc	  reasons.	  A	  heightened	  awareness	  that	  staging	  oﬀers	  the	  opportunity	  to	  
change	  the	  treatment	  plan	  to	  less	  extensive	  procedures	  may	  be	  beneﬁcial	  in	  terms	  of	  a	  
decrease	  in	  operaAve	  morbidity	  and	  mortality.	  Changes	  in	  treatment	  planning	  were	  
observed	  in	  paAents	  with	  LM	  as	  well,	  but	  not	  in	  paAents	  with	  PC.	  This	  is	  largely	  due	  to	  the	  
(failing)	  accuracy	  of	  the	  imaging	  technique	  (CT),	  not	  due	  the	  relevance	  of	  diagnosing	  
metastaAc	  CRC	  for	  opAmal	  treatment.	  To	  search	  for	  metastases	  before	  treatment	  can	  
improve	  the	  oncological	  outcome,	  but	  is	  as	  much	  dependent	  on	  logisAcs	  and	  organizaAon	  
as	  on	  the	  accuracy	  of	  the	  imaging	  technique.
	   Staging	  with	  chest	  CT	  before	  treatment	  was	  not	  supported	  by	  the	  outcomes	  of	  the	  
second	  study,	  that	  evaluated	  the	  outcome	  in	  a	  cohort	  of	  200	  consecuAve	  paAents	  (chapter	  
3).	  The	  incidence	  of	  lung	  metastases	  was	  low	  (7%),	  especially	  those	  conﬁned	  to	  the	  lung	  
(3%).	  Due	  to	  diagnosAc	  diﬃculAes,	  only	  a	  minority	  of	  lung	  metastases	  were	  diagnosed	  
before	  treatment	  (2.5%).	  Indeterminate	  lesions	  were	  frequently	  found	  (25%)	  and	  
discriminaAon	  between	  benign	  and	  malignant	  lesions	  was	  diﬃcult.	  Only	  a	  minority	  turned	  
out	  to	  be	  metastases	  (16%).	  Staging	  with	  chest	  CT	  did	  not	  result	  in	  a	  change	  of	  the	  
treatment	  plan,	  nor	  did	  it	  result	  in	  curaAve	  treatment	  of	  pulmonary	  metastases.	  It	  did	  
cause	  diagnosAc	  dilemmas	  and	  prolonged	  uncertainty.	  Accurate	  pulmonary	  staging	  was	  
most	  relevant	  in	  paAents	  that	  were	  eligible	  for	  curaAve	  treatment	  of	  metastaAc	  CRC	  on	  
other	  locaAons.	  LimitaAon	  of	  staging	  with	  chest	  CT	  to	  this	  selected	  paAent	  group	  would	  
signiﬁcantly	  save	  resources,	  but	  sAll	  meets	  the	  same	  diagnosAc	  dilemmas	  in	  respect	  to	  the	  




From	  the	  naAonal	  survey	  on	  follow-­‐up,	  we	  learned	  that	  renewal	  of	  follow-­‐up	  based	  on	  
scienAﬁc	  evidence	  is	  desired	  and	  a	  naAonal	  trial	  feasible	  (chapter	  4).	  This	  moAvated	  to	  
start	  a	  comprehensive	  review	  of	  literature	  and,	  if	  and	  where	  possible,	  design	  a	  new	  follow-­‐
up	  strategy	  (chapter	  5	  and	  6).	  Follow-­‐up,	  and	  with	  that	  serum	  CEA	  measurements,	  does	  
not	  seem	  beneﬁcial	  for	  survival;	  according	  to	  5	  meta-­‐analyses,	  evidence	  is	  sAll	  failing.	  
When	  evidence	  fails,	  beliefs	  can	  become	  ‘facts’.	  One	  such	  well-­‐known	  belief,	  that	  normal	  
CEA	  values	  before	  treatment	  implies	  CEA	  will	  not	  rise	  in	  case	  of	  recurrent	  disease,	  was	  
proven	  wrong	  (chapter	  5).	  The	  review	  on	  CEA	  in	  follow-­‐up	  stretching	  the	  past	  30	  years,	  
showed	  that	  previous	  evidence	  failed	  the	  beneﬁcial	  eﬀects	  of	  follow-­‐up,	  but	  did	  not	  
denounce	  serum	  CEA	  as	  an	  eﬀecAve	  surveillance	  tool.	  On	  the	  contrary;	  CEA	  was	  shown	  to	  
be	  the	  only	  diagnosAc	  method	  that	  has	  contributed	  to	  a	  survival	  beneﬁt,	  albeit	  the	  eﬀects	  
were	  small.	  The	  iniAal	  promise	  of	  serum	  CEA	  has	  been	  tarnished	  through	  perpetuaAon	  of	  
poorly	  designed	  and	  underpowered	  studies.	  Our	  conclusion	  was	  that	  a	  re-­‐evaluaAon	  of	  the	  
potenAal	  of	  CEA	  in	  follow-­‐up	  was	  worthwhile	  (chapter	  6).
	   At	  the	  Ame	  CEA	  was	  discovered	  as	  a	  tumor	  marker	  for	  gastrointesAnal	  malignancies	  
and	  evaluated	  for	  its	  clinical	  applicability	  (Staab,	  1978-­‐1982),	  it	  was	  suggested	  that	  
bimonthly	  measurements	  and	  dynamic	  threshold	  interpretaAon	  would	  provide	  the	  opAmal	  
accuracy	  of	  serum	  CEA.	  This	  hypothesis	  was	  reconsidered	  by	  looking	  into	  the	  evidence	  on	  
this	  approach.	  First,	  we	  studied	  how	  the	  accuracy	  of	  serum	  CEA	  would	  be	  aﬀected	  when	  a	  
dynamic	  threshold	  value	  is	  applied,	  in	  the	  context	  of	  follow-­‐up.	  The	  clinically	  opAmal	  
threshold	  value	  is	  dependent	  on	  the	  desired	  sensiAvity	  and	  speciﬁcity	  in	  the	  target	  
populaAon.	  SensiAvity	  must	  be	  high	  in	  follow-­‐up	  to	  adequately	  detect	  recurrent	  disease.	  A	  
high	  speciﬁcity	  is	  of	  importance	  to	  minimize	  unnecessary	  diagnosAc	  evaluaAon	  based	  on	  
test	  results,	  especially	  when	  the	  test	  is	  applied	  as	  a	  screening	  tool.	  Follow-­‐up	  requires	  
both,	  as	  a	  screening	  tool	  in	  a	  high-­‐risk	  populaAon.	  This	  evaluaAon	  showed	  that	  CEA	  has	  the	  
lowest	  accuracy	  in	  the	  range	  from	  2.5-­‐10	  ng/ml	  (sensiAvity	  70-­‐90%,	  speciﬁcity	  30-­‐65%),	  
that	  is	  likely	  caused	  by	  the	  overlap	  of	  abnormal	  CEA	  values	  with	  benign	  inﬂammatory	  
disease	  and	  smoking	  in	  these	  lower	  ranges.	  At	  the	  same	  Ame,	  this	  is	  the	  preferred	  range	  in	  
which	  to	  detect	  recurrent	  disease	  during	  follow-­‐up,	  in	  the	  context	  of	  being	  able	  to	  oﬀer	  a	  
second	  chance	  on	  cure.	  A	  dynamic	  threshold	  value	  may	  overcome	  the	  interferences	  in	  
these	  lower	  ranges;	  The	  diﬀerence	  between	  malignancies	  and	  inﬂammatory	  disease	  is	  that	  
malignancies	  will	  conAnue	  to	  grow	  where	  inﬂammatory	  disease	  is	  usually	  self-­‐limiAng.	  The	  
large	  inter-­‐individual	  variaAon	  (55%)	  can	  parAally	  be	  corrected	  by	  raising	  the	  lower	  limit	  
staAc	  threshold	  value	  (normal	  2.0-­‐2.5	  ng/ml)	  to	  5	  ng/ml	  and	  higher,	  as	  is	  usual	  nowadays.	  
Downside	  of	  this	  approach	  is	  that	  the	  sensiAvity	  will	  decrease.	  The	  alternaAve	  to	  consider	  
intra-­‐individual	  rise	  eliminates	  the	  inter-­‐individual	  variaAon	  and	  addiAonally	  shows	  the	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potenAally	  discriminaAve	  padern	  of	  rise.	  This	  approach	  does	  require	  frequent	  
measurements.	  A	  dynamic	  threshold	  value	  as	  measure	  was	  applied	  in	  only	  one	  prospecAve	  
cohort	  study	  on	  follow-­‐up	  (Staab,	  1985),	  but	  never	  tested	  in	  a	  comparaAve	  or	  randomized	  
trial.	  The	  prognos2c	  capacity	  of	  serum	  CEA-­‐rise	  in	  comparison	  to	  a	  staAc	  threshold	  value	  
was	  evaluated	  in	  several	  retrospecAve	  studies,	  all	  showing	  that	  CEA-­‐rise	  is	  a	  far	  befer	  
indicator	  of	  recurrent	  disease	  than	  the	  actual	  value.	  These	  ﬁndings	  support	  the	  original	  
hypothesis,	  that	  -­‐in	  a	  revised	  format	  adapAng	  to	  current	  clinical	  circumstances-­‐	  provided	  
the	  basis	  for	  a	  new	  follow-­‐up	  design.	  This	  revisited	  approach	  is	  now	  referred	  to	  as	  high	  
frequency	  dynamic	  threshold	  (HiDT)	  serum	  CEA	  measurements.	  
	   This	  ‘trying	  again’	  aTer	  several	  previous	  failures,	  consequently	  met	  skepAcal	  responses.	  
Nevertheless,	  Ame	  and	  circumstances	  have	  changed	  and	  many	  of	  these	  changes	  do	  
moAvate	  a	  new	  eﬀort	  to	  opAmize	  follow-­‐up;	  Improvements	  in	  treatment	  of	  metastaAc	  CRC	  
as	  menAoned	  before,	  the	  technical	  advancements	  in	  imaging	  techniques	  that	  facilitate	  
accurate	  non-­‐invasive	  localizaAon	  of	  recurrent	  disease	  and	  the	  possibiliAes	  of	  automated	  
support,	  all	  favored	  a	  new	  follow-­‐up	  trial.	  In	  2008,	  a	  prospecAve	  non-­‐randomized	  feasibility	  
study	  has	  started	  and	  included	  241	  paAents	  in	  two	  centers	  (UMCG	  and	  MST).	  Up	  All	  now,	  
28	  paAents	  had	  recurrent	  disease	  (12%).	  The	  sensiAvity	  of	  HiDT	  serum	  CEA	  measurements	  
in	  the	  range	  between	  2.5	  and	  10	  ng/ml	  was	  79%	  and	  the	  speciﬁcity	  88%.	  The	  outcome	  
concerning	  the	  eligibility	  for	  curaAve	  resecAon	  -­‐in	  an	  interval	  analysis-­‐	  was	  43%.	  The	  trial	  
showed	  that	  the	  protocol	  was	  feasible	  and	  supported	  the	  hypothesis	  on	  its	  theoreAcal	  
grounds.	  
	   An	  important	  part	  of	  the	  phase	  II	  trial	  was	  to	  analyze	  the	  psychological	  eﬀects	  of	  the	  
new	  follow-­‐up	  design	  on	  paAents	  (chapter	  7).	  To	  facilitate	  these	  frequent	  CEA	  
measurements	  without	  causing	  an	  unworkable	  overload	  of	  the	  outpaAent	  clinic,	  the	  
monthly	  CEA	  results	  were	  processed	  and	  communicated	  with	  the	  paAent	  by	  lefer	  and	  
phone,	  with	  less	  outpaAent	  clinic	  visits.	  From	  this	  study	  it	  became	  clear	  that	  not	  only	  was	  
this	  protocol	  feasible	  in	  terms	  of	  psychological	  impact	  (higher	  paAent	  saAsfacAon,	  no	  
diﬀerence	  on	  depression,	  cancer	  worries	  and	  anxiety	  scales),	  it	  was	  even	  preferred	  by	  
paAents	  above	  actual	  contact	  with	  the	  doctor.	  Remembering	  the	  emoAonal	  aspect	  of	  
follow-­‐up,	  this	  outcome	  was	  not	  expected	  from	  a	  doctors’	  point	  of	  view.	  
	   The	  outcomes	  of	  the	  phase	  II	  trial	  concerning	  the	  ﬁrst	  esAmates	  on	  eligibility	  for	  
curaAve	  treatment	  of	  recurrent	  disease,	  and	  the	  feasibility	  of	  the	  protocol	  concerning	  both	  
the	  automated	  support	  and	  psychological	  impact,	  have	  resulted	  in	  a	  forthcoming	  naAonal	  
phase	  III	  randomized	  trial.	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Tailoring	  follow-­‐up	  (chapter	  8)
The	  incidence	  of	  recurrent	  disease	  within	  one	  year	  aTer	  curaAve	  treatment	  of	  non-­‐
metastaAc	  CRC,	  provided	  that	  paAents	  were	  staged	  before	  treatment	  with	  abdominal	  CT,	  	  
turned	  out	  to	  be	  low	  (6%).	  Early	  recurrences	  were	  limited	  to	  paAents	  with	  locally	  advanced	  
primary	  tumors;	  in	  this	  selected	  populaAon,	  the	  risk	  on	  recurrent	  disease	  was	  17%.	  T	  stage	  
was	  the	  most	  important	  risk	  factor	  for	  early	  recurrences.	  In	  non-­‐advanced	  disease,	  follow-­‐
up	  in	  the	  ﬁrst	  year	  may	  safely	  be	  reduced	  to	  assessment	  of	  funcAonal	  outcomes	  and	  
psychological	  support,	  adapted	  to	  the	  individual	  paAent’s	  need.	  The	  outcomes	  in	  this	  study	  
quesAon	  the	  current	  emphasis	  of	  FU	  in	  the	  ﬁrst	  year	  aTer	  treatment	  that	  was	  reported	  in	  
the	  naAonal	  survey	  (chapter	  4).	  This	  study	  was	  a	  ﬁrst	  eﬀort	  to	  describe	  up-­‐to-­‐date	  
recurrence	  paferns	  and	  its	  relevance	  in	  enhancing	  the	  eﬃcacy	  and	  eﬃciency	  of	  future	  
tailored	  follow-­‐up	  designs.	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Stadiëren	  voorafgaand	  aan	  de	  behandeling
De	  relevanAe	  van	  stadiëren	  voorafgaand	  aan	  de	  behandeling	  wordt	  ondersteund	  door	  de	  
uitkomsten	  van	  het	  eerste	  onderzoek	  (hoofdstuk	  2).	  In	  de	  beschreven	  populaAe	  van	  612	  
paAënten	  werd	  een	  hoge	  incidenAe	  van	  gemetastaseerd	  colorectaal	  carcinoom	  (CRC)	  
gevonden	  (31%).	  Met	  een	  CT	  van	  het	  abdomen	  bleek	  het	  goed	  mogelijk	  om	  lever	  
metastasen	  te	  vinden,	  echter	  was	  de	  gevoeligheid	  voor	  peritoneale	  carcinomatosis	  (PC)	  
slecht.	  Inschaxng	  van	  het	  T	  stadium	  bij	  colon	  carcinomen	  was	  redelijk	  goed.	  Lokaal	  
uitgebreide	  colon	  carcinomen	  en	  PC	  zijn	  gecorreleerd;	  mogelijk	  zou	  het	  T	  stadium	  als	  een	  
alternaAeve	  indicator	  voor	  verdenking	  op	  PC	  kunnen	  dienen.	  De	  belangrijkste	  verandering	  
in	  het	  behandelplan,	  als	  een	  gevolg	  van	  de	  bevindingen	  bij	  de	  stadiëring,	  werd	  gezien	  bij	  
paAënten	  met	  gemetastaseerd	  colon	  carcinoom	  met	  een	  spoedeisende	  presentaAe.	  Bij	  
deze	  paAënten	  werd	  er	  minder	  vaak	  een	  resecAe	  verricht	  naar	  aanleiding	  van	  het	  vinden	  
van	  ongenezelijke	  ziekte.	  Dit,	  en	  de	  aanwezigheid	  van	  afstandsmetastasen	  bij	  bijna	  de	  helT	  
van	  de	  paAënten	  met	  een	  spoedeisende	  presentaAe,	  onderstreept	  de	  relevanAe	  van	  
stadiëren	  bij	  alle	  urgenAes.	  Echter	  bleek	  dat	  stadiëren	  juist	  bij	  spoedeisende	  presentaAes	  
vaker	  achterwege	  werd	  gelaten,	  voornamelijk	  om	  logisAeke	  redenen.	  Meer	  alertheid	  op	  
het	  gegeven	  dat	  vooraf	  stadiëren	  het	  behandelplan	  kan	  veranderen	  naar	  minder	  
uitgebreide	  procedures,	  heeT	  mogelijk	  een	  gunsAg	  eﬀect	  op	  de	  operaAe	  morbiditeit	  en	  
mortaliteit.	  Ook	  bij	  paAënten	  met	  lever	  metastasen	  werden	  veranderingen	  in	  het	  
behandelplan	  gezien,	  echter	  niet	  bij	  paAënten	  met	  PC.	  Dit	  is	  voornamelijk	  een	  gevolg	  van	  
het	  onvermogen	  van	  de	  CT	  van	  het	  abdomen	  om	  PC	  af	  te	  beelden,	  niet	  vanwege	  het	  
ontbreken	  van	  eventuele	  consequenAes	  voor	  de	  behandeling.	  Het	  zoeken	  naar	  
afstandsmetastasen	  kan	  de	  oncologische	  uitkomsten	  verbeteren,	  waarin	  de	  uiteindelijke	  
verbetering	  net	  zo	  aankelijk	  is	  van	  logisAek	  en	  organisaAe	  als	  van	  de	  accuratesse	  van	  de	  
beeldvormende	  techniek.
	   Stadiëring	  met	  een	  CT	  van	  de	  thorax	  werd	  niet	  ondersteund	  door	  de	  bevindingen	  van	  
de	  tweede	  studie	  (hoofdstuk	  3).	  De	  incidenAe	  van	  longmetastasen	  was	  laag	  (7%),	  met	  
name	  van	  metastasen	  die	  beperkt	  zijn	  tot	  de	  long	  (3%).	  Vanwege	  diagnosAsche	  
onzekerheden	  werd	  ook	  slechts	  een	  kleine	  minderheid	  van	  de	  longmetastasen	  
gediagnosAceerd	  vóór	  de	  behandeling	  van	  de	  pimaire	  tumor	  (2.5%).	  Indiﬀerente	  
afwijkingen	  werden	  vaak	  gezien	  (25%)	  en	  het	  maken	  van	  een	  onderscheid	  tussen	  
goedaardige	  en	  kwaadaardige	  afwijkingen	  blijkt	  heel	  lasAg.	  Slechts	  een	  klein	  deel	  van	  de	  
indiﬀerente	  afwijkingen	  bleek	  kwaadaardig	  (16%).	  Stadiëren	  met	  een	  CT	  van	  de	  thorax	  
resulteerde	  niet	  in	  een	  verandering	  van	  het	  behandelplan	  van	  de	  primaire	  tumor	  en	  heeT	  
niet	  geleid	  tot	  meer	  curaAeve	  behandelingen.	  Wel	  gaf	  het	  aanleiding	  tot	  diagnosAsche	  
dilemma’s,	  veel	  aanvullend	  onderzoek	  en	  langdurige	  onzekerheid.	  Stadiëring	  van	  de	  longen	  
was	  het	  meest	  relevant	  bij	  paAënten	  met	  metastasen	  elders	  die	  in	  aanmerking	  kwamen	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voor	  curaAeve	  behandeling	  hiervan.	  Het	  beperken	  van	  een	  CT	  van	  de	  thorax	  tot	  deze	  
doelgroep	  resulteert	  al	  in	  een	  aanzienlijk	  besparing	  van	  kosten.	  Echter	  blijven	  ook	  in	  deze	  
paAëntengroep	  dezelfde	  problememen	  met	  indiﬀerente	  afwijkingen	  bestaan.	  	  
Concluderend	  werd	  het	  stadiëren	  van	  de	  thorax	  met	  een	  CT	  scan	  niet	  geadviseerd	  als	  een	  
rouAne	  procedure.
Follow-­‐up
De	  naAonale	  enquete	  over	  de	  follow-­‐up	  liet	  zien	  dat	  een	  verbetering	  van	  follow-­‐up	  
gebaseerd	  op	  wetenschappelijk	  bewijs	  gewenst	  is	  en	  er	  voldoende	  draagvlak	  is	  voor	  een	  
landelijke	  studie	  (hoofdstuk	  4).	  Deze	  uitkomst	  heeT	  geleid	  tot	  een	  uitgebreide	  
literatuurstudie	  met	  als	  doel	  indien,	  en	  waar	  mogelijk,	  een	  nieuwe	  follow-­‐up	  strategie	  te	  
ontwerpen	  (hoofdstuk	  5	  en	  6).	  
	   Follow-­‐up	  en	  daarmee	  ook	  het	  CEA,	  lijkt	  niet	  veel	  eﬀect	  te	  hebben	  op	  de	  overleving,	  
zoals	  werd	  geconcludeerd	  in	  5	  meta-­‐analyses.	  Wanneer	  er	  geen	  bewijs	  is,	  kunnen	  
veronderstellingen	  al	  snel	  verworden	  tot	  feiten.	  Een	  voorbeeld	  van	  zo’n	  veelgehoord	  ‘feit’,	  
is	  dat	  als	  er	  een	  normale	  CEA	  waarde	  is	  voorafgaand	  aan	  resecAe	  van	  de	  primaire	  tumor,	  
het	  CEA	  ook	  niet	  zal	  sAjgen	  wanneer	  de	  ziekte	  terug	  komt.	  Dit	  bleek	  onjuist	  (hoofdstuk	  5).	  
De	  uitgebreide	  literatuurstudie	  over	  het	  CEA	  in	  de	  follow-­‐up	  over	  een	  periode	  van	  30	  jaar	  
(hoofdstuk	  5),	  toonde	  aan	  dat	  eerdere	  studies	  wel	  lieten	  zien	  dat	  follow-­‐up	  op	  zichzelf	  een	  
minimaal	  eﬀect	  had,	  maar	  niet	  dat	  de	  toegevoegde	  waarde	  van	  het	  CEA	  als	  een	  eﬀecAeve	  
tumormarker	  kon	  worden	  verworpen.	  Integendeel	  zelfs;	  het	  CEA	  was	  de	  enige	  
diagnosAsche	  methode	  in	  follow-­‐up	  studies	  met	  een	  aangetoond	  posiAef	  eﬀect	  op	  de	  
overleving,	  ook	  al	  waren	  de	  gemeten	  eﬀecten	  klein.	  De	  aanvankelijke	  beloTe	  van	  het	  CEA	  
als	  tumormarker	  zijn	  -­‐ten	  onrechte-­‐	  langdurig	  ondermijnd	  door	  slecht	  opgezefe	  en	  te	  
kleine	  studies	  in	  het	  verleden.	  Onze	  conclusie	  was	  dat	  een	  herevaluaAe	  van	  het	  potenAeel	  
van	  serum	  CEA	  bepalingen	  in	  de	  follow-­‐up	  de	  moeite	  waard	  is	  (hoofdstuk	  5).	  
	   In	  de	  Ajd	  dat	  het	  serum	  CEA	  werd	  ontdekt	  als	  een	  tumor	  marker	  bij	  gastro-­‐intesAnale	  
maligniteiten	  en	  de	  klinische	  toepassing	  werd	  ontwikkeld	  (Staab,	  1978-­‐1982),	  werd	  
beredeneerd	  dat	  een	  tweemaandelijkse	  bepaling	  en	  een	  dynamische	  aapwaarde	  de	  
meest	  opAmale	  accuratesse	  bewerkstelligen.	  Deze	  hypothese	  werd	  heroverwogen	  door	  de	  
onderliggende	  bewijzen	  te	  analyseren.	  In	  de	  eerste	  plaats	  hebben	  we	  gekeken	  naar	  de	  
voorspellende	  waarde	  van	  een	  dynamische	  aapwaarde	  van	  het	  serum	  CEA	  voor	  recidief	  
ziekte	  in	  de	  follow-­‐up.	  De	  klinisch	  opAmale	  aapwaarde	  is	  aankelijk	  van	  de	  gewenste	  
sensiAviteit	  en	  speciﬁcteit	  in	  de	  beoogde	  populaAe.	  De	  sensiAviteit	  moet	  hoog	  zijn	  om	  
recidief	  ziekte	  adequaat	  te	  kunnen	  ontdekken.	  De	  speciﬁciteit	  moet	  hoog	  zijn,	  om	  onnodig	  
aanvullende	  onderzoek	  te	  voorkomen	  wanneer	  de	  test	  wordt	  gebruikt	  als	  een	  screenings	  
methode.	  In	  follow-­‐up,	  wat	  een	  screening	  in	  een	  hoog	  risico	  populaAe	  in	  houdt,	  zijn	  beide	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nodig.	  De	  analyse	  liet	  zien	  dat	  het	  serum	  CEA	  de	  laagste	  accuratesse	  heeT	  in	  het	  gebied	  
van	  2.5	  tot	  10	  ng/ml	  (sensiAviteit	  70-­‐90%,	  speciﬁciteit	  30-­‐65%).	  Dit	  wordt	  grotendeels	  
veroorzaakt	  door	  de	  overlap	  van	  verhoogd	  serum	  CEA	  waarden	  door	  inﬂammatoire	  
aandoeningen	  en	  roken	  in	  dit	  meetgebied.	  TegelijkerAjd	  is	  dit	  het	  geprefereerde	  
meetgebied	  om	  recidief	  ziekte	  te	  ontdekken,	  met	  het	  oog	  op	  de	  kans	  een	  genezende	  
behandeling	  te	  kunnen	  bieden.	  Een	  dynamische	  awapwaarde	  kan	  de	  verstoring	  in	  dit	  
meetgebied	  sterk	  verminderen.	  Het	  verschil	  tussen	  maligniteiten	  en	  inﬂammatoire	  
aandoeningen	  is	  dat	  maligniteiten	  blijven	  groeien	  waar	  ontstekingen	  meestal	  weer	  vanzelf	  
overgaan.	  De	  aanzienlijke	  inter-­‐individuele	  variaAe	  (55%)	  kan	  (deels)	  worden	  gecorrigeerd	  
door	  de	  gebruikte	  aapwaarde	  te	  verhogen	  (normaal	  2.0-­‐2.5	  ng/ml)	  naar	  5	  ng/ml,	  zoals	  
dat	  tegenwoordig	  gebruikelijk	  is.	  Het	  nadeel	  van	  deze	  benadering	  is	  dat	  de	  sensiAviteit	  
daardoor	  lager	  wordt.	  Het	  alternaAef	  om	  de	  intra-­‐individuele	  s2jging	  te	  beoordelen,	  
elimineert	  de	  inter-­‐individuele	  variaAe	  volledig	  en	  toont	  daarbij	  ook	  het	  potenAële	  
onderscheidende	  sAjgingspatroon.	  Deze	  benadering	  vereist	  frequente	  meAngen.	  Een	  
dynamische	  aapwaarde	  werd	  slechts	  in	  één	  prospecAeve	  cohort	  studie	  toegepast	  (Staab,	  
1985),	  maar	  is	  nooit	  getest	  in	  een	  vergelijkende	  of	  gerandomiseerde	  studie.	  De	  
voorspellende	  capaciteit	  van	  de	  CEA	  sAjging	  werd	  wel	  geëvalueerd;	  al	  deze	  studies	  lieten	  
zien	  dat	  de	  s2jging	  van	  CEA	  een	  veel	  betere	  indicator	  is	  van	  recidief	  ziekte	  dan	  de	  hoogte	  
van	  het	  CEA.	  Deze	  bevindingen	  ondersteunen	  de	  originele	  hypothese,	  die	  in	  een	  
gereviseerde	  versie	  -­‐rekening	  houdend	  met	  de	  huidige	  klinische	  context-­‐,	  de	  basis	  is	  
geworden	  van	  een	  nieuw	  follow-­‐up	  ontwerp.	  Deze	  gereviseerde	  benadering	  is	  ‘high-­‐
frequency	  dynamic	  threshold’	  (HiDT)	  [hoge	  frequenAe	  dynamische	  aapwaarde]	  serum	  
CEA	  bepalingen	  genoemd.	  
	   Deze	  hernieuwde	  poging	  na	  verscheidene	  voorafgaande	  mislukkingen	  om	  de	  
eﬀecAviteit	  van	  de	  oncologische	  follow-­‐up	  te	  verbeteren,	  ontmoefe	  veel	  skepAsche	  
reacAes.	  Niefemin	  bestonden	  er	  ook	  andere	  redenen	  om	  een	  nieuwe	  poging	  te	  doen	  de	  
follow-­‐up	  gericht	  op	  de	  detecAe	  van	  recidief	  ziekte	  te	  verbeteren;	  in	  de	  aanzienlijke	  
verbeteringen	  in	  de	  behandeling	  van	  gemetastaseerde	  ziekte,	  in	  de	  snelle	  technische	  
vooruitgang	  van	  de	  beeldvormende	  technieken	  die	  non-­‐invasieve	  localisaAe	  van	  recidief	  
ziekte	  mogelijk	  maken	  en	  in	  de	  mogelijkheden	  van	  geautomaAseerde	  ondersteuning.	  In	  
2008	  werd	  een	  prospecAeve	  cohort	  studie	  gestart	  gericht	  op	  de	  haalbaarheid	  van	  het	  
protocol,	  waarin	  241	  paAenten	  werden	  geincludeerd	  in	  twee	  centra	  (UMCG	  en	  MST).	  Tot	  
nu	  toe	  zijn	  28	  paAënten	  gediagnosAceerd	  met	  recidief	  ziekte	  (12%).	  De	  sensiAviteit	  van	  
HiDT	  serum	  CEA	  bepalingen	  in	  het	  meetgebied	  van	  2.5-­‐10	  ng/ml	  was	  79%	  en	  de	  
speciﬁciteit	  88%.	  De	  uitkomsten	  wat	  betreT	  de	  mogelijkheid	  tot	  een	  genezende	  
behandeling	  in	  de	  interim	  analyse	  was	  43%.	  De	  studie	  toonde	  aan	  dat	  het	  protocol	  
uitvoerbaar	  is	  en	  ondersteunt	  de	  hypothese	  op	  de	  onderliggende	  theoreAsche	  gronden.
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   Een	  belangrijk	  deel	  van	  deze	  fase	  II	  studie	  was	  het	  analyseren	  van	  de	  psychologische	  
eﬀecten	  van	  het	  nieuwe	  follow-­‐up	  ontwerp	  (hoofdstuk	  7).	  Om	  frequente	  serum	  CEA	  
bepalingen	  mogelijk	  te	  maken	  zonder	  een	  onwerkbare	  overbelasAng	  van	  de	  polikliniek	  te	  
veroorzaken,	  werden	  de	  maandelijkse	  CEA	  bepalingen	  middels	  brieven	  of,	  bij	  een	  relevante	  
sAjging,	  middels	  telefonisch	  contact	  met	  de	  paAent	  gecommuniceerd.	  Het	  aantal	  geplande	  
polikliniek	  bezoeken	  was	  daarbij	  minder	  dan	  momenteel	  gebruikelijk.	  Uit	  deze	  studie	  werd	  
duidelijk	  dat	  het	  protocol	  niet	  alleen	  goed	  uitvoerbaar	  was	  (geen	  verschil	  in	  depressie	  -­‐,	  
angst	  en	  kanker	  zorgen	  uitkomsten,	  en	  een	  hogere	  tevredenheid	  in	  de	  intervenAegroep),	  
het	  werd	  zelfs	  geprefereerd	  door	  de	  paAënten	  boven	  direct	  contact	  met	  de	  arts.	  De	  
emoAonele	  aspecten	  van	  follow-­‐up	  in	  gedachten	  nemend,	  was	  deze	  uitkomst	  onverwacht	  
vanuit	  het	  oogpunt	  van	  de	  medische	  stand.	  
	   De	  uitkomsten	  van	  de	  fase	  II	  studie	  wat	  betreT	  de	  eerste	  inschaxngen	  op	  
mogelijkheden	  tot	  een	  in	  opzet	  genezende	  behandeling,	  de	  uitvoerbaarheid	  van	  het	  
protocol	  wat	  betreT	  de	  computer	  ondersteuning	  en	  de	  psychologische	  eﬀecten,	  hebben	  
geresulteerd	  in	  een	  aankomende	  naAonale	  gerandomiseerde	  fase	  III	  studie.	  
Follow-­‐up	  op	  maat	  (hoofdstuk	  8)
De	  incidenAe	  van	  recidief	  ziekte	  binnen	  één	  jaar	  na	  genezende	  behandeling	  van	  niet-­‐
gemetastaseerde	  ziekte,	  mits	  paAënten	  voor	  de	  behandeling	  goed	  waren	  gestadieerd,	  
bleek	  laag	  (6%).	  Vroege	  recidieven	  waren	  beperkt	  tot	  de	  groep	  paAënten	  met	  locaal	  
uitgebreide	  primaire	  tumoren;	  in	  deze	  geselecteerde	  populaAe	  was	  de	  incidenAe	  van	  
recidief	  ziekte	  17%.	  Het	  T-­‐stadium	  bleek	  de	  belangrijkste	  risicofactor	  voor	  een	  vroeg	  
recidief.	  Bij	  locaal	  beperkte	  ziekte	  kan	  de	  follow-­‐up	  veilig	  worden	  gereduceerd	  tot	  de	  
begeleiding	  ten	  aanzien	  van	  funcAonele	  uitkomsten	  en	  psychologische	  ondersteuning,	  
aangepast	  aan	  de	  behoeTe	  van	  de	  paAënt.	  Deze	  uitkomst	  stelt	  de	  huidige	  nadruk	  van	  de	  
oncologische	  controle	  in	  het	  eerste	  jaar,	  zoals	  gerapporteerd	  werd	  in	  de	  enquete	  
(hoofdstuk	  4),	  ter	  discussie.	  Deze	  studie	  was	  een	  eerste	  stap	  in	  het	  beschrijven	  van	  
hedendaagse	  recidiefpatronen	  en	  de	  relevanAe	  hiervan	  in	  het	  verbeteren	  van	  de	  





Diagnosing	  and	  localiza>on	  of	  metasta>c	  CRC
CRC	  is	  one	  of	  the	  few	  malignancies	  that	  can	  be	  cured	  in	  the	  presence	  of	  distant	  
metastases,	  and	  current	  treatment	  strategies	  can	  oﬀer	  a	  (second)	  chance	  on	  cure	  for	  
metastaAc	  or	  locally	  recurrent	  disease	  to	  an	  increasing	  proporAon	  of	  paAents.	  Finding	  and	  
localizing	  metastaAc	  disease	  at	  the	  earliest	  possible	  stage	  and	  also	  esAmaAons	  on	  the	  
chance	  on	  cure	  will	  only	  become	  more	  important.	  The	  accuracy	  of	  current	  widely	  used	  
imaging	  techniques	  (CT)	  in	  diagnosing	  and	  localizing	  metastaAc	  CRC	  falls	  short	  for	  
peritoneal	  carcinomatosis	  (PC)	  and	  lung	  metastases;	  In	  PC	  because	  of	  a	  lack	  of	  sensi2vity	  to	  
detect	  this	  typically	  small	  nodular	  disease,	  in	  lung	  metastases	  because	  of	  the	  low	  speciﬁcity	  
in	  the	  discriminaAon	  of	  small	  lung	  lesions.	  A	  step-­‐wise	  staging	  approach	  that	  takes	  the	  
strengths	  and	  limitaAons	  of	  CT	  scan	  into	  account	  may	  be	  pracAcable	  as	  a	  next	  step.	  For	  
instance,	  a	  soluAon	  to	  the	  observed	  inaccuracy	  of	  the	  abdominal	  CT	  in	  PC	  can	  be	  to	  
perform	  a	  diagnosAc	  laparoscopy	  preceding	  surgery	  in	  case	  of	  cT4	  colon	  carcinoma.	  
Standardized,	  or	  automated1	  reporAng	  of	  the	  staging	  CT,	  such	  as	  on	  cT	  stage,	  exact	  
localizaAon(s),	  number	  and	  size	  of	  metastases,	  and	  the	  index	  of	  suspicion	  of	  eventual	  
indeterminate	  lesions,	  may	  contribute	  to	  the	  clinical	  judgement.	  Newer	  and	  developing	  
techniques	  such	  as	  the	  PET/CT	  2,	  3	  or	  diﬀusion-­‐weighed	  MRI	  4	  that	  combine	  anatomical	  and	  
funcAonal	  characterisAcs	  may	  oﬀer	  a	  befer	  accuracy	  and	  await	  further	  study.	  A	  more	  
experimental	  but	  nowadays	  promising	  technique	  is	  CEA-­‐targeted	  radio-­‐nuclide	  imaging	  
techniques	  in	  PET	  and	  SPECT	  scanning.5,	  6	  	  AddiAonal	  to	  imaging	  techniques,	  biochemical	  or	  
histological	  markers	  may	  contribute	  to	  both	  ﬁnding	  -­‐or	  predicAng	  the	  risk	  on-­‐	  metastaAc	  
disease.	  Known	  biochemical	  prognosAc	  factors	  are	  serum	  CEA,	  Ca19.9	  and	  the	  CEA	  index	  of	  
pre-­‐	  and	  post-­‐operaAve	  values.7,	  8,	  9	  	  Known	  histological	  markers	  are	  angio-­‐invasive	  growth,
10	  	  perineural	  invasion,11	  stromal-­‐carcinoma	  raAo,12,	  13	  T	  stage	  (chapter	  2	  and	  8),	  gene	  
expression	  proﬁles,14	  micro-­‐metastases	  found	  with	  a	  senAnel	  node	  procedure15,	  16	  and	  
others.	  Current	  use	  of	  these	  prognosAc	  parameters	  is	  mainly	  selecAng	  paAents	  for	  
adjuvant	  treatment.	  It	  may	  be	  a	  reasonable	  next	  step	  to	  develop	  risk-­‐proﬁles	  based	  on	  
these	  parameters	  (with	  serum	  samples	  and	  histological	  biopsies)	  also	  in	  the	  context	  of	  
selecAng	  paAents	  for	  neo-­‐adjuvant	  treatment,	  for	  instance	  in	  locally	  advanced	  colon	  cancer	  
(LACC).	  Risk	  proﬁles	  based	  on	  (combined)	  prognosAc	  markers	  aimed	  at	  a	  diﬀerenAated	  
follow-­‐up	  may	  enhance	  both	  its	  eﬃcacy	  and	  eﬃciency.	  EsAmaAon	  on	  the	  chance	  of	  cure	  of	  
intended	  metastases	  treatment	  may	  be	  another	  future	  use	  of	  prognosAc	  parameters,	  and	  
may	  contribute	  to	  appropriate	  selecAon	  of	  paAents	  for	  high	  risk	  procedures	  such	  as	  
treatment	  of	  PC.	  An	  important	  consideraAon	  in	  this	  discussion	  is	  that	  not	  only	  the	  imaging	  
techniques’	  accuracy	  or	  predicAve	  capacity	  of	  prognosAc	  markers	  mafer	  in	  (re)staging.	  
New	  developments	  have	  to	  be	  evaluated	  in	  their	  clinical	  context	  and	  the	  applicability	  for	  
all	  paAents.	  Another	  elemental	  consideraAon	  in	  designing	  new	  strategies	  for	  staging,	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registraAon	  and	  follow-­‐up	  is	  that	  CRC	  is	  a	  high-­‐volume	  disease,	  of	  which	  the	  impact	  on	  
Ame	  spend	  and	  hospital	  resources	  should	  not	  be	  underesAmated.	  
Research	  methods
When	  starAng	  the	  clinical	  studies	  for	  this	  thesis	  in	  2007,	  we	  reasoned	  that	  the	  best	  way	  to	  
support	  our	  studies	  would	  be	  to	  design	  a	  prospecAve	  registraAon	  of	  all	  paAents	  that	  
underwent	  colorectal	  surgery.	  The	  eﬀorts	  that	  were	  done	  to	  design	  a	  comprehensive	  but	  
pracAcable	  database,	  did	  add	  signiﬁcantly	  to	  the	  pracAcality	  of	  doing	  research	  and	  the	  
accuracy	  of	  data.	  What	  the	  outcomes	  of	  this	  database	  revealed	  further,	  were	  relevant	  
diﬀerences	  in	  incidences	  (e.g.	  of	  synchronous	  metastaAc	  disease),	  age	  and	  outcome,	  as	  
compared	  to	  trial	  populaAons.	  This	  is	  not	  surprising;	  relevant	  co-­‐morbidity	  (WHO	  >	  1,	  ASA	  
3	  or	  higher,	  Karnofsky	  score	  <	  90%),	  emergency	  procedures	  and	  /	  or	  advanced	  age	  are	  
usually	  exclusion	  criteria	  in	  clinical	  trials.17	  However,	  as	  was	  observed	  from	  our	  registraAon	  
the	  proporAon	  of	  these	  paAents	  in	  CRC	  is	  high	  and	  also,	  that	  speciﬁcally	  these	  paAents	  are	  
the	  most	  vulnerable.	  Emergency	  presentaAons	  account	  for	  20%,	  the	  average	  age	  between	  
trial	  -­‐	  and	  unselected	  populaAons	  is	  up	  to	  7	  years;	  and	  co-­‐morbidity	  frequently	  comes	  with	  
age.	  Further,	  the	  outcomes	  of	  metastases	  treatment	  have	  been	  improving	  in	  the	  past	  
decade(s).	  These	  outcomes	  however,	  are	  usually	  evaluated	  in	  retrospecAve	  cohort	  studies	  
that	  consider	  treated	  paAents.	  What	  remains	  unknown	  meanwhile,	  is	  how	  many	  paAents	  
that	  may	  have	  been	  eligible	  for	  intended	  curaAve	  metastases	  treatment,	  are	  missed	  in	  the	  
work-­‐up	  process;	  Either	  by	  missing	  the	  metastases	  at	  staging,	  follow-­‐up	  or	  improper	  
judgement	  on	  eligibility	  for	  treatment.	  To	  summarize,	  current	  evidence	  mainly	  reﬂects	  the	  
outcomes	  of	  a	  (befer)	  selecAon	  of	  the	  CRC	  populaAon	  and	  that	  of	  the	  highest	  risk	  paAents	  
remains	  shrouded.	  	  
	   To	  gain	  a	  comprehensive	  insight	  in	  in	  this	  disease	  and	  put	  new	  developments	  in	  a	  
broader	  context,	  unselected	  populaAon	  data	  are	  needed	  to	  complement	  current	  research	  
methods.	  The	  most	  reliable	  method	  of	  data	  accrual	  is	  prospecAve	  registraAon	  from	  the	  
original	  sources.	  Advantages	  of	  prospecAve	  registraAon	  are	  not	  only	  the	  higher	  accuracy,	  
but	  also	  up-­‐to-­‐date	  data.	  Time	  is	  a	  relevant	  issue	  in	  CRC;	  many	  simultaneous	  changes	  are	  
taking	  place	  in	  (neo-­‐)adjuvant	  treatment,	  curaAve	  metastases	  treatment,	  palliaAve	  
treatment,	  staging	  methods	  and	  follow-­‐up.	  None	  is	  unrelated	  to	  the	  other	  which	  increases	  
the	  complexity	  and	  requires	  complete	  data.	  The	  availability	  of	  recent	  prospecAve	  data,	  that	  
is	  obtained	  with	  prospecAve	  data	  collecAon,	  enables	  researchers	  to	  keep	  pace	  with	  the	  
rapidly	  changing	  circumstances	  and	  put	  those	  into	  their	  appropriate	  context.	  
Disadvantages	  may	  be	  a	  data	  collecAon	  with	  no	  predeﬁned	  research	  goal,	  resulAng	  in	  
either	  too	  much	  or	  too	  lifle	  data.	  The	  availability	  of	  a	  well	  designed	  data	  set	  may	  on	  the	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other	  hand	  result	  in	  serendipitous	  observaAons	  that	  can	  iniAate	  new	  developments.	  	  One	  
such	  ﬁnding	  from	  our	  registraAon	  was	  the	  adverse	  outcome	  seen	  in	  locally	  advanced	  colon	  
cancer	  (LACC),	  that	  has	  a	  high	  incidence	  of	  synchronous	  metastases	  (chapter	  2)	  and	  a	  high	  
risk	  on	  early	  recurrences	  (chapter	  8).	  Perhaps	  neo-­‐adjuvant	  or	  mulA-­‐modality	  treatment	  
opAons	  analogue	  to	  that	  for	  LARC,	  may	  result	  in	  befer	  oncological	  outcomes.
	   ExisAng	  databases	  with	  populaAon	  data	  that	  may	  be	  complementary	  to	  other	  research	  
methods,	  are	  the	  oncological	  registry	  of	  the	  Comprehensive	  Cancer	  Centers	  (CCC)	  and	  the	  
Dutch	  Surgical	  Colorectal	  Audit	  (DSCA).	  The	  CCC	  register	  selected	  oncological	  data;	  its	  
strength	  is	  unselected	  populaAon	  data.	  However,	  its	  weaknesses	  are	  the	  limited	  and	  
retrospecAve	  data	  collecAon,	  that	  is	  neither	  adapted	  to	  speciﬁc	  (medical)	  characterisAcs	  in	  
colorectal	  cancer.	  The	  DSCA	  is	  a	  new	  iniAaAve	  that	  collects	  data	  from	  colorectal	  cancer	  
paAents	  with	  the	  aim	  of	  quality	  control	  and	  benchmarking.	  The	  strength	  of	  this	  database	  is	  
that	  it	  considers	  speciﬁc	  circumstances	  in	  colorectal	  cancer	  surgery.	  Its	  weakness	  is	  that	  it	  
is	  not	  designed	  for	  research	  purposes	  and	  only	  involves	  surgical	  paAents,	  and	  that	  there	  is	  
neither	  a	  control	  system	  to	  esAmate	  the	  proporAon	  of	  unregistered	  paAents.	  When	  a	  
research	  purpose	  would	  be	  aimed	  upon,	  both	  the	  data	  set	  and	  method	  of	  data	  accrual	  
would	  need	  alteraAons.	  To	  prevent	  ‘garbage	  in,	  garbage	  out’,	  the	  database	  design	  requires	  
limitaAon	  of	  data	  ﬁelds	  and	  unequivocal	  but	  comprehensive	  content	  opAons.18	  	  Further,	  it	  
would	  need	  acAve	  involvements	  of	  other	  disciplines.	  
	   Our	  vision	  is	  that	  a	  prospecAve	  registraAon	  of	  selected	  core	  data	  for	  research	  purposes	  
on	  a	  naAonal	  scale	  would	  signiﬁcantly	  enhance	  current	  and	  future	  research	  in	  colorectal	  
cancer.	  Ideally,	  clinicians	  from	  all	  involved	  specialiAes	  parAcipate	  in	  the	  registraAon	  with	  
speciﬁc,	  limited	  data	  sets.	  In	  respect	  to	  the	  content,	  it	  should	  include	  selected	  key	  variables	  
in	  the	  outcome	  on	  both	  medical	  factors	  (such	  as	  parameters	  inﬂuencing	  the	  treatment	  
morbidity	  and	  mortality)	  and	  oncological	  (prognosAc)	  parameters.	  In	  respect	  to	  the	  
interpretaAon	  and	  reporAng	  of	  observaAons,	  acAve	  involvement	  of	  clinical	  epidemiologists	  
in	  the	  design	  and	  development,	  appreciaAng	  internaAonal	  standards,19	  can	  secure	  the	  
scienAﬁc	  value.	  Studies	  concerning	  paAents	  with	  emergency	  presentaAons	  or	  the	  elderly,	  
or	  outcomes	  of	  metastases	  treatment	  on	  a	  populaAon	  scale	  would	  become	  feasible.	  The	  
accuracy	  of	  data	  will,	  inherently	  to	  this	  research	  method,	  be	  high	  and	  unbiased.	  When	  this	  
database	  would	  be	  coupled	  to	  a	  biodatabank	  with	  serum	  and	  Assue	  samples,	  it	  can	  result	  
in	  high	  quality	  studies	  on	  prognosAc	  markers	  for	  individualized	  treatment	  and	  follow-­‐up.	  
When	  oﬀering	  this	  data	  set	  as	  an	  (accredited)	  open	  source	  for	  researchers	  from	  various	  
backgrounds,	  new	  or	  unique	  ideas	  in	  interdisciplinary	  cooperaAon	  may	  arise.	  In	  our	  
opinion,	  such	  iniAaAve	  will	  be	  invaluable	  for	  future	  progression	  in	  research	  for	  all	  paAents.
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My	  Resumé
I	  studied	  medicine	  at	  the	  Academic	  Medical	  Center	  in	  Amsterdam	  from	  1993	  all	  
my	  graduaaon	  as	  a	  medical	  doctor	  (cum	  laude)	  in	  July	  2000.	  Alternaang	  with	  my	  
internships	  I	  have	  been	  teaching	  anatomy	  dissecaon	  courses	  and	  embryology	  to	  
medical	  and	  biology	  students	  for	  3	  years.	  From	  August	  2000	  all	  December	  2003,	  I	  
worked	  as	  a	  surgical	  resident	  (non-­‐trainee)	  in	  the	  Spaarne	  Hospital	  Heemstede,	  
the	  AMC	  in	  Amsterdam	  and	  the	  UMC	  Utrecht	  (cardiothoracic	  surgery).	  Further	  I	  
spent	  3	  months	  working	  on	  full-­‐ame	  research	  concerning	  bile	  duct	  injuries	  at	  the	  
AMC.	  
On	  January	  1st	  2004	  my	  traineeship	  in	  general	  surgery	  started	  in	  the	  UMC	  
Groningen	  (prof	  dr	  H.J.	  ten	  Duis),	  and	  was	  conanued	  in	  the	  Medical	  Spectrum	  
Twente	  in	  Enschede	  (dr	  W.J.B.	  Mastboom)	  from	  July	  1st	  2006	  all	  January	  1st	  2010.	  
My	  ﬁ*h	  year	  was	  focused	  on	  vascular	  surgery	  (dr	  R.H.	  Geelkerken).	  In	  my	  last	  year	  
of	  clinical	  surgical	  training	  I	  specialized	  in	  gastro-­‐intesanal	  and	  oncological	  surgery,	  
in	  which	  ame	  I	  gained	  interest	  and	  experience	  in	  colorectal	  surgery,	  proctology,	  
(para)	  thyreoid	  surgery	  and	  surgical	  oncology.	  
In	  February	  2010	  I	  started	  as	  a	  fellow	  in	  gastro-­‐intesanal	  surgery	  at	  the	  Catharina	  
hospital	  in	  Eindhoven	  (dr	  H.J.T.	  Ru_en),	  with	  speciﬁc	  a_enaon	  for	  locally	  advanced	  
rectal	  cancer,	  treatment	  of	  peritoneal	  carcinomatosis	  (dr	  I.H.J.T.	  de	  Hingh)	  and	  
liver	  surgery	  at	  the	  Máxima	  Medical	  Center	  Veldhoven	  (Dr	  R.M.H.	  Roumen).
My	  aim	  for	  the	  future	  is	  to	  work	  as	  a	  oncological	  surgeon,	  with	  a	  speciﬁc	  interest	  in	  
in	  colorectal	  cancer	  and	  metastases	  treatment.	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Staging	  before	  treatment	  is	  an	  important	  step	  towards	  improving	  the	  (oncological)	  
outcome	  in	  colorectal	  cancer	  
(dit	  proefschriT)
Renewal	  of	  follow-­‐up	  for	  colorectal	  cancer	  based	  upon	  scienAﬁc	  evidence	  from	  a	  
new	  trial	  is	  both	  required	  and	  feasible	  
(dit	  proefschriT)
The	  quesAon	  is	  not	  whether	  to	  use	  serum	  CEA	  as	  a	  tool	  for	  early	  detecAon	  of	  
recurrent	  disease	  of	  colorectal	  cancer,	  but	  how	  
(dit	  proefschriT)
Whether	  innovaAons	  in	  oncological	  care	  will	  also	  beneﬁt	  the	  paAent	  depends	  as	  
much	  on	  organisaAon	  and	  logisAcs	  as	  on	  content	  
(dit	  proefschriT)
Voor	  zorgmanagers	  dienen	  dan	  ook	  gelijke	  wefen	  ten	  aanzien	  van	  de	  medische	  
aansprakelijkheid	  te	  gelden	  als	  voor	  (para)	  medici
PaAents	  can	  live	  without	  their	  doctor,	  doctors	  not	  without	  their	  paAents	  
(dit	  proefschriT)
None	  is	  unrelated	  to	  the	  other	  
(dit	  proefschriT)
Leven	  en	  lot	  worden	  worden	  niet	  bepaald	  door	  wat	  je	  wilt;	  het	  wordt	  een	  richAng	  
gegeven	  door	  wat	  je	  doet	  met	  dat,	  wat	  je	  overkomt.
Make	  everything	  as	  simple	  as	  possible	  	  (but	  not	  simpler)
(Albert	  Einstein)
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